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General introduction 
The scope of this thesis is limited to the study of disturbances of 
pyruvate metabolism related to hereditary metabolic disorders. The 
elucidation of these disorders requires a sufficient knowledge of the 
normal metabolism of pyruvate and lactate in the human being. In this 
investigation we try to provide some additional knowledge. Chapter 1 
gives a brief review of some important aspects of the pyruvate utiliza-
tion in animal tissues. 
Various diseases in childhood may provoke an elevated concentration 
of lactate and pyruvate (Chapter 2). Although some clinical features 
may suggest an abnormality in pyruvate metabolism, they are not 
characteristic. Metabolic screening of children with unexplained mental 
retardation, with metabolic acidosis, with symptoms of hypoglycemia 
or irregular respiration can reveal an increased concentration of lactate 
and/or pyruvate in blood. This thesis is concerned with some aspects 
of the course of the investigation in patients with a suspected disturb-
ance in the metabolism of pyruvate and lactate (scheme). 
In the first stage patients' blood is analyzed: pH, bicarbonate, base 
excess, sodium, potassium and chloride in serum (blood); lactate and 
pyruvate concentration in blood and cerebrospinal fluid and lactate 
excretion in urine, ketoacids and aminoacids (especially alanine) 
respectively, in blood and in serum; organic acids in urine and in blood. 
In the second phase of the study in vivo tests may be performed to 
investigate whether an inborn error of metabolism is present. In some 
cases attention will be called to specific pathways of metabolism and 
to the organ, in which a defect is localized, as a result of these tests. 
Some in vivo function tests are available such as glucose-, fructose-, 
galactose- and glucagon tolerance test and the fasting test. The test of 
McArdle and the determination of lactate during exercise are useful 
when aberrations in muscle metabolism are expected. The fasting test 
is discussed in Chapter 4. 
In the third stage of the study molecular diagnosis will be performed 
in leukocytes and fibroblasts. These cells are easily available and allow 
measurement of the pyruvate oxidation and the citric acid cycle activity 
(Chapter 5). Since normal oxidation rates of pyruvate in leukocytes or 
fibroblasts do not exclude possible aberrations in the metabolism of 
pyruvate in other cells, the determination of enzyme activities in homo-
genates of liver and muscle tissue remain necessary. Investigations on 
pyruvate oxidation and citric acid cycle activity in rat liver and muscle 
tissue are described in Chapter 6. Some data concerning human liver 
and muscle tissue are also presented. Defects in the gluconeogenesis 
cannot yet be demonstrated in leukocytes. Chapter 7 concerns with 
pyruvate carboxylase in liver tissue from rat and human origin. 
The use of pyruvate as substrate in experiments requires some pre-
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cautions to prevent non-enzymic conversion of pyruvate in aqueous 
solution. The entity of the product and its influence on metabolic 
studies are reported in Chapter 8. 
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Screening: clinical symptoms 
Determination of the concentration 
of lactate, pyruvate, ketoacids, 
amino acids and organic acids 
In vivo function tests 
Measurement of the pyruvate 
oxidation rate and citric acid cycle 
activity in leukocytes and fibroblasts 
Determination of the activity of enzymes 
of metabolic pathways in liver or muscle 
tissue 
Studies in isolated mitochondria. 
Measurement of mitochondrial 
respiratory capacities or determination 
of the concentration of cytochromes 
Chapter 1. 
Pyruvate utilization 
1.1 Introduction 
This Chapter presents a review about the metabolism of pyruvate. 
The elucidation of disorders of pyruvate metabolism requires a detailed 
knowledge of the normal metabolism of this compound. 
Pyruvate has a key position in carbohydrate metabolism as is visible 
from the scheme, presented on the inner cover of this thesis. This scheme 
shows the main metabolic pathways of carbohydrates, fatty acids and 
ketoacids in liver and muscle. No information can be obtained from it 
concerning the flow rates through these pathways in various metabolic 
conditions. Neitherdoes it give information about the spatial organization 
of these processes in various cell types. 
Pyruvate is generated from glucose, lactate and some gluconeogenic 
aminoacids (alanine, serine). Pyruvate can be converted into acetyl-
CoA, which can serve as a precursor for the synthesis of citrate, ketone 
bodies and fatty acids. The oxidation of acetyl-CoA through the citric 
acid cycle is the most important pathway of acetyl-CoA. Furthermore, 
pyruvate can be converted into oxaloacetate in liver, kidney and brain. 
This chapter gathers some information on the enzymes pyruvate 
dehydrogenase and pyruvate carboxylase and their regulation. More-
over, the interaction between these two pyruvate converting enzymes 
is described. The operation of the citric acid cycle is discussed with 
respect to pyruvate oxidation. Transport of various compounds across 
the mitochondrial membrane is an important factor in the regulation of 
intermediary metabolism, especially that of pyruvate. At last the 
importance of the data presented in this chapter is discussed in relation 
to disturbances in pyruvate metabolism. 
1.2. Pyruvate dehydrogenase 
The conversion of pyruvate to acetyl-CoA catalyzed by the pyruvate 
dehydrogenase complex (EC 1.2.4.1.) serves both bioenergetic and 
biosynthetic roles. In many tissues including (heart) muscle, brain and 
kidney, acetyl-CoA is almost exclusively metabolized through the citric 
acid cycle while in other tissues such as adipose tissue, mammary gland 
and liver a significant proportion is utilized for synthesis of fatty acids 
and sterols. Acetyl-CoA cannot be used as a source of carbohydrate in 
animals and man since the conversion of pyruvate by pyruvate dehydro-
genase is an irreversible step. 
The pyruvate dehydrogenase complex catalyzes in the presence of 
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lipoic acid, thiaminepyrophosphate (TPP) and Mg2* the overall reaction: 
Pyruvate + CoA-SH + NAD+ -* acetyl-CoA + C0 2 + NADH + H
+ 
The complex is composed of three enzymes: pyruvate dehydrogenase 
(E,), dihydrolipoate transacetylase (Έ2) and dihydrolipoate dehydroge­
nase (E3) (1). The composition and organization of the bovine heart and 
kidney complexes were studied by Linn et al. (1). 
The regulation of the mammalian pyruvate dehydrogenase complex 
was reviewed by Denton et al. (2) and Hucho (3). Some of the regula­
tory features of the human enzyme were reported by Stansbie (4). 
The pyruvate dehydrogenase complex is subject to end-product inhi­
bition by high ratios of acetyl-CoA/CoA-SH and NADH/NAD+. Inhibi­
tion of pyruvate oxidation in heart muscle oxidizing fatty acids, ketone 
bodies or acetate was ascribed to elevated tissue levels of acetyl-CoA 
(5). Addition of carnitine and carnitine acetyltransferase to remove any 
accumulated acetyl-CoA increased pyruvate dehydrogenase activity (6). 
A second way of regulation was studied by Linn et al. (7,8). The 
active complex 
{K
m
 for MgTPP = 0.005 mM) 
nonactlve complex 
ATP ADP 
Fig. 1.1. Summary of the properties of pyruvate dehydrogenase phosphate phos 
phatase and pyruvate dehydrogenase kinase. The phosphatase is activated by Mg2'1 
and/or Ca2+ and inhibited by F" ions. The kinase is activated in the presence of 
acetoin and inhibited by pyruvate, dichloroacetate, ADP, TPP 
MgJ* concentrations (Hucho (3)). 
РР ; > Ca
2+
 and high 
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pyruvate dehydrogenase complex from a number of mammalian sources 
could exist in an active non-phosphorylated and an inactive phos-
phorylated form; interconversion of the two forms was catalyzed by 
pyruvate dehydrogenase phosphatase and the ATP-requiring pyruvate 
dehydrogenase kinase (4,8"~12). Many inhibitors and activators of the 
phosphatase and kinase were identified (Fig. 1.1.). The amount of the 
active form of pyruvate dehydrogenase was correlated with the intra-
mitochondrial ATP/ADP ratio, which seemed to be one of the most 
important factors controlling interconversion of the enzyme (13). Fatty 
acids may decrease the ratio of the active to the inactive form of 
pyruvate dehydrogenase by the increase of the ATP/ADP ratio (14,15). 
Taylor et al. (16) presented, however, data that octanoate inactivated 
pyruvate dehydrogenase in rat liver mitochondria without a change in 
the ATP/ADP ratio. This was interpreted as being due to the action of 
other factors, e.g. mitochondrial NADH/NAD+ or acetyl-CoA/CoA-SH 
ratios, on the interconversion of pyruvate dehydrogenase (17—19). Thus, 
the ATP/ADP ratio is not the sole regulatory parameter but the 
NADH/NAD+ and acetyl-CoA/CoA-SH ratios are of primary importance 
in the regulation of the interconversion of pyruvate dehydrogenase 
between its active and inactive forms (18). 
Pyruvate exerts its protective effect against phosphorylation of 
pyruvate dehydrogenase in the presence of fatty acids in a manner 
which depends on its concentration. In isolated rat liver mitochondria 
pyruvate may counteract the effect of acetyl-CoA and NADH on 
pyruvate dehydrogenase kinase (20—22). 
Increases in both acetyl-CoA/CoA-SH and NADH/NAD* ratio were 
shown to be inhibitory to the steady state activity of pyruvate dehydro-
genase. This effect was found at three different ATP/ADP ratios (23). 
Effects of acetyl-CoA/CoA-SH and NADH/NAD+ ratios may be additive 
but are still quantitatively less than the changes in activity of pyruvate 
dehydrogenase induced by changes in the ATP/ADP ratio (23). 
Hansford (24) showed that fatty acid oxidation leads to the inactiva-
tion of pyruvate dehydrogenase in isolated heart mitochondria, by 
changes in acetyl-CoA/CoA-SH and NADH/NAD+ ratios. An inhibition 
of the adenine nucleotide translocase was not a factor in pyruvate 
dehydrogenase inactivation in his experiments. ATP/ADP ratios were 
the same in the presence or absence of palmitoylcarnitine, which 
minimizes the importance of translocase inhibition (24). These data 
are not consistent with a recent report of Shrago et al. (25). Inhibition 
of adenine nucleotide translocase by low concentrations of palmitoyl-
CoA in mitochondria of liver and brain of the rat and a subsequent 
increase in the intramitochondrial ATP/ADP ratio could account for a 
decrease in the activity of pyruvate dehydrogenase (25). 
Portenhauser and Wieland (26) concluded that both the ATP/ADP 
and the NADH/NAD+ ratios are involved in the regulation of pyruvate 
dehydrogenase interconversion in rat heart mitochondria. 
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In the human being the pyruvate dehydrogenase complex is also 
regulated by a phosphorylation-dephosphorylation cycle and the 
properties of its kinase and phosphatase are essentially similar to those 
of the other mammalian complexes studied (4). 
1.3. Pyruvate carboxylase 
Pyruvate carboxylase (EC 6.4.1.1.) catalyzes a key reaction in inter­
mediary metabolism (27,28): 
acetyl-CoA 
Pyruvate + ATP + C 0 2 »-oxaloacetate + ADP + Pi Mg2 
Several possibilities for the regulation of pyruvate carboxylase activity 
have been proposed. Acetyl-CoA is an allosteric activator of this enzyme 
and therefore a candidate for a metabolic regulator (29). However, it is 
not clear whether changes in the intramitochondrial concentration of 
acetyl-CoA, occurring under different metabolic conditions, are within 
the K
a
 range of acetyl-CoA for the enzyme. Chicken liver pyruvate 
carboxylase exhibits an absolute requirement for activation by acyl-
CoA (30), but the enzyme purified from rat liver and sheep kidney 
cortex catalyzes oxaloacetate synthesis at a significant rate in the 
absence of acetyl-CoA (31—33). Significant differences are observed 
between mammalian and avian liver enzymes with respect t o the K
a 
value for acetyl-CoA (30). Stucki et al. (34) did not find a dependence 
of pyruvate carboxylation on intramitochondrial changes in acetyl-CoA 
concentrations in intact rat liver mitochondria. An inhibition of pyru­
vate carboxylase can be correlated with a decrease in the intramito­
chondrial ATP/ADP ratio (34—38). These results are in agreement with 
other studies of other investigators (36—38), who found that the 
purified pyruvate carboxylase is regulated by the MgATP/MgADP ratio. 
The sensitivity of pyruvate carboxylation towards the ATP/ADP ratio 
is greater at higher acetyl-CoA concentrations than at lower values (39). 
Barriti et al. (28) found a mitochondrial K
a
 value of 320 μΜ for acetyl-
CoA in chicken liver mitochondria which is much higher than the K
a
 of 
13 μΜ for the isolated enzyme (28). 
Beside the intramitochondrial ATP/ADP ratio also other factors 
influence the binding of acetyl-CoA to the isolated enzyme of rat liver 
(40). Acetyl-CoA may also be bound to other proteins (28). Calculations 
of the theoretical amount of acetyl-CoA that could be bound to proteins 
of the mitochondrial matrix indicate that a significant proportion of 
the total acetyl-CoA is likely present in the bound form. This would 
result in a concentration of free acetyl-CoA lower than the observed 
total intramitochondrial acetyl-CoA concentration (28). 
There is furthermore increasing evidence for a heterogenity of the 
mitochondria in the liver. It has been postulated (40) that the distribu-
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tion of acetyl-CoA and pyruvate carboxylase may not be equal in all 
mitochondria. An elevation of total intramitochondrial acetyl-CoA by 
the addition of fatty acids only leads to an activation of pyruvate 
carboxylase at low but not at high acetyl-CoA levels (39). 
Pyruvate carboxylase is presumably located in the mitochondria of 
liver (41,42). Dugal (43) reported, however, the existence of significant 
quantities of extramitochondrial pyruvate carboxylase in rat liver. 
Recently Spydevold et al. (44) reported the existence of pyruvate 
carboxylase activity in skeletal muscle. 
1.4. Regulation of pyruvate dehydrogenase and pyruvate carboxylase 
Two enzymes, pyruvate dehydrogenase and pyruvate carboxylase 
occupy a central position in determining the direction of pyruvate flow. 
The relative activities of both enzymes determine whether pyruvate 
serves as a carbon source of glucose or it is catabolized. Metabolic 
conditions which stimulate pyruvate carboxylation e.g., oxidation of 
fatty acids, generally inhibit pyruvate oxidation (26, 45). The intra-
mitochondrial concentrations of acetyl-CoA and NADH raise during 
fatty acid oxidation, which inhibits the pyruvate dehydrogenase com-
plex. The formed acetyl-CoA is required for optimal activity of 
pyruvate carboxylase. 
Another possible regulatory parameter is the intramitochondrial 
concentration of pyruvate in liver. The apparent Km of pyruvate 
carboxylase for pyruvate is about 0.4 mM in rat liver (35), whereas 
the apparent K m of the pyruvate dehydrogenase complex in rat liver 
tissue for pyruvate is about 0.04 mM (8). This marked difference in the 
apparent K m values of the two enzymes for pyruvate would tend to 
favour pyruvate oxidation at low levels of pyruvate (< 0.1 mM) and 
pyruvate carboxylation at high levels (> 1 mM). 
A third parameter is the intramitochondrial ATP/ADP ratio. The 
results of Walter (46) demonstrate that the ATP/ADP ratio inside the 
mitochondria regulates the two enzyme activities in the opposite 
manner. A high ratio stimulates pyruvate carboxylation and inhibits 
pyruvate oxidation; at low ratios of ATP/ADP the effects are reversed. 
1.5. Regulation of the citric acid cycle 
The identification of regulatory enzymes of the citric acid cycle is 
still a great problem. In view of the metabolic complexity it is not 
surprising that little is known about the mechanisms which control the 
flow rates through the various segments of the cycle. The citric acid 
cycle activity may also regulate the rate of pyruvate oxidation. Dis-
turbances in the citric acid cycle such as a deficiency of one of its 
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enzymes or an impaired oxidation of reducing equivalents may result 
in a decrease of the pyruvate oxidation rate. 
In tissues capable of both biosynthetic and energy generating activities 
such as liver, one of the crucial points for metabolic regulation is at the 
level of acetyl-CoA. The citrate synthase reaction of the citric acid cycle 
has been implicated as the switch for the entry of acetyl units into the 
citric acid cycle or, alternatively, into the ketogenic sequence (47). The 
rate of citrate synthesis depends on the level of citric acid cycle inter­
mediates m the extramitochondrial space. In the presence of added 
malate, citrate synthesis is stimulated by the increased availability of 
oxaloacetate and ketogenesis is diminished (48). The intramitochondnal 
NADH/NAD* ratio is an important factor in the concentration of 
oxaloacetate. If the mitochondrial malate levels remain constant and 
malate dehydrogenase establishes equilibrium between its reactants, the 
increased NADH/NAD+ ratio in State 4 as compared with State 3 will 
effect a tenfold drop in the level of oxaloacetate (48), which causes an 
inhibition of citrate synthesis (49). La Noue et al. (50) have proposed a 
model of citric acid cycle regulation in which citrate synthase activity is 
controlled by the ratio acetyl-CoA/succinyl-CoA. Succinyl-CoA will 
only be an effective inhibitor of citrate synthase when its concentration 
rises well above the K, (130 μΜ) for this enzyme and when the acetyl-
CoA concentration approaches the K
m
 region (25 μΜ) (50). Therefore, 
regulation of citrate synthase activity by succinyl-CoA is achieved under 
conditions of high oxaloacetate and low acetyl-CoA availability in rat 
heart mitochondria (50). The flux through citrate synthase, however, 
measured with pyruvate and malate as substrates in rat heart mitochon­
dria and in various respiratory states, increases as the ratio ATP/ADP 
decreases, but this increased flux is not matched by an increase in the 
ratio acetyl-CoA/succinyl-CoA (51). Thus, these results provide no sup­
port for the concept of the control of citrate synthase by the ratio 
acetyl-CoA/succinyl-CoA, but are consistent with control of citrate 
synthesis by oxaloacetate availability. 
The regulatory role of ATP on citrate synthase was reported by 
Garland (52). The enzyme is inhibited in vitro by ATP and to a lesser 
extent by ADP and AMP. The inhibition is competitive with respect to 
acetyl-CoA (52). Thus, citrate synthase is an important parameter in 
the control of the citnc acid cycle This activity of this enzyme is con­
trolled by the availability of oxaloacetate, which depends among other 
things on the intramitochondrial redox state and the activity of the 
oxaloacetate producing enzymes. Moreover, citrate synthase activity 
depends on the ATP/ADP ratio. 
Citrate is converted into 2-oxoglutarate by the acomtase- and iso-
citrate dehydrogenase- catalyzed reactions. During transition of State 4 
into State 3 an activation at the level of isocitrate dehydrogenase was 
demonstrated in rabbit heart mitochondria (51). This finding is in agree­
ment with a conclusion reached by La Noue et al. (53) about control 
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at this locus. They (53) showed that isocitrate dehydrogenase is sensi-
tive to the oxidation-reduction state of nicotinamide nucleotides. There 
are two enzymes which catalyze the oxidative decarboxylation of iso-
citrate, NADMinked isocitrate dehydrogenase and NADPMinked iso-
citrate dehydrogenase (54). Especially the NADMinked enzyme is 
involved in the activity of the citric acid cycle (51). 
2-Oxoglu tarate is produced in the citric acid cycle by isocitrate 
dehydrogenase and by oxidative deamination of glutamate (55). It is 
also formed by transamination from glutamate as part of the malate-
aspartate shuttle (56) during transfer of reducing equivalents from the 
cytosol to the mitochondria. Operation of this shuttle in heart, kidney 
and liver, requires efflux of 2-oxoglutarate from the mitochondria in 
exchange for malate on a specific carrier (57). Therefore, the 2-oxo-
glutarate dehydrogenase activity is controlled by isocitrate dehydro-
genase and glutamate dehydrogenase, both 2-oxoglutarate producing 
enzymes, and by the malate-aspartate shuttle, which is responsible for 
transport of 2-oxoglutarate out of mitochondria. The influence of the 
ATP/ADP ratio on the oxidation of 2-oxoglutarate was demonstrated 
by La Noue and Williamson (56) with rat heart mitochondria. Addition 
of oligomycin stimulates 2-oxoglutarate dehydrogenase in these mito-
chondria. Since ATP levels fell under these conditions the activation of 
2-oxoglutarate dehydrogenase was postulated to involve a lowering of 
succinyl-CoA levels (56). The concentration of the inhibitory compound 
succinyl-CoA can be regulated by substrate level phosphorylation via 
succinate thiokinase and GDP. A correlation between succinyl-CoA 
and ATP concentrations was demonstrated (6). 
Kinetic studies with purified 2-oxoglutarate dehydrogenase of rat 
liver established that succinyl-CoA is a competitive inhibitor of the 
enzyme with respect to CoA-SH (58). Neither ATP nor GTP was 
observed to have a direct effect on this enzyme (58). 
The activity of succinate dehydrogenase is not rate limiting in the 
citric acid cycle, although the enzyme varies in response to the meta-
bolic state of the mitochondria (59, 60). 
This paragraph shows that the most important sites for regulation of 
the citric acid cycle activity are located at three enzymes of this cycle: 
citrate synthase, isocitrate- and 2-oxoglutarate dehydrogenase. The 
regulation of the cycle depends furthermore on the mitochondrial redox 
state. 
1.6. Anion transport across the mitochondrial membrane 
The inner mitochondrial membrane provides a permeability barrier 
to free diffusion of ions between cytosol and the mitochondrial matrix 
(61). Anion transport is thus a consequence of compartmentation of 
functions between the mitochondria and cytosol. Hence the possibility 
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exists that under conditions of in vivo metabolism, the transport of 
metabolites across the mitochondrial membrane participates in the 
overall regulation of fluxes through metabolic pathways such as pyru-
vate dehydrogenase, pyruvate carboxylase and citric acid cycle. 
Translocators or carriers specifically facilitate the passage of meta-
bolites through the mitochondrial inner membrane. Defects or modula-
tion of transport may influence cellular and especially mitochondrial 
metabolism. All known mitochondrial anion translocators bring about 
a one to one exchange of intramitochondrial for extramitochondrial 
anions. Table 1.1. shows the translocators, which are known at the 
moment. Reviews concerning these translocators with their regulatory 
properties were given by Meyer and van Dam (70) and by Williamson 
(71). 
Table 1.1. 
ANION TRANSLOCATORS ACROSS THE MITOCHONDRIAL MEMBRANE 
Translocators Anion exchange Reference 
Adenine nucleotide 
Glutamate-aspartate 
Phosphate 
Glutamate 
Pyruvate 
Tricarboxylate 
Dicarboxylate 
2-Oxoglularate 
ADP 
glutamate 
phosphate 
glutamate 
pyruvate 
malate 
malate 
malate 
Í -
^ 
^ 
±Ϊ 
^ 
^ 
• ^ -
-
ATP 
aspartate 
hydroxyl 
hydroxyl 
hydroxyl 
citrate 
phosphate 
2-oxoglutarate 
Vignaiset al. (62) 
La Noue and Tischler (63) 
Johnson and Chapell (64) 
Brouweretal. (65) 
Halestrap (66) 
Chuma-Dhalii and Halperin 
(67) 
Palmieri et al. (68) 
Sluseetal .(69) 
The specificity of the transport process of pyruvate has been a matter 
of debate. Papa et al. (72) claimed that the presence of a specific trans-
locator on the basis of accumulation experiments. Later critisism on 
this claim by Zahlten et al. (73) was shown to be invalid by Brouwer 
et al. (65). The specific inhibition of pyruvate transport by 2-cyano-4 
hydroxycinnamate indicates the presence of a specific mechanism of 
pyruvate transport (74). The uptake is either a pyruvate/hydroxyl or a 
pyruvate/dicarboxylate exchange (75). 
Certain anion translocators are fundamental for mammalian metab­
olism. The most important one is the transport of reducing equivalents 
from the cy tosol to mitochondria and vice versa. Two major mechanisms 
have been elucidated. These are the malate-aspartate shuttle (56) and 
the 2-glycero-phosphate shuttle (71), depicted schematically in Fig. 1.2. 
Transport of various anions across the mitochondrial membrane is an 
obligatory step in nearly all the biosynthetic pathways of liver metab­
olism. For instance, since pyruvate carboxylase is a mitochondrial 
enzyme, the product of this reaction, oxaloacetate should be trans­
ported out of the mitochondrion in those cases, in which phosphoenol-
pyruvate carboxykinase is located exclusively in the cytosol. However, 
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oxaloacetate is transported very slowly across the mitochondrial 
membrane at physiological concentration (76, 77). The efflux of oxalo­
acetate from the mitochondria is unable to compete kinetically with 
the alternative processes of malate and aspartate formation and efflux 
of these anions from the mitochondria (78). Transport of malate and 
aspartate into the cytosol is obligatory for gluconeogenesis from 3-carbon 
precursors such as lactate, pyruvate and alanine, when phosphoenol-
pyruvate carboxykinase is mainly located in the cytosol, such as in rat 
liver (78). In rabbit and pigeon liver, phosphoenolpyruvate carboxy­
kinase is mainly located in the mitochondria (79), and efflux of phos­
phoenolpyruvate out of the mitochondria is obligatory for gluconeo­
genesis. The transport of phosphoenolpyruvate can be mediated by 
either the tricarboxylate carrier or by the adenine nucleotide trans-
locator (70). In guinea pig (79) and man (80) both cytosolic and mito­
chondrial phosphoenolpyruvate carboxykinase are present. 
1.7. Concluding remarks 
The knowledge of mechanisms involved in the regulation of pyruvate 
dehydrogenase is necessary to establish disturbances and defects in 
Hydrogen Transport Shuttles 
Cytoplasm 
ASf H 
OAA a K G * -
^ —«-Mai-CT INADHI NAO 
DAP aGP 
^ ^ 
^ 
^ . 
Mitochondria 
-OAA-
NAD 
•Mol-
Fp—»Cyt b—»-Cytc.Ci —•Cyta.aj -0
г 
Fig. 1.2. Schematization of transport of reducing equivalents from cytosol to mito­
chondria by way of the malate-aspartate and α-glycerophosphate shuttles. Abbre­
viations: Glu, glutamate; Asp, aspartate; OAA, oxaloacetate; α-Kg, 2-oxoglutarate; 
Mal, malate; DAP, dihydroxyacetonephosphate; α-GP, α-glycerophosphate 
(Williamson (71)). 
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pyruvate oxidation. The ratios, NADH/NAD+, acetyl-CoA/CoA-SH and 
ATP/ADP are recognized as important factors in pyruvate oxidation. 
However, relatively little is known at least at the physiological level 
about the importance of each ratio with respect to each other. The 
human pyruvate dehydrogenase complex is regulated among other 
things by a phosphorylation-dephosphorylation cycle and the properties 
of its kinase and phosphatase are essentially similar to those of the 
other mammalian complexes studied (4). Deficiencies of each of the 
components of the pyruvate dehydrogenase complex except pyruvate 
dehydrogenase kinase are known nowadays (see Chapter 2). 
The activity of pyruvate carboxylase is correlated to the acetyl-
CoA/CoA-SH and the ATP/ADP ratio in liver tissue. A close resemblance 
exists between the catalytic and effector properties of human and rat 
liver pyruvate carboxylase (81). The distribution of this enzyme in rat-
and human liver is also identical (80). Differences have been established 
between these two species with respect to the intramitochondrial 
distribution of phosphoenolpyruvate carboxykinase. 
The NADH/NAD* ratio strongly influences the rate at which the 
citric acid cycle operates. This ratio can exert its effects in mammalian 
tissue on three points of regulation in the cycle: citrate synthase, 
isocitrate dehydrogenase and/or 2-oxogIutarate dehydrogenase. Little 
is known about the regulation of the citric acid cycle in human tissue. 
Defects in the respiratory chain result in an increase of the intramito-
chondrial NADH/NAD+ ratio, which causes a diminished activity of 
the citric acid cycle and/or malate-aspartate shuttle. 
A review of disturbances in pyruvate metabolism, which are known 
at the moment, is given in Chapter 2. 
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Chapter 2. 
Hyperlactacidemia 
2.1. Introduction 
The principal sources of lactate entering the circulation under nor-
mal circumstances are skin, erythrocytes, brain, skeletal- muscle and 
intestinal mucosa (1,2); under some conditions, liver (3) and kidney 
may also be additional sources of lactate. The principal sites of lactate 
removal are the liver, the kidney and skeletal muscle (4). 
The liver readily utilizes lactate both as an oxidative substrate and as 
a gluconeogenic precursor. The velocity of lactate utilization by the 
liver increases if delivery of lactate to the liver augments (5). However, 
when a large increase in plasma lactate occurs, e.g. following strenuous 
exercise, the majority of lactate is not removed by the liver, but by 
extrahepatic oxidation in resting muscle, heart and brain (6, 7). The 
hepatic removal of lactate via oxidation or gluconeogenesis could be 
completely inhibited through lowering of pH of the perfusate in iso-
lated perfused rat liver (8). Hepatic dysfunction was claimed to play an 
essential role in the development of lactic acidosis. Perret et al. (9) 
demonstrated significant hepatic pathology in a series of cases with 
lactic acidosis with lactic acid concentration in the hepatic vein exceeding 
the arterial blood. 
The kidney is an important organ for removal of lactate mainly by 
its capacity for gluconeogenesis. Acidosis and potassium depletion 
stimulate renal gluconeogenesis from lactate and other substrates (10). 
Recent studies suggest that the contribution of renal gluconeogenesis 
to overall lactate removal is considerable (11). 
Lactate is normally produced by skeletal muscle at rest and to a 
greater extent during muscle stimulation (12). Exercizing and resting 
skeletal muscle as well as myocardium play an important role in the 
oxidative disposal of lactate. Lactate uptake appears to be a function 
of the arterial lactate concentration (1). Lactate, generated during 
muscle exercise is removed, for about 50 percent through skeletal 
muscle and heart (oxidation), for about 20 percent through kidney 
(oxidation and gluconeogenesis) and brain (oxidation) and for about 
30 percent through liver (oxidation and gluconeogenesis) (7). 
Elevated serum lactate concentrations (hyperlactacidemia) are found 
with or without concomittant metabolic acidosis. Lactic acidosis is 
defined by Oliva (13) as a state of metabolic acidosis (pH < 7.37) with 
the blood concentration of lactate > 2.0 mM. As a better definition of 
lactic acidosis we would propose a state of metabolic acidosis charac-
terized by a lowered value of base excess with a blood concentration of 
lactate > 2.0 mM. The pH value on itself is an incorrect parameter for 
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the metabolic acidosis. 
An increase in lactate concentration may occur with or without an 
alteration of the L/P ratio. The blood L/P ratio does not always reflect 
the tissue NADH/NAD+ ratio. An increase in intracellular hydrogen ion 
concentration may alter the L/P ratio independent of the NADH/NAD+ 
ratio in the cytoplasm as can be seen in equation 1 (14). 
(Lactate) (NADH). (H*) 
(Pyruvate)" ' (NAD+) 
К = equilibrium constant 
There are indications that blood lactate does not always equilibrate with 
cytosolic lactate. Consequently, blood L/P and tissue L/P ratios do not 
necessarily always change in the same direction (15). The free NADH/ 
NAD+ ratio in the mitochondria can be calculated from the 3-hydroxy-
butyrate/acetoacetate ratio. This ratio can be altered by change of the 
intramitochondrial hydrogen ion concentration. 
2.2. History 
The study of Cannon (16) established that circulatory failure could 
be an important factor in the pathogenesis of metabolic acidosis. The 
recognition that lactic acid was the organic acid whose accumulation was 
responsible for some cases of metabolic acidosis, became evident when a 
chemical method for its estimation was available. Barr and Himwich (17) 
who investigated the physiology of muscular exercise in man showed that 
the metabolic acidosis which followed strenuous exercise was due to lactic 
acid. These authors called this condition 'lactic acid acidosis'. The de­
monstration that lactic acid accumulation could contribute to ametabolic 
acidosis occurring as a complication of illness was made by Clausen (18). 
He described a metabolic acidosis characterized by lactate accumulation 
in children who were dehydrated as a result of diarrhoea. 
The recent revival of interest in lactic acidosis stems from the work 
of Huckabee, who brought lactic acidosis into clinical perspective 
through an analysis of the causes of an elevated blood lactate concentra­
tion in thirty-seven patients and drew attention to the entity of spon­
taneous lactic acidosis (19, 20). Huckabee carried out a systematic 
study of lactate and pyruvate concentrations in the blood of patients 
who had a wide variety of illnesses. During the last fifteen years there 
has been an increasing interest in lactic acidosis as a manifestation of 
disordered intermediary metabolism and it has been realized that abnor­
malities of lactate metabolism may occur as congenital disorders. 
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2.3. Nonhereditary lactacidemia 
Elevateci blood lactate levels are found in a variety of conditions with 
or without concomittant metabolic acidosis. The most common cause 
of lactic acidosis appears to be phenformin toxicity (3). 
An enumeration of conditions associated with elevated blood lactate 
levels is given in Table 2 .1 . An extensive classification and discussion 
concerning these different forms of lactacidemia can be found in 
'Clinical and biochemical aspects of lactic acidosis' by Cohen and 
Woods (3). 
Table 2.1. 
CONDITIONS ASSOCIATED WITH ELEVATED 
LEVELS OF LACTATE IN BLOOD 
1. Infusion of: 
Pyruvate 
Glucose 
Fructose 
NaHCO, 
2. Transfusion of stored blood 
3. Hyperventilation 
4. Exercise 
5. Acute hypoxemia 
6. Adrenaline administration 
7. Various disorders. 
Diabetes mellitus 
Circulatory shock: septicemia 
Malignancy: e.g. acute leukemia, Hodgkin's disease 
Severe anemia 
8. Ingestion of drugs or toxic substances: 
Phenformin 
Ethanol 
2.4. Hereditary lactacidemia 
Hereditary lactacidemia with or without acidosis in childhood is rare. 
Many different metabolic disorders with lactacidemia, however, have 
been described. 
The description of Hartmann et al. (21) of a child with prolonged 
metabolic acidosis due to lactate accumulation drew attention of pedia-
tricians to this disorder as a cause of continuing disability. Descriptions 
of other children with chronic lactic acidosis resulting from a number of 
different causes were described in the next few years. Many of these 
reported cases were not studied according to the current biochemical 
methods. In Table 2.2. the physical signs and in Table 2.3. the main 
clinical features of these patients are summarized. 
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Table 2.2. 
PHYSICAL SIGNS AND SYMPTOMS IN 23 
CASES OF CONGENITAL IDIOPATHIC LAC-
TIC ACIDOSIS. (Israels et al. (22)). 
Symptom 
Tachypnoe 
Convulsions 
Vomiting and/or growth failure 
Muscular hypotonia 
Disturbances of consciousness 
Table 2.3. 
No. Cases 
15 
6 
6 
4 
4 
MAIN CLINICAL FEATURES IN 23 CASES OF CONGENITAL 
IDIOPATHIC LACTIC ACIDOSIS (Israels et al. (22)). 
Clinical Feature 
Mental retardation 
Muscular hypotonia 
Convulsions 
Obesity 
Other neurologic signs 
Growth failure 
Hepatomegaly (with or without splenomegaly) 
Hypoglycemia 
Eye abnormalities 
Down's syndrome, osteoporosis, 
melena 
anemia, hematemesis, 
No. Cases 
16 
14 
12 
6 
6 
5 
7 
2 
2 
1 each 
The review of Israels et al. (22) discussed these early described dis-
orders associated with chronic lactic acidosis in childhood. This chapter 
will describe the inborn errors of lactate metabolism, in which an enzyme 
deficiency was demonstrated. 
2.4.1. Defects in pyruvate oxidation 
2.4.1.1. Pyruvate dehydrogenase complex 
The clinical course in all the patients, described with a deficiency in 
the pyruvate dehydrogenase complex, is different. 
A partial deficiency of pyruvate dehydrogenase has been reported in 
two unrelated patients with intermittent ataxia (23—25). The activity 
of pyruvate dehydrogenase was measured with a radiochemical assay 
using (l-14C)pyruvate with ferricyanide as electron acceptor in sonicated 
fibroblasts and in muscle homogenate. The activity was less than 
30 percent of that of controls. A similar defect was demonstrated in the 
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oxidation of pyruvate in white blood cells of one patient (24). Therapy 
with high doses of thiamine seemed to be associated with improvement 
inintelligence and coordination in the patient described by Lonsdale (23). 
An other case has been described by Willems et al. (26). A boy, with 
mental and motor retardation, microcephaly and severe hypotony 
showed a deficiency of pyruvate dehydrogenase in liver homogenate. In 
contrast to the findings of Blass et al. (24) anormal oxidation of [1-14C]-
pyruvate and [2-14C] pyruvate was observed in leukocytes and 
fibroblasts. This case is described in more detail in Chapter 9. 
An infant who was born after 35 weeks of gestation (birth weight 
1320 g) showed rapid respirations and several abnormal neurological 
signs during the first days of life (27). In homogenates of liver and brain 
obtained post-mortem, these was no measurable activity of pyruvate 
dehydrogenase, due to a deficiency of the first enzyme (Ei ) of pyruvate 
dehydrogenase complex. 
An infant suffering from metabolic acidosis attributable to hyper-
lactacidemia accompanied by hyperalaninemia and hyperserinemia was 
described by Strömme et al. (28). Intact fibroblasts of the patient 
showed 5—17 percent of the activity of pyruvate dehydrogenase as 
compared to fibroblasts of controls. Enzyme studies with sonicates of 
fibroblasts revealed a deficiency of pyruvate dehydrogenase complex 
(8 percent of normal). This error was localized to the first unit of the 
complex (Ei). Detailed studies, using gas-chromatography and mass-
spectrometry, of the urinary organic acids revealed markedly increased 
levels of lactate and pyruvate, 2-oxoglutaric, malic, isocitric, 2-hydroxy-
glutaric, fumarie, succinic and glyceric acid and a reduced citric acid 
excretion (29). The explanation of the increased excretion is rather a 
matter of speculation. 
Haworth et al. (30) described a family in which three of the children 
were mentally retarded, had seizures and other neurological abnor-
malities. Enzyme assays revealed a low level of activity of both the 
pyruvate and 2-oxoglutarate dehydrogenase complexes in disrupted 
cultured fibroblasts. However, activity measured in the ferricyanide-
linked assay for pyruvate decarboxylase (Ei) was not different from 
controls. In another case, a 9-years old boy with severe mental and 
growth retardation and diffuse neurological damage, the activity of 
the pyruvate dehydrogenase complex in disrupted fibroblasts was 
about 15 percent of that of controls but the activity of pyruvate 
decarboxylase and the 2-oxoglutarate dehydrogenase complex was 
normal (31). Intact cultured skin fibroblasts oxidized (l-14C)pyruvate 
and (2-14C)pyruvate to 14C02 at a significantly lower rate than control 
cells (16 percent and 30 percent, respectively). The data in the first 
family are consistent with an inherited defect in the third enzyme of 
the pyruvate dehydrogenase complex, in the second patient with an 
inherited defect in the second enzyme. Sakurai et al. (32) has shown 
that the third enzyme of the pyruvate dehydrogenase complex is the 
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same protein as the third enzyme of 2-oxoglutarate dehydrogenase 
complex from pig heart. 
Robinson and Sherwood (33) reported a male infant with congenital 
lactic acidosis in whom investigation of tissue, obtained after his death 
at 6 months of age did suggest a defect in the phosphorylation/dephos-
phorylation mechanism controlling the activity of the pyruvate dehydro-
genase complex. This defect was attributed to a markedly reduced 
activity of pyruvate dehydrogenase phosphatase. Although the pyruvate 
dehydrogenase phosphatase was lowered, a normal activity of pyruvate 
dehydrogenase was found. This discrepancy and the observed lactic 
acidosis in this patient remain to be explained. 
The possibility of dietary treatment of patients suffering from a 
deficiency of pyruvate dehydrogenase was stressed by Falk et al. (34) 
and Cederbaum et al. (31). When the patients ate a diet high in fat to 
cause ketonemia, there was a fall in blood pyruvate and a decrease in 
the frequency and severity of episodes of neurological deterioration. 
Acetyl-CoA derived from the oxidation of fatty acids enters the citric 
acid cycle distal to the pyruvate dehydrogenase step. The patients 
deteriorated clinically on a high carbohydrate diet. 
Abnormalities of pyruvate metabolism have been found in the muscle 
of several patients with Friedrich's ataxia (35, 36). Kark et al. (36) 
reported low levels of the pyruvate dehydrogenase and the 2-oxo-
glutarate dehydrogenase complex in cultured fibroblasts. The activity 
was 43 percent and 50 percent, respectively, of those in controls. This 
residual activity is higher than in the other cases described above. 
Recently, 47% of control activity of the third step in the pyruvate 
dehydrogenase and 2-oxoglutarate dehydrogenase complex was shown 
in disrupted skin fibroblasts of patients suffering from Friedrich's 
ataxia (37). 
A partial defect of pyruvate dehydrogenase in fibroblasts in a patient 
suffering from subacute necrotizing encephalomyelopathy (Leigh's 
disease) was described by Farmer et al. (38) and in two other patients 
reported by Blass et al. (39). Oka et al. (40) reported clinical improve-
ment in a patient with a pyruvate dehydrogenase deficiency by the oral 
administration of citrate. Citrate was administered in order to restore 
the activity of the citric acid cycle. 
Cerebellar ataxia is one of the most prominent symptoms of patients 
with pyruvate dehydrogenase deficiency. Reynolds and Blass (41) were 
able to demonstrate that pyruvate oxidation was impaired in the cere-
bellum by deficiencies of pyruvate dehydrogenase too mild to affect 
pyruvate oxidation in the other areas of the brain they examined. 
2.4.1.2. Citric acid cycle 
Blass et al. (42) studied a patient with a severe diffuse neurologic 
disease. Studies of fibroblasts of this patient showed a defect in the 
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conversion of radioactive pyruvate, palmitate and citrate to 1 4 C 0 2 . The 
activity of the thiamine-dependent, first enzyme of the pyruvate dehy­
drogenase complex was within normal limits. The patient, a child of 
consanguineous parents, appeared to have a partial genetic defect affect­
ing the tricarboxylic acid cycle and presumably the second or third 
enzyme of the pyruvate dehydrogenase complex. A further biochemical 
study of this patient is eagerly required. 
Several patients with a deficiency of 2-oxoglutarate dehydrogenase 
were described in the preceding paragraph. 
2.4.1.3. Respiratory chain 
An increasing number of patients have been reported with a defect in 
biological oxidation. Luft et al. (43) and Afifi et al. (44) reported two 
patients with the triad of hypermetabolic state, myopathy and abnor­
mal muscle mitochondria. Mitochondrial respiration was loosely coupled 
with phosphorylation. Other cases showing loosely coupled oxidative 
phosphorylation, have been demonstrated. However, none of them 
showed clinical hypermetabolism (45—47). Mackler et al. (48) found a 
decreased oxidative phosphorylation possibly caused by a defect in the 
first phosphorylation site in human achondroplasia. 
Two siblings with extreme stunting of growth and severe mental 
retardation revealed elevated lactate and normal pyruvate levels. The 
mitochondria failed to utilize 3-hydroxybutyrate, glutamate or malate. 
A failure of oxidation of NADH was suggested (49). 
Reports concerning proven defects in the respiratory chain itself are 
rare. Spiro et al. (50) described a marked reduction in the cytochrome b 
content in isolated muscle mitochondria. In this report the figure of the 
cytochrome difference spectrum could hardly be judged because of the 
dominating contamination with hemoglobin or myoglobin of the mito­
chondrial preparation. 
Studies of brain, liver and muscle tissue of an infant suffering from 
the cerebro-hepato-renal syndrome pointed to a defect between the 
succinate dehydrogenase flavoprotein and coenzyme Q (51). 
Two sisters with a mitochondrial myopathy associated with chronic 
lactic acidemia, growth failure and nerve deafness were described by 
Hackett et al. (52). Studies on isolated mitochondria revealed a defi­
ciency of cytochrome с oxidase in muscle tissue in a similar patient (53). 
A patient suffering from a disease similar to the cerebro-hepato-renal 
syndrome was extensively studied by Versmold et al. (54). Mitochondria 
showed normal succinate and glutamate respiration, and normal coupling 
of respiration to phosphorylation. The cytochrome content was dimin­
ished to one-third. Nocatalase was found. An abnormally inversed redox 
pattern of the respiratory chain in the controlled state was present. The 
authors could not explain the relationship between the observed 
peroxisomal (catalase) and mitochondrial (cytochromes) defects. More-
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over, the observations of a normal glutamate and succinate oxidation in 
the presence of ADP in coupled mitochondria and the normal lactate 
concentration in blood are in contradiction with a severe defect in the 
respiratory chain. 
A child with a Detoni-Fanconi-Debré syndrome and a defective 
respiratory chain in voluntary striated muscle was described recently 
(55). Cytochrome ааз and b were absent, but cc! content was normal. 
In heart muscle cytochromes ааз and b were normal. An extensive 
report of this patient can be found in Chapter 9. 
A patient with subacute necrotizing encephalomyelopathy associated 
with a disorder of mitochondrial oxidation was studied by Willems et 
al. (56). A cytochrome с oxidase deficiency was shown in peripheral 
muscle tissue with some residual cytochrome с oxidase activity in heart 
muscle. More details and discussion concerning this case are given in 
Chapter 9. 
2.4.2. Defects in gluconeogenesis 
2.4.2.1. Pyruvate carboxylase 
A deficiency of pyruvate carboxylase was reported for the first time 
by Hommes et al. (57) in a patient with Leigh's disease proven by 
autopsy. In liver tissue an almost complete absence of this enzyme could 
be demonstrated. It was suggested that the syndrome of Leigh could be 
due to alack of pyruvate carboxylase. Therapeutic approaches consisted 
of administration of lipoic acid which causes a fall in the blood lactate 
and pyruvate levels. 
The most prominent clinical and biochemical findings of patients 
with pyruvate carboxylase deficiency reported in the literature are 
presented in Table IV of Chapter 9 (Case 2). Additional patients were 
described by Maesaka et al. (58) and Saudubray et al. (59). 
Some findings in the described patients need more emphasis. A par­
tial deficiency of pyruvate carboxylase was described by Brunette et al. 
(60). The loss of activity was due to the absence of the low-K,,, com­
ponent of the enzyme which would metabolize pyruvate in the physio­
logical concentration (61). In normal liver tissue we were unable to 
detect more than one K
m
 value of the enzyme (Chapter 7). 
Neonatal congenital lactic acidosis with pyruvate carboxylase defi­
ciency in liver and kidney was demonstrated in two infants in one 
family. Hyperlactacidemia was associated with a dramatic increase in 
lactate/pyruvate ratio in contrast with a slightly decreased 3-hydroxy-
butyrate/acetoacetate ratio. This metabolic pattern was explained by a 
decreased oxaloacetate synthesis as a result of pyruvate carboxylase 
deficiency and impairment in redox shuttle (59). In our patient, how­
ever, the 3-hydroxybutyrate/acetoacetate ratio was normal (62, Chap­
ter 9, Case 2). 
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In an attempt to supply the Ca-dicarboxyhc acids, the formula was 
supplemented with L-glutamine and large doses of vitamine B6 to insure 
maximal rate of transamination (63). This resulted in chemical and bio-
chemical improvement (decrease of blood lactate and pyruvate). The 
same result was obtained by de Groot and Hommes (64) by the addi-
tion of aspartate to the diet. These authors and Tang et al. (63) suggested 
that a defect of pyruvate carboxylase would impair the tricarboxylic 
acid cycle due to oxaloacetate deficiency. 
Recently a patient with no symptoms of Leigh's disease and a pyru-
vate carboxylase deficiency was demonstrated (62). A complete report 
of this case can be found in Chapter 9 (Case 2). 
2.4.2 2. Phosphoenolpyruvate carboxykinase 
Two boys, who suffered from hypoglycemia and liver impairment, 
were described by Hommes et al. (65). Lactate, pyruvate, 3-hydroxy-
butyrate and acetoacetate levels reported in one patient were within 
normal limits. Assays of gluconeogenic enzymes in liver samples taken 
immediately after death demonstrated a deficiency of phosphoenol-
pyruvate carboxykinase. Massive fat deposition in liver and kidney was 
demonstrated. 
Fatty infiltration of liver and kidney was also found in a boy, who 
was suffering from severe, persistent hypoglycemia and who died at the 
age of 2 years and 10 months (66, 67) The total activity of phospho-
enolpyruvate carboxykinase was normal, but the enzyme showed an 
abnormal subcellular distribution, virtually no activity being detected 
in the extramitochondnal fraction of a liver homogenate. The observa-
tion of Vidnes et al. (66, 67) indicates that phosphoenolpyruvate 
carboxykinase should be measured both in the mitochondrial and extra-
mitochondrial compartment in study of patients suspect from a defect 
in gluconeogenesis. Autopsy revealed severe cerebral atrophy and 
atrophy of the optic nerve (66 -68). It may be noted that lactate and 
pyruvate concentrations were not elevated as in the case described by 
Hommes et al. (65). 
In the infant descnbed by Fiser et al. (69) mild lactacidemia was 
evident This infant was suffering from episodic hypoglycemia. A liver 
biopsy showed reduced levels of pyruvate carboxylase and markedly 
lowered levels of phosphoenolpyruvate carboxykinase. The low activity 
of pyruvate carboxylase was not explained by the authors 
2.4.2.3. Fructose-l,6-diphosphatase 
The symptoms of patients suffering from fructose-l,6-diphosphatase 
deficiency were descnbed by several authors (70—77). In five cases 
evidence of metabolic acidosis, hypoglycemia and hepatomegaly was 
documented within the first 48 houis of life. In three of the patients 
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significant hypotonia was also present. In each case, recurrent episodes 
of metabolic acidosis, fasting hypoglycemia, elevated lactate levels and 
ketonuria supported the diagnosis, which was confirmed on the basis of 
demonstration of FDPase deficiency in liver. Melancon et al. (78) 
suggested that measurement of FDPase activity in white blood cells 
could be an alternative for the diagnosis. The FDPase present in white 
blood cells appears to be identical with the enzyme found in liver and 
kidney. 
In addition to abnormalities of liver function, a marked still unex-
plained disturbance in aminoacid metabolism was described in a patient 
by Hülsmann et al. (71) and by Bakker et al. (76). 
2.4.2.4. Glucose-6-phosphatase 
Glucose-6-phosphatase deficiency also called type I glycogen storage 
disease, orvon Gierke's disease, is a metabolic defect in the glycogenolysis 
and gluconeogenesis (79). The symptoms appear manifest in the first 
year of life and consist of hepatomegaly, hypoglycemia, bouts of 
acidosis, hypertriglyceridemia, hyperuricemia and hypercholesterolemia. 
The acidosis is largely related to the accumulation of lactate and is 
evident in the fasting state. Administration of glucose after a fasting 
period decreases the lactate concentration in blood. No increase of the 
blood glucose concentration can be observed after injection of glucagon. 
Deficiency of glucose-6-phosphatase activity can only be demon-
strated in liver tissue, small intestine and kidney (79). 
2.4.3. Methylmalonic acidemia and propionic acidemia 
Both metabolic abnormalities are included in this Chapter because 
they can be accompanied by raised levels of lactate, pyruvate and 
alanine in blood (80, 81) and show fasting hypoglycemia (82). Levels 
of blood lactate can rise up to 5.6 mmol/1 in patients with methyl-
malonic acidemia. The accumulation of methylmalonic acid itself only 
amounts to about 2 mmol/1. At present, four types of methylmalonic 
acidemia are known (83). The lactate accumulation can be explained 
by the inhibitory action of methylmalonic acid on pyruvate carboxylase 
(84). An alternative explanation was suggested by Halperin et al. (85). 
Methylmalonate blocks the transport of malate from mitochondria to 
cytosol. The amount of extramitochondrial oxaloacetate is reduced and 
hence there is a lack of substrate for the formation of phosphoenol-
pyruvate and finally glucose. The mechanism of the hyperlactacidemia 
and the hypoglycemia in patients with propionic acidemia, has not been 
investigated. 
27 
2.4.4. Subacute necrotizing encephalomyelopathy (Leigh's encephalo-
myelopathy) 
Leigh's disease is characterized by symmetrical areas of necrosis of 
varying degree in the brain. The diagnosis is in fact a post-mortem one 
(86). The onset of subacute necrotizing encephalomyelopathy occurs 
usually in the first two years of life and the development of the child 
may be normal for the first year. The diagnosis is suspected when there 
are recurrent episodes of ataxia, choreo-athetosis, hypotonia and 
vomiting. The child may present with feeding difficulties, vomiting, 
difficulties in swallowing or sucking, hypotonia and weakness, and with 
developmental retardation and sometimes regression. Among the less 
common presenting symptoms are epileptic seizures, dystonic move­
ments and abnormalities of gait (87). As the disease progresses, the 
weakness and hypotonia became more marked and respiratory abnor­
malities such as 'air hunger' are often a particular feature. The neuro­
logical abnormalities are many, but the suggestive combination consists 
of ocular abnormalities and long-tract signs: these include nystagmus, 
bizarre rolling eye movements, ptosis, strabismus, pupil abnormalities, 
optic atrophy and pyramidal, extrapyramidal and cerebellar signs. 
Vomiting, seizures and developmental regression can become an increas­
ing problem. Death seems often to be related to the respiratory com­
plications (88). In many cases reported in the literature a metabolic 
acidosis is found and blood lactate and pyruvate levels are elevated. 
The pathogenesis of Leigh's disease has not been elucidated. Yet 
three different enzyme deficiencies have been described in Leigh's 
disease, a deficiency of pyruvate carboxylase (57, 88—91), of pyruvate 
dehydrogenase (38) and of cytochrome с oxidase (56). 
Cooper et al. (92) demonstrated that extracts from urine, blood or 
cerebrospinal fluid from patients suffering from Leigh's disease inhibit 
thiamine pyrophosphate-adenosine-triphosphate phosphotransferase. 
They showed that thiamine triphosphate, the neurologically active 
form of the vitamin, is deficient in the brain in Leigh's disease. Till now 
this finding could not be confirmed. 
It may be concluded that Leigh's disease should not be associated 
with a single enzyme deficiency such as pyruvate carboxylase. To 
achieve a better understanding of the pathophysiological bases of sub­
acute necrotizing encephalomyelopathy more biochemical research is 
needed. 
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Chapter 3. 
Quantitative analysis of lactate, pyruvate, 
3-hydroxybutyrate and acetoacetate 
3.1. Introduction 
An accurate, precise, readily available method for measurement of 
lactate, pyruvate and ketoacids (3-hydroxybutyrate and acetoacetate) 
is necessary for the study of patients suffering from an aberration in 
carbohydrate or fatty acid metabolism. 
Many methods are available now for the chemical or enzymatic deter-
mination of these substances (1—12). The most specific technique for 
measurement of lactate and pyruvate is based on the lactic dehydro-
genase (EC 1.1.1.27) catalyzed reaction and for measurement of 
3-hydroxybutyrate and acetoacetate on the 3-hydroxybutyric dehydro-
genase (EC 1.1.1.30) catalyzed reaction. 
After withdrawing the blood sample the lactate and pyruvate levels 
increase as a result of glycolysis in erythrocytes. Therefore, standard 
procedures are required in order to obtain a protein-free sample at the 
bedside of the patient, immediately after collection of the blood sample. 
Two methods of fixation have been described: deproteinization of 
blood with cold perchloric acid or deproteinization of blood with cold 
perchloric acid after stabilizing the blood lactate content with Long's 
mixture, containing citric acid, sodium fluoride and cetavlon, adjusted 
to pH 4.0 with sodium hydroxide (13). 
Many factors influence separately or in combination the concentra-
tion of lactate in blood such as the technique of venepuncture (14, 15), 
muscular contraction (16), hyperventilation (17, 18), epinephrine 
release (19), preceding food intake and administration of drugs. The 
concentration of lactate in arterial blood is slightly lower than in 
peripheral or venous blood (20, 21). 
In this study normal values for lactate, pyruvate and ketoacids in 
blood and cerebrospinal fluid are given. When lactate levels in blood are 
intermediate between normal and abnormal, or if they vary greatly in a 
patient investigation of the lactate excretion in the urine appears useful. 
Normal values for the lactate excretion in the urine are given in this 
Chapter. 
3.2. Methods 
The enzymatic spectrophotometric method is based on the oxidation 
of lactate or 3-hydroxybutyrate by NAD* or the reduction of pyruvate 
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or acetoacetate by NADH. The change in absorbance at 340 nm is pro­
portional to the amount of the compound. For measurement of lactate, 
hydrazine is added to the incubation mixture in order to remove pyru­
vate as its hydrazone to complete the reaction. 
LDH 
Lactate + NAD + hydrazine »-
pyruvate-hydrazone + NADH + H+ 
• LDH 
Pyruvate +NADH + H+ ^lactate + NAD* 
t 3-HBDH 3-Hydroxybutyrate + NAD »-acetoacetate + NADH + H 
, 3-HBDH 
Acetoacetate + NADH + H »-3-hydroxybutyrate + NAD* 
Venous blood samples were withdrawn after an overnight fast. Sam­
ples of C.S.F. are obtained by lumbar puncture. 24 h Urine samples are 
collected for the analysis of lactate and creatinine from 56 hospitalized 
children. Stock solutions in aqua dest were prepared from the sodium 
salts in the following concentrations: 1.5 mM L-lactate, 0.1 mM pyruvate, 
2 mM DL'3-hydroxybutyrate, 0.25 mM acetoacetate. 
Standard solutions were run simultaneously with blood, cerebrospinal 
fluid (C.S.F.) or urine samples to control the assays. Analytical grade 
reagents were used. The enzymes and cofactors were purchased from 
Boehringer, Mannheim, W.-Germany. All reagents were kept at 40C. 
L-Lactate assay: 
Blood samples were deproteinized with 1 M ice-cold perchloric acid 
(1:1; by vol) immediately after venepuncture. Exact volumes of blood 
were determined by weighing. After thoroughly mixing, the mixture 
was centrifuged at about 3000 χ g for 10 min. The lactate assay was 
performed according to Scheme I. 
Scheme I 
VOLUMES OF REAGENTS FOR LACTATE (in ml) 
Lactate assay Reagent blanc Sample blanc Sample 
E, E, E, E4 
Buffer* 2.02 2.0 2.02 2.0 
NAD+ (27 mM) 0.2 0.2 0.2 0.2 
Supernatant — — 0.2 0.2 
HCIO, (1.0 M) 0.2 0.2 - -
LDH (650 U/ml) - 0.02 — 0.02 
*0.5 M glycine buffer containing 0.4 M hydrazine (pH 9.0). 
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Lactate 
Pyruvate 
3-Hydroxybutyrate 
Acetoacetate 
1945 
268 
1808 
501 
1 
1 
0.8 
0.8 
1* 
1* 
0.6 
0.6 
After incubation for 1 h at 25CC absorbance was read at 340 nm 
(E,, Ез, Ез, E 4 ). Determination of L-lactate was performed in C.S.F./ 
urine/standard as described for blood. 1 ml sample was added to 1 ml 
1 M perchloric acid. 
Calculation 
Δ
 Еэ4опт = (E4—Ез)--(E2—E,). The concentration of L-lactate (μπιοΐ/ΐ) was calculated using the data given in Scheme II. 
Scheme II 
DATA USED FOR THE CALCULATION OF LACTATE, PYRU­
VATE, 3-HYDROXYBUTYRATE AND ACETOACETATE CON­
CENTRATION. 
Blood C.S.F./urine/standard 
1 1 
1 1 
1 1 
1 1 
•Exact volume of blood was determined by weighing. Specific gravity of perchloric 
acid and blood is assumed to be 1.0 and 1.06, respectively. 
Δ E x C x ( A + 0.85xB) 
Blood: * = jumol/l 
В 
Δ E x С (А + В) 
C.S.F./urine/standard: =μιηο1/1 
В 
A: Perchloric acid (ml) 
В: Blood/C.S.F./urine/standard (ml) 
С: Constant 
Pyruvate assay: 
1 ml of the supernatant (see lactate assay) was mixed with 0.5 ml 
34 
0.7 M K3PO4 solution (40C). The precipitate was developed for 20 min 
at 40C, centrifuged (3 min at 3000 χ g) and discarded. The pyruvate 
assay was performed according to Scheme III. 
Scheme III 
VOLUMES OF REAGENTS FOR PYRUVATE ASSAY 
Sample 
Supernatant (pH 7.4) 
NADH(2.5mM) 
LDH (650 U/ml) 
1 ml 
0.1 ml 
0.01 ml 
E3 
E4 
Blanc 
0.1 M K-phosphate buffer (pH 7.4) 
NADH (2.5 mM) 
LDH (650 U/ml) 
1 ml 
0.1 ml 
0.01 ml 
E. 
E, 
The absorbance in both cuvettes (sample and blanc) was measured at 
340 nm before and 1 min after addition of LDH (E,, E 2, Ej, E4). The 
determination of pyruvate in C.S.F. and standard was performed as 
described for blood. 
Calculation 
Δ
 Ej,«,
 n m
 = (E3—E4)—(E,—E2). The concentration of pyruvate (μπιοΐ/ΐ) was calculated using the data given in Scheme II. 
Assay of ketoacids 
Blood samples were deproteinized with 1 M ice-cold perchloric acid 
(6:8; by vol.) After thoroughly mixing, the mixture was centrifuged at 
about 3000 χ g for 10 min. A solution of 1 M perchloric acid was added 
to C.S.F. and standard in a ratio 1:1 (v/v). 
3-Hydroxybutyrate assay 
0.2 ml supernatant was adjusted to pH 8.8 with a mixture of 0.3 ml 
35 
0.5 M Tris solution, containing 0.2 M KCl, and 0.1 ml 1.0 M КОН. The 
precipitate (KCIO4 ) was developed for 20 min at 4°C, centrifuged (3 min 
at 3000 χ g) and discarded. The 3-hydroxybutyrate assay was performed 
according to Scheme IV. 
Scheme IV 
VOLUME OF REAGENTS FOR 3-HYDROXYBUTYRATE 
ASSAY 
Sample 
Supernatant (pH 8.8) 
Aqua dest. 
NAD* (60 mM) 
3-HBDH (5 U/ml) 
0.1 ml 
0.25 ml 
0.02 ml 
0.01 ml 
E3 
E4 
Blanc 
0.5 M Tris-HCl buffer (pH 8.8) 
Aqua dest. 
NAD* (60 mM) 
3-HBDH (5 U/ml) 
0.1 ml 
0.25 ml 
0.02 ml 
0.01 ml 
E, 
E, 
The absorbance in both cuvettes (sample and blanc) was measured at 
340 nm before and 15 min after addition of 3-HBDH (E,, E 2, E3, E4). 
Calculation 
Δ
 E340 nm = (E4—Еэ) -(E2—E,). The concentration of 3-hydroxy­
butyrate (μιηοΐ/ΐ) was calculated using the data given in Scheme II. 
Acetoacetate assay: 
0.4 ml supernatant was neutralized with 0.8 ml 0.5 Μ Κ2ΗΡθ4 solu­
tion, containing 0.17 M КОН. The precipitate (KCIO4) was developed 
for 20 min at 40C, centrifuged (3 min at 3000 χ g) and discarded. The 
acetoacetate assay was performed according to Scheme V. 
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Scheme V 
VOLUMES OF REAGENTS FOR ACETOACETATE ASSAY 
Sample 
Supernatant (pH 7.4) 
NADH(11.3mM) 
3-HBDH (5 U/ml) 
0.35 ml 
0.01 ml 
0.01 ml 
E, 
E, 
Blanc 
0.5 M k-phosphate buffer (pH 7.4) 
NADH(11.3 mM) 
3-HBDH (5 U/ml) 
0.35 ml 
0.01 ml 
0.01 ml 
E, 
E, 
The absorbance in both cuvettes (sample and blanc) was measured at 
340 nm before and 5 min after addition of 3-HBDH (E!, E 2 , E3, E4 ). 
Calculation 
Δ
 E340 nm = (E3—E4)—(Ei—E2). The concentration of acetoacetate 
(μπιοΐ/ΐ) was calculated using the data given in Scheme II. 
3.3. Results. 
Table 3.1. gives normal values of lactate, pyruvate and lactate/ 
pyruvate ratio in blood and cerebrospinal fluid. Blood samples have 
been obtained after an overnight fast from children (1 month — 10 years), 
all hospitalized for pathology not interfering with lactate metabolism. 
Table 3.1. 
LACTATE AND PYRUVATE CONCENTRATION 
AND LACTATE/PYRUVATE RATIO IN BLOOD 
AND CEREBROSPINAL FLUID OF CHILDREN 
The concentrations of lactate and pyruvate are given 
as the mean + S.D. (μπιοΐ/ΐ) of the number of samples 
given in parentheses. 
Blood C.S.F. 
Lactate 1054 ± 441 (101) 1444 ± 268 (92) 
Pyruvate 54+ 20 (95) 92 ± 17(93) 
L/P ratio 16 ± 3 (96) 15 ± 3(95) 
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There was no correlation between lactate and pyruvate concentration 
and age of the children. Lactate and pyruvate levels in C.S.F. are higher 
than in blood. 
Distribution curves for lactate and pyruvate in both physiological 
fluids are shown in Fig. 3.1. All the curves are normally distributed. The 
effect of stress and muscular movements, caused by direct venepuncture 
and venestasis, on the lactate and pyruvate levels in children can be 
evaded by inserting an in termi Want infusion set. After 45 min of bedrest 
the blood sample can be obtained (14). The data presented in Table 3.1. 
were not collected in this way but by single venepuncture. 
% relative frequency 
30-, a 
20 
10 
BLOOD lactate - pyruvate 
an tm 
30 -, с 
20 
10 
o-
lactate CSF pyruvate d ι 
tbu J 1 | 1 1 1 1 
—| 
500 1000 1500 2000 
/umol/l lactate 
50 100 150 
ΛΙΠΊΟΙ/Ι pyruvate 
Fig. 3.1. Frequency distribution of values in children of: 
a. lactate in blood (n= 101) 
b. pyruvate in blood (n=95) 
с lactate in C.S.F. (n=92) 
d. pyruvate in C.S.F. (n=93) 
The lactate excretion was expressed as lactate/creatinine quotients as 
recommended by Femandes et al. (22). An irregular frequency distri­
bution curve can be observed (Fig. 3.2.). The mean value for normal 
children (5 months —10 years) is 4μΜ lactate/mM creatinine; range 
2—116 (n=56) which corresponds to values reported in the literature 
(22,23). 
The establishment of normal values of the ketoacids (3-hydroxy-
butyrate and acetoacetate) is difficult, since the composition and quan­
tity of the preceding food intake, period of fasting and age of children 
are all factors which influence the ketoacid concentration in blood. 
More information about the influence of the period of fasting will be 
given in Chapter 4. Blood samples of children (2 months — 10 years) 
contain maximally up to 600 μτηοί/Ι of ketoacids with a ratio of 
3-hydroxybutyrate/acetoacetate below 3 after an overnight fast. 
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% relative frequency 
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20 H 
— • 
20 40 60 80 10O 
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Fig. 3.2. Frequency distribution of lactate values in urine (n=56) of children 
(5 months — 10 years). 
The low concentration of ketoacids in C.S.F. hampered the deter­
mination of these acids. The concentration amounts to approximately 
one fifth of that of blood. Sampling of blood and C.S.F. after a fasting 
period of 22 h yields a ratio of ketoacids between C.S.F. and blood of 
0.19 with a range of 0.13 — 0.22 (n=8). These data are in contrast with 
the findings reported earlier (24). 
3.4. Discussion 
Lactate, pyruvate and ketoacids concentrations were determined 
with modified enzymatic spectrophotometric techniques firstly described 
by Hohorst (6, 10) and Wildenhoff (9), respectively. These methods 
allow rapid and specific measurement with a small volume of blood or 
C.S.F. For clinical service the enzymatic method is more convenient 
than other methods such as gaschromatography. 
Normal values of lactate, pyruvate and L/P ratio in blood and C.S.F. 
agree fairly well with values reported in the literature (Table 3.2.) 
except for those by Kaasik (25) and Oliva (26). The discrepancy remains 
unexplained. 
The lactate concentration of C.S.F. (in itself presenting no intrinsic 
metabolic activity) depends on exchange with adjacent metabolically 
active compartments i.e. blood and brain tissue. Studies on exchange of 
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Table 3.2. 
LACTATE AND PYRUVATE CONCENTRATIONS 
AND LACTATE/PYRUVATE RATIO IN HUMAN 
VENOUS BLOOD AND CEREBROSPINAL FLUID 
Concentrations of lactate and pyruvate are given in 
μτηοΐ/ΐ. 
Blood 
Lactate 
2 8 4 0 
1 6 0 0 
900 
740 
950 
1380 
1054 
Pyruvate 
1 0 2 
185 
7 0 
60 
214 
54 
L/P ratio 
15.5 
10.6 
15.8 
7.3 
16.0 
Reference 
Haerer(27) 
Kaasik (26) 
Bland ( 2 8 ) 
Brooks (29) 
Alberti ( 3 0 ) 
Gilbert (31) 
Oliva (28) 
Present study 
Cerebrospinal fluid 
1 6 8 0 
1601 
2780 
1 4 3 0 
1620 
1 6 3 0 
1 6 0 0 
1 4 4 4 
58.5 
98 
179 
115 
120 
126 
9 2 
16.5 
13.6 
13.7 
15.0 
Pry ce ( 3 2 ) 
Haerer(27) 
Svenningsen (33) 
Kaasik (25) 
Bland ( 2 8 ) 
Blenow ( 3 4 ) 
Simpson (35) 
Brooks (29) 
Thurston (12) 
Present study 
lactate across the blood- C.S.F, and blood-brain barrier have yielded 
variable results. Generally the permeability for both barriers to lactate 
is considered to be low as for most polar substances. This was illustrated 
by an experiment performed on dogs by Weyne and Leusen (36). After 
an intravenous infusion of lactate, there was an increase of C.S.F. lactate 
only in the course of several hours. In the steady state there is a diffusion 
equilibrium between C.S.F. and the tissue fluid of the brain. However, 
when changes in brain lactate content occur rapidly, a latency in the 
appearance of these changes in C.S.F. lactate in either direction becomes 
manifest (36). 
Interest in blood-brain transport of ketoacids arose from publications 
indicating a significant brain utilization of 3-hydroxybutyrate and 
acetoacetate during fasting ketonemia (24, 37). The transport of these 
substances across the blood-brain barrier probably occurs by facilitated 
diffusion (38). This carrier system shows adaptation during fasting (38). 
The cerebral uptake of acetoacetate and 3-hydroxybutyrate by children 
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could account for approximately 13 percent of the measured oxygen 
uptake by the brain assuming complete oxidation of the ketoacids (39). 
The uptake of ketone bodies by the brain is dependent on their 
circulation concentrations in blood. The cerebral capacity to oxidize 
ketoacids is higher in newborns than in infants (40). In comparison with 
values of adults, the capacity of the brain of newborns and infants to 
oxidize ketoacids is five and four times higher, respectively, at a given 
arterial concentration (41). This explains perhaps the low ratio of C.S.F.-
ketoacids/blood ketoacids in children in comparison with adults (24). 
After an overnight fast Owen et al. (24) found a C.S.F.-ketoacid/blood-
ketoacid ratio of 0.67 ± 0.07. 
The lactate/creatinine ratio is a useful parameter to differentiate 
between normal and abnormal excretion (22). Data of lactate excretion 
in 24-hours urine may reflect lactate overflow and thus allow a good 
insight in an abnormal lactate production (22). Lactate is freely filtered 
across the glomerular capillary. It has been shown that only minute 
amounts of lactate appear in the final urine at normal blood lactate 
levels (42). The tubular reabsorption mechanism seems to be saturated 
at a blood concentration of 4—6 mM (43). Temporary increase of the 
lactate concentration for instance by stress situations or hyperventilation 
are not reflected by an augmented lactate excretion in the urine. 
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Chapter 4. 
Fasting test 
4.1. Introduction 
When an inborn error of metabolism is suspected to be associated 
with increased levels of lactate and pyruvate in blood and/or cerebro-
spinal fluid, some function tests can be performed to obtain additional 
information to the existence of an enzymatic defect. The results of 
these tests may indicate the metabolic pathway affected: e.g. glyco-
genolysis, glycogenesis, gluconeogenesis, glycolysis or pyruvate oxida-
tion. Some of them allow localization of the defect in a specific organ, 
such as muscle, liver and/or brain. 
At this moment some in vivo function tests have been well developed 
such as glucose-, fructose-, galactose- and glucagon tolerance tests and 
the fasting test (1—2). The test of McArdle (3) and the determination 
of lactate during exercise (4) can be used especially when aberrations in 
muscle metabolism are expected. Disturbances in the gluconeogenesis 
can be supposed to exists when the increase of the glucose concentration 
after an intravenous gift of precursors of gluconeogenesis such as pyru-
vate and dihydroxyacetone (5) is less than normal. 
The 22 hours fasting condition is generally considered as a steady 
state condition with regard to glucose homeostasis. Normally, circulating 
glucose levels show little fluctuation as hepatic glucose production 
keeps pace with peripheral glucose utilization. 
In the fasting individual, the maintenance of a normal blood glucose 
level is dependent on: 
1. an adequate supply of endogenous gluconeogenic substrates. 
2. functionally intact glycogenolytic and gluconeogenic enzyme systems. 
3. a normal endocrine system. 
The adult human being is quite capable of maintaining a normal 
glucose level even when totally deprived of calories for weeks, or in the 
case of obese subjects, for months. In contrast, the normal child exhibits 
a progressive fall in blood glucose to hypoglycemic levels when fasted 
for even short periods (e.g. 24 to 48 h). The reasons for this different 
behaviour between the child and adult human being are not clear. 
Specific measurements of glucose requirements in the young child are 
lacking, but on the basis of animal studies, it would appear that they 
are 2- to 3-fold greater than in the adults (6). One of the factors which 
probably contributes to the high glucose requirement of the young 
child is the relative increase of brain mass to total body mass in this 
age group (7, 8). The significant smaller protein mass of the young 
child relative to total body mass as compared to the adult is certainly 
another factor responsible for the reduced fasting tolerance of the 
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child. Over 50 percent of the de novo glucose production via gluco-
neogenesis is derived from protein stores, especially alanine (9). Despite 
the increased requirement of glucose, the glycogen stores of the liver 
are sufficient to meet these demands for at least 8 to 12 h in the young 
child. After 24 to 36 h, the young child is totally dependent on gluco-
neogenesis for glucose supply (10, 11). 
The availability of adequate supply of gluconeogenic substrates 
represents a rate limiting factor for gluconeogenesis (9), (Fig. 4.1.). In 
the fasting adult approximately 50 percent of net glucose production is 
derived from amino acid precursors, 30 percent from lactate and 
10 percent from glycerol (lipolysis).Of the various gluconeogenic amino 
acids, alanine is quantitatively by far the most important. The major 
source of alanine is pyruvate which is derived from the glycolytic break-
down of glucose in muscle (12). Glutamine is another important poten-
tial gluconeogenic substrate and represents a significant portion of the 
total aminoacid efflux from the skeletal muscle during fasting (13). 
ENMGY SOUKCe CONVE«SION UTILIZATION 
Fig. 4.1. Schematic representation of fuel metabolism in a normal fasted man, illus-
trating the energy sources and their hepatic conversion and peripheral tissue utili-
zation (adapted from Cahill, 27). 
The findings of Pagliara et al. (10) support the hypothesis that a 
deficiency of the gluconeogenic precursor, alanine, rather than a defect 
in one of the enzymes of gluconeogenesis represents the most likely 
factor in the pathogenesis of ketotic hypoglycemia. 
Deficiency of one of the enzymes either in glycogenolysis or gluco-
neogenesis results in a rapid Ml in blood glucose concentration during 
a fasting period. A deficiency of gluconeogenesis can be established 
in vivo by administration of alanine (250-500 mg/kg of body weight 
i.v.) and determination of the blood glucose response following this 
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administration. Prior to this test a fasting period is required in order 
to lower the blood glucose level to approximately 3 mmol/1. A normal 
response, an increase of about 1 mmol/1, may indicate that no deficiency 
of a gluconeogenic enzyme is present (14). However, this interpretation 
(14) can be severely criticized. No response points to a defect in gluco-
neogenesis but a positive response does not exclude such a defect. 
Glycogen stores should have been depleted during the fasting period, 
since administration of alanine results in release of glucagon which 
stimulates glycogenolysis (15). Glycémie response to glucagon in nor-
mal children after a 24 h fast was variable in intensity and did not corre-
late with the level of blood sugar at the end of the fasting period (11). 
Preliminary experiments in our group indicate that a gluconeogenic 
test can be performed by administration of pyruvate (500 mg/kg of 
body weight i.v.) instead of alanine. Since pyruvate does not stimulate 
glucagon release this test is superior to the alanine loading test (16). 
Adrenal insufficiency, deficiency of glucagon, growth hormone, 
thyroxine, as well as hyperinsulinism may be responsible for sympto-
matic hypoglycemia in childhood. These endocrine disorders are exten-
sively discussed by Pagliara et al. (9 ,14) . It is important to realise that 
these causes of hypoglycemia occur more frequently than enzymatic 
deficiencies in gluconeogenesis. 
The acceleration of ketone body production by the liver during 
fasting is due to an increased capacity for the oxidation of long-chain 
fatty acids, caused by an increased activity of the carnitine acyltrans-
ferase reaction (17). This enzyme catalyzes the transfer of long-chain 
fatty acids across the mitochondrial membrane. It seems probable that 
this transport is under control of the glucagon/insulin ratio (17). 
The accumulation of ketoacids in the blood is a consequence of an 
imbalance between the rate of production and its removal of acetyl-
CoA by action of the citric acid cycle (18). The liver is the only organ 
that delivers ketone bodies to the blood. Muscle, kidney and brain are 
quantitatively the most important tissues that remove ketone bodies 
from the blood. 
We use the fasting test as a primary approach in the study of patients 
with hyperlactacedemia.In this Chapter the results of the fasting tolerance 
test of thirteen normal children (4 months-4 years) will be presented. 
During a fasting period of 22 h the blood concentrations of glucose, 
lactate, pyruvate, alanine, free fatty acids, triglycerides and ketoacids 
were measured. The fasting test was also applied in the cases described 
in Chapter 9. 
4.2. Methods 
During a fasting period of 22 h three blood samples are withdrawn 
at 12.5, 18.5 and 22 h postprandially. The fasting period always started 
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at 6 post meridiem. During the preceding days the children received a 
normal diet. Their age varied from four months to four years. The 
children were kept in bed during the test. 
Blood glucose was determined using the ferricyanide method by auto-
analyzer (19). Blood lactate, pyruvate, acetoacetate and 3-hydroxy-
butyrate were determined as described in Chapter 3. Alanine was deter­
mined by ion exchange chromatography with a Beckman/Multichrom 
aminoacid analyzer. A microcolorimetric procedure was used for 
measurement of long-chain fatty acids (NEFA) (20). The determination 
of triglycerides was carried out by assay of its glycerol content, liberated 
through saponification (21). 
4.3. Results 
Fig. 4.2. presents the mean values (± 1 χ S.D.) of glucose, lactate, 
pyruvate, alanine, triglycerides, free fatty acids and ketoacids during 
the fasting period at three time intervals for 13 normal children. The 
course of the curves for the individual children was almost identical 
with that of the curve of the mean. The fall in blood sugar concentra­
tion is approximately 1 mmol/1. Lactate and pyruvate blood levels 
remain almost constant during the fasting period. Alanine levels how­
ever decrease (p < 0.001) mainly in the period between twelve and 
eighteen hours fasting. Plasma triglyceride levels remain constant or 
decrease slowly. An obvious increase (p < 0.001) of the fatty acids 
(NEFA) concentration results in a large increase (p < 0.001) of keto­
acids, 3-hydroxybutyrate and acetoacetate, while the intramitochondrial 
NADH/NAD* ratio represented by the ratio between these ketoacids 
tends to increase from 2.0 to 2.7. The cytosolic redox potential expressed 
by the ratio between lactate and pyruvate does not change significantly. 
The relation between the concentration of free fatty acids and keto­
acids after 22 h fasting is shown in Fig. 4.2. (correlation coefficient 
= 0.85). 
4.4. Discussion 
The values of the mean blood sugar after 22 h fasting in our group of 
13 children (3.7 ± 0.7 mmol/1) agree with the values of Chaussain (11) 
for 56 children (age 1 to 9 years). 
Serum alanine decreased significantly in our children as was previously 
reported by Chaussain et al. (22). In six normal healthy children (2-6 
years of age) the terminal value of serum alanine was 178 ± 18 (1 χ S.D.) 
Aimol/1 (22). 
During the fasting period the free fatty acid concentration was 
increased significantly as was reported by several other investigators 
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Fig. 4.2. Mean blood values (± 1 χ S.D.) for concentrations of metabolites after 
3 time intervals during a 22 h fast in a group of 13 normal children (4 months-
4 years). 
(22—24). Only fragmentary data ara available of the 3-hydroxybutyrate 
and acetoacetate concentration and ratio during fasting in normal 
children (24). The concentration of free fatty acids and ketoacids after 
a 22 h fasting period showed a good correlation for normal children 
(Fig. 4.3.). A divergent ratio between both groups of substances, indi­
cates a defect in the/3-oxidation, ketogenesis or ketoacid utilization (25). 
The value of the application of the fasting test at patients with 
hyperlactacidemia is illustrated by the results obtained in the cases 
reported in Chapter 9. The patient with a deficiency of pyruvate 
carboxylase was unable to maintain a normal glucose concentration 
during the fasting test (Chapter 9, Case 2). In normal children the ratio 
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Fig. 4.3. Correlation between concentrations of total ketoacid and free fatty acid in 
blood after a 22 h fast in control children. 
between 3-hydroxybutyrate eind acetoacetate, maximally rises to 2.7 
between 12.5 and 22.0 h of fasting. In our patient with a cytochrome с 
oxidase deficiency, described in Chapter 9 (Case 4), the ratio 3-hydroxy-
butyrate/acetoacetate rises during fasting from 2.0 to 5.0 indicating an 
impairment of the NADH oxidation. 
Pyruvate, lactate and alanine levels are elevated in blood in our 
patient with a pyruvate dehydrogenase deficiency (Chapter 9, Case 1). 
The increase of the concentration of ketoacids in blood during fasting 
was less than that in controls, which may suggest more consumption 
of the ketoacids by extrahepatic tissues such as the brain. The keto­
acids can replace pyruvate as energy source in these tissues. A glucose 
tolerance test with the simultaneous determination of the lactate and/or 
pyruvate concentration in this patient should have given additional 
information (24, 26). In control subjects no rise of lactate and pyruvate 
is observed. However, in patients suffering from defects in pyruvate 
oxidation an increase of pyruvate and lactate levels occurs. We may 
conclude that the performance of the fasting test may give relevant 
information not only in the case of deficiencies in glycogenolysis or 
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gluconeogenesis but also when aberrations of the pyruvate oxidation 
are suspected. 
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5.1. Summary 
We measured pyruvate oxidation in intact leukocytes and fibroblasts 
by measuring 1 4 C 0 2 production. The optimal pyruvate concentration 
appeared to be higher than that usually applied. Activities remained con­
stant during the incubation and were proportional to the amount of 
tissue protein added. Mean values (± SD) were 2.8 ± 0.9 nmol/h per 106 
cells and 37 ± 14 nmol/h per milligram of protein for leukocytes and 
fibroblasts, respectively for [1-14C] pyruvate oxidation; and 2.1 ± 0.8 
nmol/h per 10' cells and 18 ± 7 nmol/h per milligram of protein, respec­
tively for [2-14C] pyruvate oxidation. 
We compared oxidation rates of pyruvate and 2-oxoglutarate by 
intact cells with those of isolated mitochondria. The ratio of 14C02 pro­
duction vs. activity of mitochondrial marker enzyme demonstrated that 
the rate of pyruvate oxidation can adequately be assayed in intact cells, 
but the permeability of the cell membrane was rate-limiting in the oxi­
dation of 2-oxoglutarate. No significant oxidation of other intermediates 
of the citric acid cycle was found presumably owing to a low rate of 
transport of these substances across the cell membrane. 
Additional Keyphrase : pyruvate oxidation — use of intact cells to mea­
sure enzyme activity — transport across cell membrane. 
5.2. Introduction 
During the last years there has been increasing interest in determining 
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enzyme activities in cultured fibroblasts and leukocytes. Though enzyme 
defects can be established in liver, kidney or muscle biopsy materials, 
these studies are rather limited. Frequently only fibroblasts are available 
for enzyme assays. Because leukocytes can easily be obtained, they are 
also an important source for the study of enzyme activity. We have pre­
ferred to work with intact cells to approach physiological conditions, 
insofar as possible. Use of intact cells has the advantage that the intra­
cellular relationships are intact. Moreover, the cytoplasm and the intra­
mitochondrial content are diluted on sonication, which necessitates 
addition of cofactors to the incubation medium. Our procedure is 
superior to most of the previous methods because deficiencies of co-
factors may be established as well. Our aim in the present investigation 
was to study the contribution of transport across the cell membrane in 
the assay of pyruvate oxidation with [I-1 4CI pyruvate and the citric 
acid cycle activity with [2-14C] pyruvate and [1-14C] 2-oxoglutarate in 
intact leukocytes and fibroblasts. 
5.3. Materials and Methods 
5.3.1. Leukocytes 
One volume of 50 g/liter dextran solution (T500, Pharmacia, Uppsala, 
Sweden) containing, per liter, 7 g NaCl and 15 g of disodium ethylene-
diaminetetra-acetate was added to five volumes of blood. Blood samples 
were obtained after an overnight fast from children (1-10 years), all 
hospitalized for pathology not interfering with pyruvate metabolism. 
The total white blood cell count was in the range 5.109 to 10.10' per 
liter. The differential white cell count was: 60—70% neutrophils, 
20—30% lymfocytes and 2—10% monocytes. After 30 min at 40C the 
supernatant plasma containing leukocytes, some erythrocytes and 
platelets was centrifuged for 8 min at 300 χ g. The supernatant plasma, 
which contained most of the platelets, was discarded. The pellet was 
suspended in 1 ml of buffered saline (40 mmol/liter phosphate buffer, 
pH 7.4, containing 0.11 mol of NaCl/liter). The remaining erythrocytes 
were removed by applying an hypotonic osmotic shock by exposure to 
distilled water for 90 sec after which isotonicity was restored(l). After 
washing with saline the final pellet was suspended in buffered saline and 
the cells were counted in a Coulter Counter. 
Mitochondria were prepared from a concentrated suspension of 
leukocytes (30.109 /liter) in 0.25 mol/liter sucrose. The cell membrane 
was disrupted with a French press at 3.5 χ IO6 Pa. The cell debris was 
removed by centrifugation (10 min at 70 χ g) and the mitochondria 
obtained by centrifugation for 13 min at 8000 χ g were washed once 
with 0.25 mol/liter sucrose. 
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5.3.2. Fibroblasts 
Skin biopsy material was cut into small fragments and cultured in 
TC-199 medium (Flow Laboratories, Irvine, Scotland) enriched with, 
per liter 200 g of fetal calf serum and 50 g of chicken embryo extract, 
supplemented with 1 χ 10 s USP units of penicillin and 100 mg of strepto­
mycin. After trypsinization for 5 min at 370C (2.5 g trypsine per liter; 
Difco. Detroit, Michican, 1:250 pancreas) the fibroblasts were washed 
with the phosphate buffered saline. The cells were counted under the 
microscope in a special glass counting chamber after dilution of the cell 
suspension. 
For isolation of mitochondria fibroblasts were suspended in a medium 
containing per liter 0.27 mol of mannitol, 0.1 mmol of disodiumethylene-
diaminetetra-acetate, 0.5 g of bovine serum albumin and 10 mmol of 
tris(hydroxymethyl)aminomethane-HCl (pH 7.3). The cells (4.109/liter) 
were disrupted at 40C with a Potter-Elvejhem homogenizer and the 
mitochondria were isolated by differential centrifugation for 7 min at 
770 χ g and 10 min at 10,000 χ g. 
5.3.3. Enzyme assays 
Leukocytes (5.106 to 10.106) were incubated in the phosphate 
buffered saline and either pyruvate or 2-oxoglutarate (0.5 mmol/ 
liter). The final volume was 2.1 ml. The specific activity of the used 
substrates was 1.0 mCi/mol. Incubation WEIS done in a shaking water-
bath at 37°C in 20 ml glass scintillation vials, sealed with rubber stoppers, 
containing two small tubes, one fitting inside the other (2). The reac­
tion was stopped at 60 min by injecting of 0.3 ml of 3 mol/liter per­
chloric acid and the 1 4 C 0 2 produced was trapped in Hyamine hydroxide; 
p-(diisobutyl-cresoxyethoxyethyl) dimethylbenzylammonium hydro­
xide, during further incubation for 30 min at 370C. The trapped 1 4 C 0 2 
was measured after adding 10 ml of scintillation fluid (4 g Omnifluor/ 
liter of toluene) in a liquid scintillation counter. For the determination 
of the blank values the cells were omitted. 
Fibroblasts (5.10s to 1.106) were incubated under identical condi­
tions as described for leukocytes except for the substrate concentra­
tions of pyruvate and 2-oxoglutarate (0.2 mmol/liter). The final volume 
was 1.5 ml. Protein was assayed according to Lowry et al. (3). 
5.3.4. Mitochondria 
Pyruvate oxidation by mitochondria isolated from fibroblasts and 
leukocytes was measured at 370C in an incubation mixture containing, 
per liter, 50 mmol of potassium phosphate buffer (pH 7.4), 0.5 mmol 
of disodium ethylene-diaminetetra-acetate, 2 mmol ADP, 75 mmol of 
KCl, 10 mmol MgCh, 1 mmol of the substrate (0.5 mCi/mol), and 
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0.2—0.4 mg of mitochondrial protein. The final volume was 0.5 ml. 
Incubation time was 60 min. 
Leukocytes and fibroblasts yielded about 4 and 40 mg of mitochon­
drial protein per 109 cells, respectively. The assay procedure was as 
described for intact cells. 
Cytochrome с oxidase (EC 1.9.3.1.) activity and glutamate dehydro­
genase (EC 1.4.1.2.) activity were measured in cells and mitochondria, 
both after freezing and thawing three times. Assays were performed 
according to Cooperstein and Lazorow (4) and Schmidt (5), respec­
tively. Respiratory control index of mitochondria of fibroblasts was 
measured in simplified Dow (6) medium containing 1 mmol of pyru­
vate and 1 mmol of malate per liter. ADP was added in a final concen­
tration of 0.2 mmol/liter. 
5.3.5. Radiolabeled Materials 
[1-14C] Pyruvate, [2-14C] pyruvate and [1-14C] 2-oxoglutarate were 
obtained from the Radiochemical Centre, Amersham and stored at 
—20oC in small aliquots as the dry sodium salts, under nitrogen. 
5.4. Results 
5.4.1. Isolation of leukocytes and fibroblasts 
The differential leukocyte count remained unchanged after isolation 
in comparison with that in the peripheral blood. Recovery of leukocytes 
in the final preparation averaged 50—60%; 6% of the original amount of 
platelets was found in the final leukocyte suspension, which contained 
on the average equal amounts of erythrocytes and leukocytes. 
After trypsinization, 2—5% of the fibroblasts were non-viable as 
judged by trypan blue uptake. 
5.4.2. Isolation of mitochondria 
Leukocytes are relatively resistant to the usual homogenization proce­
dures (7). The best disruption of cells was obtained by a more vigorous 
method: use of a French press. The respiratory control index of the 
mitochondria of leukocytes could not be established because of the low 
oxidative capacity. 
Fibroblasts could be well homogenized with a Potter-Elvejhem homo-
genizer in isotonic medium. The respiratory control index of the iso­
lated mitochondria was 4.0 with pyruvate/malate as substrates. 
5.4.3. Enzyme assays 
'"СОг production from [1-I4C] pyruvate was lower without added 
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cells than that in the presence of boiled cells. Nearly identical blank 
values were obtained either in the absence of cells or after inhibition of 
pyruvate oxidation with arsenite (4.4 mmol/liter). The presence of boiled 
cells appeared to give an incorrect blank value by a higher nonenzymatic 
decarboxylation of [1-14C] pyruvate (8). 
The results (Figure 5.1.) indicate that the reaction rate of the oxidation 
nmol / mg protein 
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Fig. 5.1. Oxidation rates of [1-1 4C] pyruvate and [2-1 4C] pyruvate in intact cultured 
fibroblasts incubated for various periods of time (using 1.0 mg protein) and with 
increasing enzyme concentrations (incubation time 1 h). 
of [1-14C] pyruvate and [2-14C] pyruvate by fibroblasts remained con­
stant during 60 min of incubation, and also was proportional to the 
amount of cellular protein. Similar results were obtained f or leukocytes. 
Table 1 shows control values of the pyruvate oxidation rate in leuko­
cytes and fibroblasts. The variation coefficient of the assay amounts to 
7% both for leukocytes and fibroblasts. The Lineweaver-Burk plots 
Table 5.1. 
PYRUVATE OXIDATION IN HUMAN LEUKOCYTES AND CUL­
TURED FIBROBLASTS. 
Values are given as the mean ± SD. 
Substrate [ l - ^ C ] Pyruvate [г-^С] Pyruvate 
Leukocytes* 2.8 ± 0.9 
range 1.4 — 4.1 ( n = l l ) 
Fibroblasts0 37 ± 14 
range 19 — 61 (n=10) 
2.1 ± 0.8 
range 1.1 —3.5 (n=12) 
18± 7 
range 12 — 30 (n=5) 
x
nmol/h. 10' leukocytes 
0
nmol/h. mg protein 
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Table 5.2. 
PYRUVATE DEHYDROGENASE AND 2-OXOGLUTARATE DEHYDROGENASE ACTIVITY IN INTACT 
CELLS AND MITOCHONDRIA OF FIBROBLASTS AND LEUKOCYTES. 
Pyruvate dehydrogenase 
Activity 2-Oxoglutarate dehydrogenase 
(nmol/h. mg protein) Cytochrome с oxidase 
Glutamate dehydrogenase 
Ratio ( x l O 3 ) 
Pyruvate dehydrogenase 
cytochrome с oxidase 
2-Oxoglutarate dehydrogenase 
cytochrome с oxidase 
Pyruvate dehydrogenase 
glutamate dehydrogenase 
2-Oxoglutarate dehydrogenase 
glutamate dehydrogenase 
Fibroblasts 
Intact cells M 
38 
5 
1 242 
3 060 
30.6 
4.0 
12.4 
1.6 
[itochondria 
218 
77 
6 930 
11 820 
31.5 
11.1 
18.4 
6.5 
Leukocytes 
Intact cells Mitochondria 
2.9 
0.2 
492 
— 
— 
5.9 
0.5 
16.6 
10.7 
1 270 
— 
-
13.0 
8.4 
with [l- 1 4 С] pyruvate as a substrate revealed an apparent Km value for 
leukocytes of 0.14 mmol/liter and for fibroblasts of 0.11 mmol/liter. 
Determination of citric acid cycle activity in intact leukocytes and 
fibroblasts with its intermediates as substrates, was almost impossible. 
Citric acid cycle activity could be only demonstrated by using [2-I4C] 
pyruvate as substrate (Table 5.1.). No measurable activity was found with 
[U-14C] malate, [1,5- ,4C]- and [6-14C] citrate, [ІД-^С] succinate and 
[5-I4C] 2-oxoglutarate as substrates. The oxidation rate with [1-14C] 
2-oxoglutarate and [1-14C] glutamate was low in intact cells. 
Table 5.2. compares the oxidation rates of [ 1-14C] pyruvate and [1-14C] 
2-oxoglutarate by intact leukocytes and fibroblasts and by their mito­
chondria. Cytochrome с oxidase and glutamate dehydrogenase were 
measured as mitochondrial markers. The ratio pyruvate dehydrogenase 
activity/activity of mitochondrial markers is in the same order of 
magnitude for intact cells and mitochondria. The discrepancy of the 
ratio for pyruvate dehydrogenase to the activity of glutamate dehydro­
genase between intact cells and mitochondria might be due to leakage 
of glutamate dehydrogenase out of the mitochondrial matrix. The ratio 
for 2-oxoglutarate dehydrogenase activity was, however, much higher in 
mitochondria than in intact cells. Cytochrome с oxidase activity in 
leukocytes was too low to be used as a reliable marker. 
5.5. Discussion 
Several clinical disorders are associated with increased levels of lac­
tate and/or pyruvate in blood and/or cerebrospinal fluid. The main 
clinical features of patients, suffering from these disorders are mental 
retardation, muscular hypotonia and convulsions (1). Measuring of 
pyruvate oxidation rate in leukocytes and fibroblasts can be helpfull in 
the diagnosis of children suffering from lactic acidemia. 
Leukocytes and fibroblasts contain the enzymatic equipment for 
pyruvate oxidation (9—11), such as pyruvate dehydrogenase (1), the 
citric acid cycle (12) and the electron transport system (13—15). 
The oxidation rates of [ I-1 4 C] pyruvate and [2-14C] pyruvate in 
intact leukocytes and fibroblasts (Table 1) much exceed those previously 
published (1, 16,17), perhaps because of the higher substrate concen­
tration we used. In other investigations (1, 16, 17) pyruvate concentra­
tion was below the K,^  value. 
The rate of pyruvate oxidation in fibroblasts is much higher than that 
in leukocytes. The oxidative pathway in leukocytes is of minor impor­
tance (18). The generation of ATP is quantitatively less dependent on 
oxidative phosphorylation than on the operation of the glycolysis (7). 
The approximately equal '"СОг production from [l-14C]pyruvate 
and [2-14C] pyruvate with intact leukocytes and fibroblasts (Table 1) is 
in contrast with the results presented by Cederbaum et al. (16) and with 
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the observations on rat adipose tissue (19). Our data suggest that in 
leukocytes and fibroblasts acetyl-CoA produced from pyruvate is almost 
completely oxidized in the citric acid cycle under the used conditions. 
No reliable measurements of citric acid cycle activity could be per­
formed with intermediates of the citric acid cycle as substrates in intact 
leukocytes and fibroblasts. This might be due to a low activity of the 
citric acid cycle or to the limited transport of these substrates across the 
cell membrane or the mitochondrial membrane. The experiments with 
[2-14C] pyruvate as substrate show that in vitro measurement of the 
overall citric acid cycle activity is feasible. Moreover, earlier studies 
(9,12) demonstrated a definite citric acid cycle activity in both types 
of cells. The low transport rate of 2-oxoglutarate across the cell mem­
brane will cause the differences in its oxidation rate between intact cells 
and mitochondria. 
We conclude that pyruvate oxidation can be reliable measured in 
intact leukocytes and fibroblasts with [1-14C] pyruvate. Concomitant 
assay of '"СОг production from [2-14C] pyruvate can provide an indi­
cation for the total activity of the citric acid cycle, but the individual 
steps of this cycle can only be determined by using mitochondria or 
disrupted cells. Prolonged trypsinization of fibroblasts may increase the 
cellular uptake of di- and tri-carboxylic acids (12) but may disturb cellular 
metabolism. We suggest that use of intact leukocytes and especially 
fibroblasts may be appropriate to detect defects in pyruvate oxidation. 
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Chapter 6. 
Determination of pyruvate oxidation rate 
and citric acid cycle activity in liver 
and muscle tissue 
6.1. General introduction 
Normal oxidation rates of pyruvate in leukocytes or fibroblasts do 
not exclude possible aberrations in the oxidation of pyruvate in cells of 
other organs like liver, muscle or brain ( 1 , 2). Moreover, defects in the 
citric acid cycle can not be demonstrated directly in intact leukocytes 
and fibroblasts using citric acid cycle intermediates as substrates (Chap­
ter 5). In this chapter it was attempted to establish the experimental 
conditions to elucidate defects in the oxidation of pyruvate and the 
citric acid cycle in liver and muscle tissue. 
Some data are available concerning defects in pyruvate oxidation in 
liver and muscle tissue such as deficiency of pyruvate dehydrogenase 
( 1 , 3, 4), pyruvate dehydrogenase phosphatase (5) and defects in the 
respiratory chain (2, 6—8). Defects in the citric acid cycle were only 
established in fibroblasts (9, 10). 
In the present chapter we report the results of our investigation on 
the activities of pyruvate dehydrogenase and the citric acid cycle in 
liver and muscle tissue of rat and man. 
6.2. Materials and Methods 
6.2.1. Preparation of homogenates and isolation of mitochondria 
Liver and hind leg muscle were obtained from male Wistar rats weigh­
ing 100—200 g and fasted overnight. The rats were killed by cervical 
fracture. All subsequent preparation procedures were performed at 4 0 C. 
A 5 percent (w/v) liver homogenate was prepared in 10 mM Tris-HCl 
buffer (pH 7.4) containing 0.25 M sucrose and 2 mM EDTA with a 
Potter-Elvejhem homogenizer after mincing the tissue. When muscle 
tissue was used a 10 percent homogenate was made and heparin was 
supplemented to the homogenization medium at a final concentration 
of 50 I.U./ml. The supernatant obtained after centrifugation at 600 χ g 
for 10 min was used for the experiments with homogenates or for the 
isolation of mitochondria. 
Human liver and muscle homogenates were prepared identically as 
described for rat homogenate. 
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For isolation of liver and muscle mitochondria the supernatant was 
centrifuged at 600 χ g for 10 min once more. Subsequently mitochondria 
were obtained by centrifugation at 14 000 χ g for 10 min. They were 
washed once in the afore mentioned Tris-sucrose-EDTA buffer, (pH 7.4). 
The mitochondria were finally suspended in the same medium at a con­
centration of approximately 1 mg mitochondrial protein per ml. 
Respiratory control indices of mitochondria in simplified Dow 
medium (11) containing 1 mM pyruvate and 1 mM malate amounted to 
4—6, indicating coupling of oxidation and phosphorylation. 
6.2.2. Incubation procedures 
Incubations were carried out in a 50 mM potassium phosphate buffer, 
containing 0.5 mM EDTA, 10 mM MgCl2, 2 mM ADP and 75 mM KCl 
adjusted to pH 7.4. Unless otherwise stated the final concentration of 
all substrates amounted to 1 mM. The final volume was 0.5 ml. A pre­
incubation time of 5 min was always applied before addition of the sub­
strate. Incubations were performed at 31°C in 20 ml glass scintillation 
vials, sealed by rubber stoppers. The vials contained two small glass 
tubes, one fitting inside the other (Fig. 6.1.). Further experimental con­
ditions are indicated in the legends to the tables and figures. The incuba­
tion was terminated by addition of 0.2 ml of 3 M perchloric acid and the 
liberated '"СОг was trapped in Hyamine hydroxide, which was present 
in the inner tube. The radioactivity of 1 4 C02 was measured after trans­
ferring this tube to a vial containing 10 ml of scintillation fluid (4 g 
omnifluor/1 toluene) with a Nuclear Chicago scintillation counter (type 
Mark II). Statistical analyses were performed with the Student ' t-test. 
Fig. 6.1. Incubation flask. Complete (left) and in different parts. 
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6.2.3. Assay of cytochrome с oxidase and glutamate dehydrogenase 
Cytochrome с oxidase activity and glutamate dehydrogenase activity 
were measured in homogenates and mitochondria, both after three times 
freezing and thawing. Assays were performed according to Cooperstein 
and Lazorow (12) and Schmidt (13), respectively. 
6.2.4. Measurement of metabolites 
Pyruvate, 3-hydroxybutyrate and acetoacetate in the incubation 
mixture were determined as described in Chapter 3 for blood. 
For determination of malate, citrate and 2-oxoglutarate the acidified 
incubation mixture was neutralized with 50 μΐ 5 M K2CO3 solution. The 
precipitate was developed in the cold (10 min at 40C) and centrifuged 
for 10 min at 3 000 χ g. Malate was measured by a malate dehydrogenase 
catalyzed reaction (14). Citrate was determined with citrate lyase and 
malate dehydrogenase according to Dagley (15). 2-Oxoglutarate was 
measured with glutamate dehydrogenase according to Schmidt (13). 
Protein was determined by the method of Lowry et al. (16) with 
bovine serum albumin as standard. 
6.2.5. Chemicals 
Sodium salts of [ I - 1 4 C ] pyruvate, [U- l 4 C] malate, [1,4- 1 4C] succinate, 
[6- 1 4 C] citrate, [1,5- I 4C] citrate and [5- 1 4C] 2-oxoglutarate were pur­
chased from the Radiochemical Centre, Amersham, England. 
[1- I 4 C] 2-oxoglutaric acid was purchased from NENChemicals, GmbH, 
Germany. [ I - 1 4 C ] pyruvate, [ l - 1 4 C ] - a n d [5- 1 4C] 2-oxoglutarate were 
freeze dried immediately after dilution and stored under nitrogen in 
sealed ampules at —20oC to minimize decomposition (Chapter 8). Pyru­
vate was purchased from Fluka AG, Buchs, Switzerland; malate, succi­
nate, citrate, 2-oxoglutarate from Sigma Chemical Co., St.-Louis, Miss., 
U.S,A. L(—) carnitine and hexokinase (freeze dried, 40 U/mg) from 
Koch-Light Laboratories Ltd., Colnbrook, England; ADP, ATP, citrate 
lyase, malate dehydrogenase, lactate dehydrogenase, glutamate dehydro­
genase, NAD+, NADH and cytochrome с from Boehringer Mannheim 
GmbH, Mannheim, W-Germany. Omnifluor and Hyamine hydroxide 
10X were obtained from NEN Chemicals GmbH, W-Germany and from 
Packard Instruments, Brussel, Belgium, respectively. All reagents were 
of analytical grade. 
6.3. Pyruvate dehydrogenase 
6.3.1. Introduction 
The activity of pyruvate dehydrogenase complex is dependent among 
other things on the ratios of acetyl-CoA/CoA-SH, NADH/NAD* and 
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ATP/ADP (17, 22). Pyruvate oxidation was inhibited when rat hearts 
were perfused with medium containing palmitate, acetoacetate or acetate 
(18, 19). In this section the activity of pyruvate dehydrogenase was 
measured in respect with time, protein and substrate concentration. The 
influences of malate, ATP and carnitine on the activity of this enzyme 
were studied. It was the aim of the present investigation to find optimal 
conditions in order to establish a deficiency of the pyruvate dehydro­
genase complex. 
6.3.2. Results 
The production of 1 4 C 0 2 from [1-14C] pyruvate is linear for at least 
1 h and with respect to the amount of protein present (see legend Table 
6.1) in the incubation medium. This holds for homogenates and isolated 
mitochondria from rat liver and muscle. The Lineweaver-Burk plots 
revealed an apparent K
m
 value for liver homogenate and mitochondria 
of 34 μΜ and 40 μΜ pyruvate, respectively and for muscle homogenate 
and mitochondria of 190 μΜ and 60 μΜ pyruvate, respectively. 
Table 6.1. shows the activity of pyruvate oxidation in homogenate 
and mitochondria of liver and muscle. Addition of malate resulted in a 
highly significant (p < 0.001) stimulation of pyruvate oxidation. The 
optimal concentration of malate is 0.5 mM for muscle homogenate and 
mitochondria and 1.0 mM for liver homogenate and mitochondria. 
Malate does not influence the linearity with respect to time, protein 
concentration and the K
m
 values. The degree of stimulation of pyruvate 
oxidation by malate is relatively low in liver mitochondria in comparison 
Table 6.1. 
EFFECT OF MALATE ON THE PYRUVATE OXIDATION IN HOMOGENATE AND 
MITOCHONDRIA OF RAT LIVER AND MUSCLE 
Liver Muscle 
Addition Homogenate Mitochondria Homogenate Mitochondria 
- 217 ± 6 9 (28) 1040 ± 2 6 0 (5) 32 ± 13 (7) 1 100 ± 210(5) 
1 mM malate 293 ± 39 (10) 1 590 ± 360 (5) 157 ± 50 (7) 15 800 ± 1 180 (6) 
Incubations were performed during 60 min in the basic medium as outlined in Mate­
rials and Methods. The incubation time for muscle mitochondria was 30 min maxi­
mally. The incubation was started with the addition of 1 mM pyruvate (0.5 дСі/ттоІ) 
to the medium after a preincubation of 5 min. The pyruvate oxidation rates were 
calculated from the '^CO, production at 15 and 30 min (muscle mitochondria) or at 
30 and 60 min (liver homogenate and mitochondria and muscle homogenate) and 
expressed in nmol '^COj/h. mg proteia Values are given as the mean ± S.D. for the 
number of samples between parentheses. Protein concentrations per ml incubation 
medium were for liver homogenate: 0.1 — 0.5 mg protein; for liver mitochondria: 
0.02 — 0.2 mg protein; for muscle homogenate: 0.05 — 0.6 mg protein; for muscle 
mitochondria 0.01 — 0.1 mg protein. 
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Table 6.2. 
PYRUVATE OXIDATION WITH AND WITHOUT MALATE IN RELATION WITH GLUTAMATE DEHYDRO­
GENASE AND CYTOCHROME С OXIDASE IN RAT LIVER TISSUE 
Pyruvate oxidation Pyruvate oxidation 
Pyruvate oxidation rate Ratio Ratio 
Glutamate dehydro- Cytochrome с oxidase 
genäse χ 10э 
Addition Homogenate Mitochondria Homogenate Mitochondria Homogenate Mitochondria 
- 138 683 0.34 0.34 9.9 8.4 
1 mM malate 216 1029 0.53 0.51 15.7 12.6 
Specific activity of pyruvate was 0.5 ßCi/mmol. 0.61 mg protein of liver homogenate or 0.11 mg mitochondrial 
protein were present in the incubation medium. The rate of pyruvate oxidation is given in nmol '"CO, /h. mg 
protein. The ratios of pyruvate oxidation/mitochondrial marker enzymes were calculated with the activities in the 
same units (nmol/h. mg protein). 
СП 
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with that in muscle mitochondria (Table 6.1.)· The values of the rate of 
pyruvate oxidation (240 ± 40 nmol/h. mg protein) and the rate of pyru­
vate disappearance (229 ± 32 nmol/h. mg protein) are equal when rat 
liver mitochondria are incubated with pyruvate and malate as substrates. 
These findings demonstrate that no pyruvate carboxylase activity is pre­
sent under these conditions. 
The stimulatory effect of malate on pyruvate oxidation is for liver 
homogenate in the same order of magnitude as for liver mitochondria 
(Table 6.1. and 6.2.). The activity of pyruvate oxidation, based on the 
activity of mitochondrial marker enzymes, is almost equal in homo­
genate and mitochondria. Thus the malate concentration, present in 
cytoplasm is negligible in comparison with the amount of added malate. 
Table 6.3. presents the production of ketoacids by rat liver mitochon­
dria during pyruvate oxidation with and without malate. The 14C02 
production from [1-14C] pyruvate is higher in the presence of malate 
than in its absence, in spite of the higher NADH/NAD+ ratio expressed 
by the ratio 3-hydroxybutyrate/acetoacetate. Moreover, addition of 
malate results in a diminished ketogenesis. 
Since a small amount of ketoacids is produced during oxidation of 
pyruvate even in the presence of malate, it seemed worthwhile to investi­
gate the influence of L(—Carnitine. Table 6.4. shows the influence of 
carnitine (10 mM) and for malate (5 mM) on the pyruvate oxidation 
and ketogenesis in rat liver mitochondria. Addition of L(—)carnitine did 
Table 6.3. 
EFFECT OF MALATE ON THE 1 4 СО
г
 PRODUCTION FROM f 1-14C] PYRUVATE 
BY RAT LIVER MITOCHONDRIA 
Without malate 
Time ' "CO, 
(min) 
3-Hydroxybutyrate 
3-Hydroxybutyrate 
Acetoacetate Ratio: 
Acetoacetate 
15 
30 
45 
60 
259 
458 
677 
875 
With malate 
15 
30 
45 
60 
432 
804 
1 138 
1 420 
6 
10 
17 
17 
6 
11 
15 
23 
81 0.07 
146 0.07 
227 0.07 
287 0.06 
8 0.68 
14 0.78 
16 0.96 
18 1.30 
The pyruvate and malate concentrations were 5 mM. Specific activity of pyruvate was 
0.1 м С і / т т о ! . 0.89 mg mitochondrial protein was used. The 1 4 С 0 2 production and the 
amounts of 3-hydroxybutyrate and acetoacetate produced are given in nmol/mg pro­
tein. Both ketoacids were determined enzymatically. 
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Table 6.4. 
THE INFLUENCE OF MALATE AND/OR CARNITINE ON THE OXIDATION RATE OF 
PYRUVATE IN RAT LIVER MITOCHONDRIA 
Addition 
Time (min) 
1 4 C 0 2 formed 
Ketoacids formed 
None 
15 
333 
166 
45 
862 
389 
15 
488 
18 
Malate 
45 
1 195 
48 
Carnitine 
15 
352 
78 
45 
880 
221 
Malate 
Carnitine 
15 
489 
16 
45 
1 234 
52 
Pyruvate and malate were added to the incubation medium (0.96 mg mitochondrial protein) 
at a concentration of 5 mM. The L(-)carnitine concentration was 10 mM. The values are 
given as nmol/mg protein. Specific activity of pyruvate was 0.1 дСі/ттоІ . 
г mol '4C02 formed / mg protein UTO"2) 
30 45 
time (mm) 
Fig. 6.2. 
a. The influence of ATP and ADP on the pyruvate oxidation in rat liver homogenate. 
A preincubation was applied for 10 min in 10 mM Tris-HCl buffer (pH 7.4) con­
taining 0.25 M sucrose and 2 mM EDTA, with 5 mM ATP ( · · ) and 30 mM 
ATP (o o). 0.1 ml of these mixtures were thereafter diluted with 0.4 ml of 
the basic medium containing a.o. 2 mM ATP, as outlined in Materials and Methods. 
The final ATP/ADP ratio amounts to 0.5 and 3.0, respectively. 0.94 mg protein 
per incubation was used. 
b. The influence of Mg2* and ADP on the pyruvate oxidation in rat liver homo­
genate. ( · · ) 10 mM Mg3* and 2 mM ADP present during 10 min preincu­
bation as well as during incubation, (o o) no preincubation, 10 mM Mg2+ 
and 2 mM ADP present during incubation, (x x), Mg2* and ADP absent 
during preincubation but present during incubation (1.04 mg protein per incuba­
tion). 
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not increase the rate of pyruvate oxidation in rat liver mitochondria but 
decreased the rate of ketoacid production (Table 6.4.). In the presence 
of malate carnitine influences neither pyruvate oxidation nor ketogenesis 
in rat liver. In muscle mitochondria carnitine did not increase pyruvate 
oxidation in the presence of malate (Bookelman et al., to be published). 
The influence of the ATP/ADP ratio on the pyruvate oxidation was 
studied with rat liver homogenate (Fig. 6.2.). The presence of 5 mM ATP 
during preincubation of rat liver homogenate for 10 min, inactivates 
the pyruvate dehydrogenase complex. The activity of the complex is 
restored when ADP (2 mM final concentration) is added at the start of 
the incubation and the ATP/ADP becomes 0.5. The rate of pyruvate 
oxidation with time becomes linear after a lag phase of 10 min. Prolonged 
preincubation up to 30 min does not influence the pyruvate oxidation 
rate between 20 and 60 min. The presence of 30 mM ATP during pre-
incubation and an ATP/ADP ratio of 3.0 at the start of the incubation 
results in a low oxidation rate of pyruvate (Fig. 6.2a). 
The presence of 10 mM Mg2+ and 2 mM ADP in the preincubation 
medium results in an almost constant rate of pyruvate oxidation (Fig. 
6.2b) immediately after the start. Without preincubation or with pre-
incubation with or without Mg2+ and ADP the '"COj production rates 
from [1-14C] pyruvate were equal between 15 min and 45 min. This 
holds also for muscle tissue. Addition of Ca2* (10 mM) did not result 
in an increase of the pyruvate oxidation rate in rat liver homogenate. 
6.3.3. Discussion 
To measure pyruvate dehydrogenase activity under optimal conditions 
it is important to minimize the acetyl-CoA/CoA-SH and NADH/NAD+ 
ratio. Addition of malate to the incubation medium increases the con-
centration of intramitochondrial oxaloacetate, which results in a decrease 
of the acetyl-CoA concentration by increased activity of citrate synthase. 
Reduction of the acetyl-CoA concentration prevents inhibition of 
pyruvate dehydrogenase (17, 23, 24). The higher stimulatory effect of 
malate on the 14C02 production from [1-14C] pyruvate with muscle 
mitochondria as compared with that in liver mitochondria suggests the 
arise of a higher concentration of acetyl-CoA in rat muscle mitochon-
dria. The acetyl-CoA concentration in liver mitochondria is kept 
lower by the capacity of liver to produce ketoacids. The produc-
tion of ketoacids is dependent on the activity of citrate synthesis (25). 
Acetyl-CoA from the pool is preferentially used for citrate synthesis, 
when citrate synthase is adequately supplied with its other substrate 
oxaloacetate (25). 
The oxidation rate of pyruvate in the presence of malate remains 
almost linear with respect to time in spite of doubling of the NADH/ 
NAD+ ratio, which might be due to the limiting capacity of the respira-
tory chain. Doubling of the NADH/NAD* ratio does not decrease the 
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rate of pyruvate oxidation since for the high concentrations of pyruvate 
used (1 mM) may diminish the inhibitory action of the NADH/NAD* 
ratio on pyruvate dehydrogenase (26). 
A high ATP/ADP ratio favours the conversion of pyruvate dehydro­
genase into the inactive form (27). At an ATP/ADP ratio of 3.0 pyru­
vate dehydrogenase was almost completely inactivated (Fig. 6.2a.). 
Similar results were reported earlier with mitochondria of rat liver, fat 
cells and heart muscle (28, 29). In these reports a generally inverse 
PYRUVATE 
PVBUVATE DEHVDHOoeNASC 
COMPLEX 
-ін-
1
-
H O C H - C O O H 
I 
G c H j - c p o H 
•MALATE1* 
H - C - C O O H 
H O O C - C - H 
FUMARATE 
J ІОЕН 
C H , - C O O H 
С - C O O H 
II 
C H - C O O H 
C/S- ACQUIT ATE 
Y*i 
г С Н ^ - C O O M 
3 ¿ H j - ^ C O O H 
SUCCINATE 
^ ] l | SUCCINATE I I f « - ^ | THIOKINASE | 
G T P 
Ρ 
G D P ¿S ^ 
[ACONITASC 
Fe** 
CH^-COOH 
сн-соои 
I 
H O - C H - C O O H 
ISOCITRATE 
•NAO 1 " 
k N A D H + H + y¿ 
C H , — COOH 
ι
 x 
co-s-
SUCCINVL-COA 
N A D H + H * 
C o A . S H 
.CO. 
с H ^ c o o H 
C H - C O O H 
C O - COOH 
OXALOSUCCINA ТЕ 
JÍ-KETOGLUTABATE 
DEHYDROGENASE COMPLEX 
N A D ,• 2 ^ 0 - C O O H 
<* - KETOGLUTARATE 
Fig. 6.3. The citric acid cycle. The carbon atoms of the used labeled substrates are 
marked by their number. 
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relationship was found between mitochondrial ATP concentration and 
the activity of pyruvate dehydrogenase measured in extracts of the 
mitochondria. 
We compared the activities of pyruvate dehydrogenase in rat liver and 
muscle from the literature with our values (Table 6.1.). In the presence 
of malate the 1 4 C0 2 production rate from [1-14C] pyruvate are higher in 
our experiments than those previously published: rat liver homogenate: 
34 nmol/h. mg w.w. (31); rat liver mitochondria: 180—960 nmol/h. mg 
protein (17, 29, 30, 32—35); rat muscle homogenate; 46 nmol/h. mg 
protein (36) and rat(heart)muscle mitochondria: 1580—5400 nmol/h. 
mg protein (36—38). 
One may conclude that the pyruvate dehydrogenase activity can be 
measured as the 1 4 C0 2 production rate from [1-14C] pyruvate in the 
presence of malate. The described method gives a sensitive assay for the 
activity of this enzyme. The finding of the same ratio of pyruvate oxida-
tion/mitochondrial marker enzymes for mitochondria and homogenate 
indicates that a reliable assay of pyruvate dehydrogenase is possible in 
homogenates. 
6.4. Citric acid cycle 
6.4.1. Introduction 
In this section our attention is focussed on the different parts of the 
citric acid cycle. Von Korff and Kerpel-Fronius (39) concluded from 
their experiments that the citric acid cycle in brain mitochondria 
operates in at least three segments; 1. citrate to 2-oxoglutarate; 2. 2-oxo-
glutarate to malate and 3 . pyruvate plus malate to citrate (Fig. 6.3.). Our 
investigation of the citric acid cycle in rat liver homogenate and mito-
chondria are presented according to this scheme. The oxidation of 
citrate, 2-oxoglutarate, succinate and malate was studied. The effects of 
malate on citrate oxidation and of pyruvate on 2-oxoglutarate, succinate 
and malate oxidation were also investigated. 
6.4.2. Results 
6.4.2.1. Citrate oxidation 
The oxidation of citrate was measured with [6-14C] citrate to study 
the conversion of citrate to 2-oxoglutarate and with [1,5-14C] citrate to 
study the conversion of citrate to succinate (Fig. 6.3.). These experi-
ments were only performed with liver homogenates and mitochondria. 
Muscle mitochondria are unable to transport citrate across the mito-
chondrial inner membrane (40). 
The 1 4 C0 2 production from [6-14C] citrate and [1,5-14C] citrate with 
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homogenate and mitochondria is linear with respect to time of incuba­
tion up to 1 h and with respect to the amount of protein (for homo­
genate per ml incubation medium 0.2 — 1.0 mg protein and 0.1 — 1.0 mg 
protein, respectively and for mitochondria per ml incubation medium 
0.05 — 0.4 mg protein and 0.1 — 0.6 mg protein, respectively). 
Since malate facilitates the entry of citrate into the mitochondria via 
the tricarboxylate carrier (39), the effect of L-malate on citrate oxida­
tion in rat liver mitochondria was studied (Fig. 6.4.). Maximal stimula­
tion is obtained at 1 mM malate. 
relative rate of '"СОг production (7.0 -
1ΘΟ 
1 6 0 
1 4 0 
1 2 0 
100 - · -
io 2 0 
mM [malate] 
Fig. 6.4. The influence of malate on the " C O , production from [1,5-MC] citrate in 
rat liver mitochondria. The oxidation rate of [1,5- I 4C] citrate without addition of 
malate is set at 100 (110 nmol 1 4 C 0 1 / h . mg protein). Final citrate concentration 
was 1 mM with a specific activity of 0.5 /jCi/mmol. 0.05 mg protein was used. 
1 4 C 0 2 production from [1,5-14C] citrate is initiated by the 2-oxoglu-
tarate dehydrogenase catalyzed reaction. Half of the molecules [1,5-I4C] 
citrate delivers 1 4 C 0 2 through this reaction in the first turn of the cycle. 
Fluxes through isocitrate dehydrogenase, measured with [6-I4C] citrate, 
and through 2-oxoglutarate dehydrogenase, measured with [1,5- ,4C] 
citrate are almost identical in the absence of malate (Fig. 6.5. and Table 
6.5.). This finding agrees with the observation that no accumulation of 
2-oxoglutarate occurs (Table 6.5.). 
The stimulatory effect of malate on , 4 C 0 2 production is more pro-
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citrate oxidation 
cytochrome с ox.dase 
A 
homogenate 
Fig. 6.5. The ratio citrate oxidation/cytochrome с oxidase in homogenate and mito­
chondria of rat liver. The experiments shown in Fig. 4a b were performed with 
0.92 mg protein (homogenate) and 0.23 mg mitochondrial protein, respectively. 
Specific activity for both substrates was 0.5 ¿iCi/mmol. The final substrate concen-
trations of citrate and malate were 1 mM. (o о [б-^С] citrate, · · 
[ l .S-^C] citrate). 
Table 6.5. 
CITRATE OXIDATION IN RAT LIVER MITOCHONDRIA 
Without malate With malate 
Flux through isocitrate dehydrogenase 
Flux through 2-oxoglutarate dehydrogenase 105 
Malate utilization 
2-Oxoglutarate accumulation 
Citrate utilization 
0.17 mg mitochondrial protein was incubated with 1 mM [ 1 4 C] citrate (0.5 мСі/ 
mmol) with and without 1 mM malate for 60 min. Flux through isocitrate 
dehydrogenase was calculated from the 1 4 C 0 2 production with [6-1 4C] citrate, 
flux through 2-oxoglutarate dehydrogenase was calculated from the 1 4 CO, pro­
duction with [ Ι , ο - ' Ό ] citrate. This value was multiplied by 2. Fluxes are given 
in nmol/h. mg protein. Amounts of malate, citrate and 2-oxoglutarate (nmol/h. 
mg protein) were determined enzymatically. 
n.d. = not detectable 
125 
n.d. 
n.d. 
282 
441 
246 
1 147 
171 
376 
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nounced with [б-^С] citrate as substrate in comparison with [l,5- l 4C] 
citrate (Table 6.5.). 
Table 6.6 gives the 1 4 C 0 2 production rates of [6-14C]- and [1,5-14C] 
citrate in the presence and absence of malate (1 mM) in rat liver homo-
genate and mitochondria, calculated per mg protein. 
The 1 4C02 production from citrate, expressed as the ratio citrate 
oxidation/cytochrome с oxidase activity is equal for homogenate and 
for isolated mitochondria (Fig. 6.5.). This is also the case in the pres­
ence of malate. 
Table 6.6. 
, 4 C O , PRODUCTION RATE FROM [ 1 4 C] CITRIC AND CYCLE INTER­
MEDIATES IN HOMOGENATE AND MITOCHONDRIA OF RAT LIVER 
Activity 
Substrate 
[6-1 4C] Citrate 
6-14C] Citrate 
1,5-14C] Citrate 
1,5-14C] Citrate 
1-,4C 2-Oxoglutarate 
1-14C 2-Oxoglutarate 
5- ,4C 2-Oxoglutarate 
5-I4C] 2-Oxoglutarate 
;1,4-MC] Succinate 
:
 ІД-
1 4
С ] Succinate 
U-1 4С] Malate 
U-1 4С] Malate 
Addition 
— 
malate 
— 
malate 
— 
pyruvate 
— 
pyruvate 
— 
pyruvate 
— 
pyruvate 
Homogenate 
80 
316 
20-
76 
85 
90 
l l -
SS 
59 
59 
30 
26 
1 1 3 
185 
- 69 
117 
9 5 
94 
- 49 
- 65 
85 
89 
41 
50 
(13) 
(8) 
(3) 
Mitochondria 
7 1 -
2 5 9 -
3 5 -
9 6 -
5 1 5 -
538; 
3 0 -
3 5 -
150; 
200; 
1 1 6 -
1 2 3 -
2 1 3 
491 
194 
424 
L 400 
672 
1 8 8 
141 
2 0 3 
2 7 8 
240 
290 
(3) 
(3) 
(5) 
(5) 
(5) 
(7) 
(4) 
(4) 
(5) 
The values are given in nmol/h. mg protein for two separate preparations or as 
a range for the number of samples between parentheses. When a lag phase was 
present, the activity was calculated from the linear part of the curve. Incuba­
tions were performed in the basic medium as outlined in Materials and Methods 
for 60 min, except with [1-14C] 2-oxoglutarate as substrate, at which 30 min 
was applied. The concentration of the substrate (0.5 дСі/ттоІ) and of the 
added compound amounted to 1 mM. 
6.4.2.2. 2-Oxoglutarate and succinate oxidation 
The oxidation of 2-oxoglutarate and succinate forms part of the 
second segment of the citric acid cycle (Fig. 6.3.). The oxidation of 
these two intermediates was investigated in homogenate and mitochon­
dria of rat liver and muscle. 
1 4C02 production from [1-14C] 2-oxoglutarate is only dependent 
from the activity of 2-oxoglutarate dehydrogenase but the production 
of 14C02 from [5- l4C] 2-oxoglutarate is a parameter of the activity of 
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[ 1 - M C ] 2-oxoglutarate 
θ 
[ 5 - M C ] 2-oxoglutarate 
nmol '\Χ%/η rng protein («IO"1) 
16 
τ -
9 0 120 
time ( t i m e ) 
Fig. 6.6. The 1 4 C 0 2 production from t '
4 C ] 2oxoglutarate in mitochondria of rat 
muscle and rat liver. Final substrate concentration was 1 mM, with a specific activity 
of 0.5 ^Ci/mmol for [5-1 4C] 2-oxoglutarate and [ l - ^ C ] 2-oxoglutarate. 0.28 and 
0.21 mg mitochondrial protein were used in the experiments with mitochondria of 
rat liver and muscle, respectively. ( · muscle mitochondria, о liver mitochondria, 
[І С] 2-oxoglutarate, [b-'O] 2-oxoglutarate). 
the total citric acid cycle. The 1 4 C 0 2 production from this labeled com­
pound is formed through the isocitrate or 2-oxoglutarate dehydrogenase 
catalyzed reaction in the second turn of the cycle. 
The activity of 2-oxoglutarate dehydrogenase with [1-I4C] 2-oxoglu­
tarate, remained constant in rat liver and muscle for homogenate as well 
as mitochondria (Fig. 6.6.) during 60 min of incubation. The reaction 
rate was proportional to the amount of protein. Lineweaver-Burk plots 
with [1-14C] 2-oxoglutarate as substrate revealed an apparent K
m
 value 
for rat muscle homogenate of 0.25 mM and for rat liver homogenate of 
0.10 mM. The activities of 2-oxoglutarate dehydrogenase in homogenate 
and mitochondria of both tissues are given in Table 6.6. and 6.7. 
The 1 4C02 production from [5-14C] 2-oxoglutarate is linear as a func­
tion of time except for a lag phase of about 30 min (Fig. 6.6.). This lag 
phase, which was absent with homogenates, could be accounted for by 
a transport phenomenon or, a decrease of the specific activity of the 
radioactive compound due to endogenous 2-oxoglutarate or acceleration 
of the activity of the citric acid cycle itself. 
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Table 6.7. 
, 4 C 0 2 PRODUCTION RATE FROM [ , 4 С] CITRIC ACID CYCLE INTERMEDIATES 
IN HOMOGENATE AND MITOCHONDRIA OF RAT MUSCLE 
Activity 
Substrate 
[1-1 4C] 2-Oxoglutarate 
l - ^ C 2-Oxoglutarate 
5-14C 2-Oxoglutarate 
5-14C 2-Oxoglutarate 
1,4-14C Succinate 
[1,4- I 4C Succinate 
U- , 4C] Malate 
[U-' 4С] Malate 
Addition 
— 
pyruvate 
— 
pyruvate 
— 
pyruvate 
— 
pyruvate 
Homogenate 
570; 1 100 
3 2 - 40 
33; 40 
7 8 - 125 
90; 130 
120; 145 
135; 140 
(3) 
(3) 
Mitochondria 
4 460-12 600 
3 050 
1 0 - 66 
2 5 0 - 520 
1 0 - 24 
5 0 5 - 1 300 
2 5 - 150 
1 200 
(5) 
(6) 
(4) 
(3) 
(3) 
(3) 
The values are given in nmol/h. mg protein for two separate preparations as a range for 
the number of samples between parentheses. When a lag phase was present, the activity 
was calculated from the linear part of the curve. 
Incubations were performed in the basic medium as outlined in Materials and Methods 
for 60min;except with [1-1 4C] 2-oxoglu tarate as substrate in mitochondria. In these 
experiments 30 min of incubation was applied. The concentration of the substrate 
(0.5 ^iCi/mmol) and of the added compound amounted to 1 mM. 
nmol 1 4 C02/mg protein («IO"2) 
^ "i ' A rat muscle 
nmol 1 4 COj/mg protein (ж 10"1) 
9 0 120 
time (mm ) 
Fig. 6.7. The influence of pyruvate on the 1 4 CO, production from [5- , 4C] 2-oxo-
glutarate in mitochondria of rat muscle (a) and rat liver (b). The 2-oxoglutarate 
concentration was 1 mM (0.5 мСі/ттоІ). 0.16 and 0.33 mg mitochondrial protein 
were used in the experiments with mitochondria of muscle and liver, respectively. 
( · · without pyruvate, о о with pyruvate (1 mM)). 
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A transport phenomenon can be ruled out because production of 
1 4 C02 with [l- '^C] 2-oxoglutarate does not demonstrate a lag phase 
(Fig. 6.6.). This result is consistent with the view that the 2-oxoglutarate 
entry is faster than its oxidation rate (41, 42). 
No endogenous 2-oxoglutarate could be detected in the isolated mito­
chondria. Moreover, depletion of intermediates of the citric acid cycle 
by preincubation of the mitochondria without substrate in State 3 con­
ditions (2 mM ADP, 10 mM Mg2+) did not diminish the lag phase. 
A lack of acetyl-CoA at the start of the incubation could also be the 
cause of the lag phase. To examine this hypothesis the rate of 1 4 C02 
production from [5- 1 4C] 2-oxoglutarate was investigated in the presence 
of pyruvate (Fig. 6.7.). The addition of pyruvate eliminated the lag 
phase with isolated liver mitochondria. In rat muscle mitochondria the 
oxidation rate of [5- 1 4C] 2-oxoglutarate was low. Addition of pyruvate 
markedly increased the [5- 1 4C] 2-oxoglutarate oxidation rate, but a signi­
ficant lag phase remained. In homogenate of rat muscle and liver (Table 
6.6. and 6.7.) the 1 4 C 0 2 production rate of [5- 1 4C] 2-oxoglutarate was 
not stimulated by pyruvate suggesting that no limitation of the avail­
ability of acetyl-CoA exists in homogenates. Since pyruvate dehydro-
nmol 14СОг/Ь mg protein (хЮ"г) nmol 14СО
г
/Ь mg protein (xlO"3) 
V / 
Ί / 
/ 
* Λ-
7 
'7 
02 04 0 6 Οθ 10 12 
mM [pyruvate] 
Fig. 6.8. The influence of the pyruvate concentration on the 1 4 CO, production 
from [1-1 4C]- and [5-1 4C] 2-oxoglutarate in rat muscle mitochondria. The substrate 
concentration was 1 mM with a specific activity of 0.5 д С і / т т о ! . 0.10 mg mito­
chondrial protein was used. ( · · , [5- l 4 C] 2-oxoglutarate, о о [1- , 4C] 
2-oxoglutarate). 
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genäse and 2-oxoglutarate dehydrogenase complex have some cofactors 
in common it seemed worthwhile to study the influence of pyruvate 
addition on the 2-oxoglutarate dehydrogenase activity. Fig. 6.8. shows 
that 0.5 mM pyruvate inhibits the oxidation of [1-14C] 2-oxoglutarate 
about 40 percent in rat muscle mitochondria. 
The oxidation rate of [1,4-14C] succinate was constant during 60 min 
in rat liver and muscle homogenates and in liver mitochondria. More-
over, the production of 14C02 from this substrate was linear with respect 
to the amount of protein (homogenate and liver mitochondria 0.1 — 
1.0 mg protein/ml incubation medium and muscle mitochondria 0.05— 
0.5 mg protein/ml incubation medium). 
The presence of pyruvate in the incubation medium containing rat 
muscle or liver mitochondria stimulates the production of 1 4 C0 2 from 
[1,4-14C] succinate (Fig. 6.9.). The oxidation of [1,4-14C] succinate in 
the presence of pyruvate shows a similar phase in rat muscle mito-
20 40 60 20 40 60 
time ( mm ) 
Fig. 6.9. The influence of pyruvate on the , 4 C0 2 production of [1,4-I''C] succinate 
in homogenate and mitochondria of rat muscle and liver. The incubation media con-
tained 1 mM succinate (0.5 мСі/ттоІ) and 0.1—0.9 mg protein per incubation. 
( · · without pyruvate, о с with pyruvate (1 mM)). 
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chondria as that of [5- l 4C] 2-oxoglutarate. Values of the '"CC^ produc­
tion from [1,4-14C] succinate in homogenate and mitochondria of liver 
and muscle are given in Table 6.6. and 6.7. 
6.4.2.3. Malate oxidation 
In this section the attention is focussed on the third segment of the 
citric acid cycle from malate to citrate (Fig. 6.3.). An attempt is made 
to get an impression of the fluxes of the citric acid cycle under our 
experimental conditions in rat liver mitochondria, metabolizing malate 
and pyruvate. 
Malate oxidation was studied with [U-14C] malate in homogenates 
and mitochondria of rat liver and muscle. The rate of malate oxidation 
was constant for at least 90 min in homogenates and mitochondria of 
both tissues. The production of 14C02 from [U-14C] malate was also 
linear with the amount of protein (liver and muscle homogenate 0.1 — 
0.5 mg/ml incubation medium and mitochondria of both tissues 0.1 — 
1.0 mg/ml incubation medium) present in the incubation medium. 
The oxidation of malate was measured in the presence of 1 mM pyru­
vate to supply the mitochondria with acetyl-CoA to achieve optimal 
conditions for malate oxidation. Addition of pyruvate to rat muscle 
mitochondria, oxidizing [U-14C] malate, results in a 10-fold increase in 
the rate of I 4C02 production. Maximal stimulation was achieved at 
0.5 mM pyruvate. Rat liver mitochondria are less dependent on the 
supply of pyruvate in the incubation medium than those of muscle. A 
small varying stimulation (0—50 percent) was found at 10 mM pyru­
vate. 
The productionof 14C02 liberated from [U-14C] malate was considered 
as a parameter for malate oxidation. Since oxidation of one molecule of 
[U-14C]malate can yield two molecules '"СОг (at the isocitrate and the 
2-oxoglutarate dehydrogenase) during the first turn of the cycle the 
Table 6.8. 
CHANGES IN PYRUVATE, MALATE, CITRATE AND 2-OXOGLUTA­
RATE CONCENTRATIONS IN RAT LIVER MITOCHONDRIA OXIDIZING 
MALATE AND PYRUVATE 
Time (min) Δ malate Δ pyruvate Δ citrate Δ 2-oxoglutarate 
10 - 304 - 305 202 59 
30 -1 045 — 899 590 169 
60 -1 470 —1 420 895 302 
Rat liver mitochondria (0.18 mg protein/incubation) were incubated in 
0.5 ml of the basic medium as described in Materials and Methods supple­
mented with 1 mM malate, 1 mM pyruvate, 20 mM D-glucose and 1-2 U 
hexo kinase. 
Changes in concentrations are given in nmol/mg protein. 
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amount of 14C02 produced was measured simultaneously with the 
amount of malate converted. To prevent further oxidation of succinate 
malonate was added in a concentration of 10 mM, which almost com­
pletely inhibits succinate dehydrogenase (43). In that manner a second 
turn of the cycle was blocked. Addition of malonate resulted m a minor 
inhibition (20%) of the rate of 14C02 production from malate This sug­
gests that also in the absence of malonate a major part of malate was 
oxidized not further than to succinate during a single turn of the cycle 
Intermediates of the citric acid cycle (citrate and 2-oxoglutarate) 
were also measured during malate oxidation in order to elucidate the 
fate of malate during oxidation (Table 6.8.). Since 2-oxoglutarate can 
be converted in glutamate, the concentration of this compound during 
malate oxidation was determined. No glutamate could be demonstrated. 
Malate and pyruvate were converted almost stoichiometncally in State 3 
conditions. Moreover, about 60 percent of the metabolized malate was 
recovered as citrate and about 20 percent as 2-oxoglutarate 
The fluxes through citrate synthase, isocitrate- and 2-oxoglutarate 
dehydrogenase (Table 6.9.) were calculated from the data presented in 
Table 6 9 
FLUX THROUGH INDIVIDUAL STEPS OF THE CITRIC ACID CYCLE 
DURING OXIDATION OF [U- 1 4C] MALATE IN THE PRESENCE OF 
1 mM PYRUVATE 
nmol/mg protein 
Time (mm) 10 30 60 
Malate »-citrate 305 899 1 420 
Citrate »-2 oxoglutarate 103 309 525 
2-Oxoglutarate »-succinate 44 140 223 
Malate »-C02 88 304 551 
The flux, malate to citrate, could be obtained from the pyruvate dis­
appearance since no production of ketoacids or pyruvate carboxylase 
activity were observed Subsequent fluxes were calculated as follows 
Citrate »-2-oxoglutarate = Δ pyruvate — Δ citrate 
2-Oxoglutarate ••succinate = Δ pyruvate — Δ citrate — Δ 2-oxo­
glutarate 
The changes in the concentration of pyruvate, citrate and 2 oxogluta­
rate were obtained from Table 6 8 
The number ot nmoles of malate, which deliver CO, is calculated from 
the ' "CO, production from [U-^C] malate (Table 6 8 ) divided by the 
total radioactivity and multiplied by the total amount of malate (500 
nmoles) per incubation The total radioactivity is dependent on the 
number of | 4 С 0 2 molecules, which are originating from one molecule [U-'^C] malate This information can be obtained through the ratio 
between the activity of 2-oxoglutarate and isocitrate dehydrogenase, 
which is constant in respect to time and amounts to 0 42—0 45 Thus, 
one molecule [U- 1 4C] malate delivers 1 43 molecules 1 4 С 0 2 Since the 
radioactivity per incubation and per 1 4 C atom of malate is 100 000 dpm, 
the total radioactivity per incubation amounts to 142 000—145 000 dpm. 
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Table 6.8. The knowledge of the ratio between both dehydrogenases 
makes it possible to calculate the amount of [U-'4C] malate, which 
yields '"COj. From the ratio 2-oxoglutarate dehydrogenase/isocitric 
dehydrogenase it is calculated that 1.43 nmoles 14C02 are produced 
from 1.0 nmol [U-I4C] malate. The amount of malate responsible for 
the 1 4C02 production appears to agree with the flux through isocitrate 
dehydrogenase especially at 30 and 60 min (Table 6.9.). 
Table 6.10. shows the changes in the concentration of malate, citrate 
and 2-oxoglutarate with malate as substrate without pyruvate. The 
decrease in the concentration of malate and the increase in the concen­
trations of citrate and 2-oxoglutarate are less than in the presence of 
pyruvate, indicating that the flux through the citric acid cycle is smaller. 
Also in this case no glutamate could be demonstrated. No calculations 
of the flux through the citric acid cycle can be performed because the 
activity of citrate synthase is not known in the absence of pyruvate. 
Values of the '"COj production rate from [U-I4C] malate in homogenate 
and mitochondria of rat liver and muscle are given in Table 6.6 and 6.7. 
Table 6.10. 
CHANGES IN CONCENTRATION OF MALATE, CITRATE 
AND 2-OXOGLUTARATE WITH RAT LIVER MITO­
CHONDRIA OXIDIZING MALATE 
Time (min) 
10 
20 
30 
45 
60 
75 
Δ malate 
- 59 
- 2 4 4 
- 5 0 2 
- 7 7 8 
- 8 5 1 
- 9 8 5 
Δ citrate 
32 
69 
75 
159 
198 
219 
Δ 2-oxoglutarate 
23 
30 
41 
50 
77 
86 
Rat liver mitochondria (0.18 mg protein/incubation) were 
incubated in the basic medium as described in Materials and 
Methods, supplemented with 1 mM malate, 20 mM D-glucose 
and 1—2 U hexokinase. 
Changes in concentrations are given in nmol/mg protein. 
6.4.3. Discussion 
6.4.3.1. Citrate oxidation 
In rat liver mitochondria citrate is transport across the inner-mito-
chondrial membrane via the tricarboxylate carrier (44, 45). The activity 
of this transport system is low in heart and skeletal muscle (40). 
Earlier studies (39,45) revealed that L-malate facilitates tricarboxylate 
anion transport through the mitochondrial membrane. Maximal stimula-
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tion is obtained at 1 mM malate, which is in agreement with previous 
results (48). Addition of L-malate to sonicated preparations of rat liver 
mitochondria has no effect on the oxidation rate of citrate (40). 
The stimulatory effect of malate on l 4 C 0 2 production is more pro­
nounced with [6- 1 4C] citrate as substrate in comparison with [1,5-1 4C] 
citrate (Table 6.5. and 6.6.), since exchange of 2-oxoglutarate with 
added malate results in a net loss of labeled 2-oxoglutarate with [1,5-1 4C] 
citrate as substrate. This explanation is supported by the observation 
that accumulation of 2-oxoglutarate occurs in the presence of malate. 
Similar findings with rabbit heart mitochondria were reported by La 
Noue et al. (47). 
The finding of the same ratio of citrate oxidation/cytochrome с 
oxidase activity for homogenate and mitochondria (Fig. 6.5.) with both 
substrates supports the view that a reliable assay of citrate oxidation is 
possible with rat liver homogenate. The citrate oxidation rate in rat 
liver mitochondria measured as the l 4 C 0 2 production from [6- 1 4 C] 
citrate in the presence of malate is in the same order of magnitude as 
reported by Cederbaum et al. (48). 
6.4.3.2. 2-Oxoglutarate and succinate oxidation 
The 2-oxoglutarate dehydrogenase activity can be measured with 
[1- I 4 C] 2-oxoglutarate (Table 6.6.). Our values of the , 4 C 0 2 production 
rate from this substrate in rat liver mitochondria do well agree with 
the values reported earlier (48, 49). 
Pyruvate inhibits 2-oxoglutarate dehydrogenase in rat muscle mito­
chondria. The most likely explanation for this inhibition is that pyru­
vate may cause a high acetyl-CoA to CoA-SH ratio so that the oxidation 
of 2-oxoglutarate is inhibited by a shortage of CoA-SH (50,51). 
Addition of 1 mM pyruvate to rat liver mitochondria oxidizing [1- , 4C] 
2-oxoglutarate does not cause inhibition of the 2-oxoglutarate dehydro­
genase. These observations may be explained by the low K
m
 of 2-oxo­
glutarate dehydrogenase in rat liver mitochondria for CoA-SH (2.7 μΜ), 
which is several orders of magnitude less than the intramitochondrial 
CoA-SH concentration (43). The K
m
 value of this enzyme in pig or 
bovine heart muscle mitochondria for CoA-SH amounted to 20 μΜ (52). 
The activity of the citric acid cycle can be established by measure­
ment of the 1 4 C02 production from [5- 1 4C] 2-oxoglutarate. The 
stimulation of the ' "COj production of [5- 1 4 C] 2-oxoglutarate oxi­
dation through pyruvate in rat muscle mitochondria is the resultant 
of two opposite effects: inhibition of 2-oxoglutarate dehydrogenase 
by a limitation of CoA-SH and a stimulation of the citrate synthase 
reaction by an increase of the intramitochondrial concentration of 
acetyl-CoA. 
The 1 4 C 0 2 production from [1,4- 1 4C] succinate is not a parameter of 
the total citric acid cycle activity, since 1 4 C 0 2 can be produced from 
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(1,4-MC) succinate in the absence of 2-oxoglutarate dehydrogenase 
activity. The activity of the cycle measured with [1,4-I4C] succinate in 
rat liver mitochondria is lower than that measured by Cederbaum et al. 
(48). 
6.4.3.3. Malate oxidation 
Liver mitochondria are for malate oxidation less dependent on the 
addition of pyruvate into the incubation medium than muscle mitochon­
dria. This was also observed with [5-14C] 2-oxoglutarate and [1,4-14C] 
succinate. These results may indicate that rat liver mitochondria better 
maintain an adequate acetyl-CoA concentration than muscle mitochon­
dria, since the K
m
 values of citrate synthase for acetyl-CoA are in the 
same order of magnitude in both tissues (42, 49). 
The malate oxidation is stimulated by addition of pyruvate as can be 
concluded from the measured 1 4 C 0 2 production and the malate dis­
appearance in the presence of pyruvate. The equal rate of disappearance 
of pyruvate and malate indicates that the depletion of malate and pyru­
vate may be taken as an index of flux through citrate synthase, accord­
ing to Hansford and Johnson (53). Knowledge of this flux allows calcu­
lation of the fluxes through isocitrate- and 2-oxoglutarate dehydro­
genase. This calculation could be verified by the amount of malate, 
which is oxidized through isocitrate dehydrogenase and which can be 
calculated with the l 4 C 0 2 production from [U-I4C] malate (Table 6.9.). 
Both calculations agree, especially at 30 and 60 min. 
It is not justified to conclude from the accumulation of citrate and 
2-oxoglutarate during malate oxidation that aconitase or isocitrate 
dehydrogenase and 2-oxoglutarate dehydrogenase are rate-limiting 
enzymes. For the accumulation of citrate and 2-oxoglutarate can be 
explained in terms of carrier mediated transport out of the mitochondria 
stimulated by addition of malate (47, 54). 
The measured 14С02 production from [U-14C] malate in rat liver mito­
chondria (Table 6.6.) is approximately half of that found by Cederbaum 
et al. (48). 
6.5. The activities of pyruvate dehydrogenase, citric acid cycle and cyto­
chrome с oxidase in human liver and muscle tissue 
6.5.1. Introduction 
Since human tissue is scarcely available to collect data about the 
regulation of pyruvate oxidation only some of the experiments earlier 
described in this Chapter could be repeated with human tissue. 
Normal liver and muscle tissue for determination of control values 
can rarely be obtained. There are three ways to collect human tissue: 
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Autopsy material, material obtained at surgery and at needle biopsy 
The only advantage of using liver obtained post mortem is the piac-
tical unlimited amount available During the time between death and 
autopsy autolytic changes are taking place in the liver, to a greater 
extent than in most organs, even under optimal conditions of storage 
Collection of liver tissue by surgery permits removal of up to several 
grams. But no surgeon will perform a laporotomy just for the purpose 
of the biopsy The liver material obtained from necessary surgery due 
to diseases of other organs can only with rare exceptions be considered 
as normal. 
The small amount obtained by needle biopsy which is generally about 
20 mg constitutes a disadvantage of this technique. This drawback may 
in most cases be made up by employment of micro-methods for the 
determination of enzyme activities. 
6.5.2 Results 
The 1 4 C 0 2 production rate from [1- , 4 C] pyruvate and various radio­
active intermediates of the citric acid cycle was constant with human 
liver homogenate during 60 mm of incubation Moreover, the reaction 
rate was proportional to the amount of protein (0.1 — 0.5 mg/ml incu­
bation medium). Similar results were obtained with 1 4 C 0 2 production 
from [1- 1 4C] pyruvate and [5- 1 4C] 2-oxoglutarate in human muscle 
homogenate. 
Table 6 11 
OXIDATION RATES OF PYRUVATE AND VARIOUS INTERMEDIATES OF THE 
CITRIC ACID CYCLE IN HUMAN LIVER HOMOGENATE 
"^-^. Liver sample 
Substrate ^^--.^^ 
'1 " 
1 u 
6-u 
6-u 
'1,5 
1,5 
l-1" 
s-'
4 
1,4 
'C Pyruvate 
'C Pyruvate + malate 
'С Citrate 
'С Citrate + malate 
-
I 4 C ] Citrate 
1 4
 С ] Citrate + malate 
'С 2 Oxoglutarate 
1
С 2-Oxoglutarate 
-
M C ] Succinate 
[ U M C ] Malate 
[U- 1 4CJ Malate + pyruvate 
1 
48 
58 
2 
42 
65 
51 
3 
77 
79 
58 
189 
11 
11 
Oxidation rate 
4 
194 
205 
48 
5 
41 
45 
82 
115 
17 
27 
6 
175 
205 
7 
100 
117 
26 
36 
8 
101 
116 
156 
4 0 
106 
4 6 
167 
83 
84 
9 
56 
94 
13 
24 
The conditions of incubation are given in Materials and Methods The concentration 
of the substrates (0 5 juCi/mmol) and the added compounds were 1 mM Values are 
given in nmol 1 4 С О , formed per h per mg protein 
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Table 6.12. 
OXIDATION RATES OF PYRUVATE AND 2-OXOGLUTARATE IN HUMAN 
MUSCLE HOMOGENATE 
Oxidation rate 
Muscle sample 
Substrate" 
[ l - 1 4 С] Pyruvate 42 146 98 65 52 
[ l- 1 4 С І Pyruvate + malate 90 
[l- 1 "С] 2-Oxoglutarate 
[5-1 4CJ 2-Oxoglutarate 30 
22 
72 
49 
27 
67 
16 
56 
231 
48 
The incubation procedure was the same as outlined in Materials and 
Methods. The concentration of the substrates (0.5 дСі/ттоІ) and the added 
compound were 1 mM. 
Values are given in nmol '"COj formed per h. per mg protein. 
Table 6.13. 
VALUES OF CYTOCHROME С OXIDASE 
IN HOMOGENATES AND MITOCHONDRIA 
OF HUMAN LIVER AND MUSCLE TISSUE 
Material Activity 
Liver Homogenate 37 ± 13 (7) 
Mitochondria 90, 90 
Muscle Homogenate 156 ± 56 (5) 
Mitochondria 1 529 ± 464 (8) 
Activities are given in nmol/min mg protein 
as the mean ± S.D. for the number of sam­
ples between parentheses. 
Table 6.11. and 6.12. give some values of the oxidation rate of pyru­
vate and of various intermediates of the citric acid cycle. Addition of 
malate, to the incubation medium results in a slight stimulation of the 
pyruvate oxidation in human liver homogenate. In muscle the effect of 
malate on the pyruvate oxidation was more pronounced. The increase of 
1 4C02 production from [6-14C] citrate through malate in liver homo­
genate indicates activation of the transport rate of citrate. 
A well functioning respiratory chain is necessary for pyruvate oxida­
tion.In ourinvestigation only cytochrome с oxidase activity was measured 
in human material since determination of the other cytochromes 
requires a relative high amount of mitochondrial protein (1 mg protein) 
and this quantity cannot be obtained with a needle biopt. Values of 
cytochrome с oxidase activity in homogenates and mitochondria of 
liver and muscle tissue are presented in Table 6.13. Cytochrome с 
oxidase activity in muscle is considerably higher than in liver tissue. 
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6.5.3. Discussion 
Data concerning pyruvate dehydrogenase and citric acid cycle activity 
and respiratory chain in normal human tissue are scarce. Comparison of 
findings, reported in the literature, with our results is difficult because 
of the different preparation procedures of homogenates and mitochon­
dria, the different experimental conditions during enzyme assays and 
the difference in the manner of expression of enzyme activities (3—5, 
55,56). 
A few data are available from the literature. The values of the pyru­
vate dehydrogenase activity as reported earlier by other investigators 
are for human liver homogenate: 120—246 nmol/h. mg protein (56), 
139, 143, 260 nmol/h. mg protein (57) and 40—80 nmol/h. mg w.w. 
(58); for human muscle homogenate: 336—1236 nmol/h. mg protein 
(56) and 340—2400 nmol/h. mg protein (55). The mean activity of 
pyruvate dehydrogenase in liver homogenate (Table 6.11.) agrees with 
these values. Our activities of this enzyme in muscle homogenate 
(Table 6.12.) are lower than the values of other investigators. In human 
tissue the 1 4 C 0 2 production rate from [1 4C] citric acid cycle inter­
mediates and values of the cytochrome с oxidase activity has not been 
reported by other investigators. 
6.6. General discussion 
The activity of pyruvate dehydrogenase can be measured in liver and 
muscle tissue by the 1 4 C 0 2 production from [1-14C] pyruvate in the pres­
ence of malate. Pyruvate dehydrogenase represents the rate limiting step 
in the 1 4 C 0 2 production from [1-14C] pyruvate in rat liver (paragraph 
6.3.). The activity of pyruvate dehydrogenase in human tissue is some­
what lower than the activity of this enzyme in rat tissue. 
The citric acid cycle can be studied with [6-14C] citrate, [1,5-14C] 
citrate, [1-14C] 2-oxoglutarate, [5-14C] 2-oxoglutarate, [1,4-,4C] succi­
nate and [U-14C] malate. The 1 4 C 0 2 production rate from [5-14C] 2-oxo­
glutarate is a parameter of the overall citric acid cycle activity. The first 
segment of the cycle (citrate to 2-oxoglutarate) can be measured with 
[6-14C] citrate in liver tissue. This substrate cannot be used in muscle 
tissue because of its low permeability across the innermembrane of 
muscle mitochondria. In the second segment (2-oxoglutarate to malate) 
only the first step can be measured with [1-14C] 2-oxoglutarate. The 
oxidation of [1,4-I4C] succinate is a parameter of the activity of the rest 
of the second segment. Measurement of the oxidation rate of [1,5-14C] 
citrate gives information of both the first and second segment of the 
cycle. The third segment (malate to citrate) can be investigated with 
malate and pyruvate as substrates by measuring of the accumulation of 
citrate and 2-oxoglutarate. The 1 4 C 0 2 production from [U-14C] malate 
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is not a correct parameter of the overall activity of the citric acid cycle, 
since a major part of malate is oxidized not further than to succinate, 
probably due to transport of citrate and 2-oxoglutarate out of the 
mitochondria in exchange with malate. 
The I 4C02 production rates from (14C) citric acid cycle intermediates 
in rat and human liver are in the same order of magnitude, which holds 
also for the 14C02 production rate from [5-14C] 2-oxoglutarate in rat 
and human muscle. 
In biopsy materials of patients, probably suffering from a defect in 
pyruvate dehydrogenase or citric acid cycle, the 1 4C02 production from 
[1-14C] pyruvate in the presence of malate and from [5-14C] 2-oxogluta­
rate should be measured in first instance. If the size of the biopt permits 
or a second biopt is taken the activity of the segments of the citric acid 
cycle can be measured separately by the '"СОг production from [6-I4C] 
citrate (first segment, not in muscle) and from [1-14C] 2-oxoglutarate 
and [1,4-14C] succinate (second segment) and by the accumulation of 
citrate and 2-oxoglutarate arising from malate and pyruvate. 
It remains necessary to perform more extensive studies with human 
material because results obtained with rat tissue may not be considered 
generally as control values for suspected cases of enzyme deficiencies. 
For the present we are obliged to use also the results obtained with rat 
tissue in the elucidation of enzyme defects. 
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Chapter 7. 
Pyruvate carboxylase in liver tissue 
7.1. Introduction 
Besides defects in the oxidation of pyruvate, disturbances in the car-
boxylation of pyruvate are known as well. After the discovery of pyru-
vate carboxylase (pyruvate: C02 ligase (ADP) EC 6.4.1.1.) by Utter and 
Keech (1) it became evident that this enzyme catalyzes a key reaction 
in intermediary metabolism: 
acetyl-CoA 
Pyruvate + ATP + CO2 — - • oxaloacetate + ADP + Pi 
Mg2 
The enzyme has a function in gluconeogenesis from lactate, pyruvate 
and some amino acids, and in the replenishment of intermediates of the 
citric acid cycle. The rat liver enzyme is a tetrameer of molecular weight 
of 500,000 containing 4 molecules of biotin. Manganese is also bound 
to the enzyme. It requires ions such as K+ or NH¡ in addition to acetyl-
CoA and free Mg2+ for maximal activity (2—9). 
The regulation of the activity of pyruvate carboxylase was more 
extensively discussed in Chapter 1. Considerable effort has been expended 
to demonstrate that the concentration of acetyl-CoA is the most impor-
tant factor which regulates the rate of pyruvate carboxylation in mamma-
lian liver (9—12). The Ka value, describing the activation of rat liver 
pyruvate carboxylase by acetyl-Co A, is dependent on pH, ionic strength, 
temperature and concentrations of bicarbonate, potassium, magnesium, 
ATP and pyruvate (13—16). The activation of pyruvate carboxylase 
through addition of ATP is greater at higher than at lower acetyl-CoA 
concentrations (17). The catalytic properties of human and rat liver 
pyruvate carboxylase resemble closely (12). 
The acetyl-CoA concentration is subject to changes through supply 
by the pyruvate dehydrogenase system and fatty acid oxidation and by 
utilization for citrate synthesis and ketogenesis in incubation systems 
for measuring pyruvate carboxylase activity. A constant level of acetyl-
CoA can be achieved by introduction of the regenerating system of 
acetyl-CoA proposed by Henning and Seubert (18). 
The present investigation was intended to develop a reliable assay of 
pyruvate carboxylase activity in order to establish a possible deficiency 
of pyruvate carboxylase in liver samples of patients. The determination 
of pyruvate carboxylase activity in liver homogenate is based on the 
assay of [14C] oxaloacetate formed from NaH14C03 and pyruvate in the 
presence of the acetyl-CoA regenerating system. The acid-labile oxalo-
acetate is converted to citrate by citrate synthase (EC 4.1.З.7.), added to 
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the incubation mixture. The acetyl-CoA regenerating system consists of 
acetylphosphate and phosphotransacetylase (EC 2.3.1.8.). 
7.2. Materials and Methods 
Fresh rat and human liver (10 mg wet weight/ml) were homogenized 
in 5 mM Tris-HCl buffer (pH 7.3) containing 2 mM EDTA with a Potter-
Elvejhem homogenizer. The homogenate was centrifuged at 600 χ g for 
10 min and the supernatant was lyophilized. By this treatment mito­
chondria were disrupted. All procedures were carried out at 0—30C. 
Prior to the assay the lyophilized material was suspended with water 
to the same volume as before lyophilization. The incubation medium 
consisted of 100 mM Tris-HCl buffer (pH 7.8), 10 mM MgCl2, 2.5 mM 
ATP, 0.7 mM CoA-SH, 5.0 mM sodium pyruvate, 20.0 mM KHCO3, 
0.5 μΟΊ NaH 1 4СОз, 4.0 mM acetylphosphate, 1.1 U citrate synthase and 
5 U phosphotransacetylase in a final volume of 1.0 ml. A preincubation 
period of 3 min was used to form acetyl-CoA. Thereafter the incuba­
tion was started by addition of 0.2 ml homogenate and continued at 
30°C up to 1 h. An enzyme blank was run under identical conditions 
with pyruvate omitted. The reaction was terminated by the addition of 
0.4 ml ice-cold 3 M perchloric acid solution. A tube with 0.2 ml Hyamine 
hydroxide was added to trap the non-bound 14C02 during a postincuba-
tion for 30 min at 30oC and an additional one at room temperature for 
16 h. Radioactivity was measured with a liquid scintillation counter 
after addition of 10 ml Instagel to the incubation medium. 
Acetyl-CoA, sodium pyruvate, ATP, citrate synthase and phospho­
transacetylase were obtained from Boehringer, Mannheim, West-
Germany, Instagel and Hyamine 10X hydroxide from Packard Instru­
ments Co., Brussel, Belgium, МаН14СОз was obtained from The Radio­
chemical Centre, Amersham, England. Protein was determined according 
to the method described by Lowry et al. (19). 
7.3. Results 
The activity of pyruvate carboxylase in freeze-dried samples of rat 
liver homogenate remained constant during a period of two months 
when samples were stored at — 20oC The homogenization procedure 
was performed in a hypotonic medium since Nakashima et al. (20) 
reported that rat liver enzyme is inactivated at low temperature in the 
presence of high salt concentrations. Pyruvate carboxylase activities of 
fresh biopsies of seven postulated cases of Leigh's disease were not 
significantly different from values obtained from frozen samples (21). 
Grover et al. (22) reported similar results. 
In our assay citrate synthase was used to convert the acid-labile oxalo-
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acetate into the acid-stable citrate. An alternative assay is based on the 
conversion of oxaloacetate to malate by addition of malate dehydro­
genase and NADH. Addition of the latter can stimulate, however, the 
conversion of pyruvate into lactate with lactate dehydrogenase present 
in rat liver homogenate. Oxidation of citrate was not observed under the 
conditions used in our assay. No '"COj production was detected at an 
incubation with [6-14C] citrate. 
Fig. 7.1A shows the influence of the concentration of acetyl-CoA on 
the activity of pyruvate carboxylase of rat liver in the absence of the 
regenerating system. Saturating levels of acetyl-CoA are obtained at a 
concentration of 1.0 mM, as previously published (15). In order to 
maintain a constant level of acetyl-CoA the regenerating system of 
acetylphosphate plus phosphotransacetylase was introduced. Fig. 7.IB 
nmoles C 0 2 fixed (жІСГ2) 
A 
Fig. 7.1 
A (left). 
Fig. 7.1 
В (right) 
The effect of varying concentrations of acetyl-CoA on the activity of pyru­
vate carboxylase in lyophilized rat liver homogenate. The incubation 
medium (final volume of 1 ml) consists of 100 mM Tris-HCl buffer (pH 
7.8.), 10 mM MgClj, 2.5 mM ATP, 0.4 CoA-SH, 4 mM pyruvate, 12.5 mM 
KHCO,, 0.5 jiCi NaH^CO, and 0.84 mg protein. The acetyl-CoA concen­
trations were: • 0 mM; π 0.2 mM; · 0.4 mM; Û 0.7 mM; о 1.0 mM. 
The effect of varying concentrations of CoA-SH on the activity of pyru­
vate carboxylase in lyophilized rat liver homogenate. The incubation 
medium was composed as described in Materials and Methods and con­
tained 0.63 mg protein. The CoA-SH concentrations were: • 0 mM; 
α 0.17 mM; · 0.35 mM; Δ 0.52 mM; о 0.7 mM. 
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shows the influence of the CoA-SH concentration on the pyruvate 
carboxylase activity in the presence of the regenerating system. Maximal 
activity was achieved at a concentration of 0.7 mM of CoA-SH. Intro-
duction of the regenerating system results in a linearity of the reaction 
up to 20 min even at the lowest CoA-SH concentration (0.17 mM), 
while in its absence non-linearity was observed at a concentration of 
acetyl-CoA as high as 0.4 mM. A preincubation period of 3 min was 
optimal in all cases. 
The activity of pyruvate carboxylase is linear with the amount of 
protein (range 0.4—1.0 mg protein/ml incubation medium) and con-
stant during 60 min of incubation in the presence of the regenerating 
system (0.7 mM CoA-SH). 
The kinetic properties of pyruvate carboxylase from human and rat 
liver homogenate were established by measurement of the Km value for 
pyruvate and for HCOJ in the presence of the acetyl-CoA regenerating 
system. For HCO3 a linear double-reciprocal plot (Lineweaver-Burk) 
was obtained with a Km of 2.3 mM in rat liver and of 3.2 mM in human 
liver homogenate. One Km value for pyruvate was found, in rat liver 
homogenate of 0.20 mM and in human liver homogenate (stored as liver 
tissue at —20oC for 1 week) of 0.67 mM (Fig. 7.2.). 
The activities of pyruvate carboxylase in rat and human liver homo-
genate in the presence of the regenerating system are compared with 
those from the literature in Table 7.1. 
1
'V Inmoles - 1 min mg w w ) 
15 
pyruvate ) 
Fig. 7.2. Lineweaver-Burk plots for pyruvate carboxylase in rat ( · ) and human liver 
homogenate (o) with varying pyruvate concentrations. 
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Table 7.1. 
PYRUVATE CARBOXYLASE ACTIVITY IN RAT AND HUMAN LIVER HOMOGENATE 
Species Activity References 
nmol/min mg. w.w. nmol/min mg. protein 
Rat 
Human 
Table 7.2. 
2.8 
3.0 
5.1 
16.6 
15.6 
11.7 
4.4 
3 . 3 ( 2 . 1 - 1 0 . 6 ) 
2 .1 ;6 .2 
1.1 
1.2; 0.9; 0.7 
1.8 
0 .03 
1.2 
1.9 
12.2 
1 .7 ;2 .1 ;2 .5 
0.9 ( 0 . 6 - 1 . 7 ) 
1 .3;0 .8 
23.0 
72.7 
26.6 
2 5 . 9 ( 1 3 . 1 - 5 2 . 8 ) 
36.8; 
10.4; 
; 26.4; 21.4 
5.7 
Henning and Seubert (18) 
H o m m e s e t a l . (23) 
T a n g ( 2 4 ) 
Grover et al. (22) 
Garthoff (23) 
Söling (26) 
Weiss (27) 
This report 
H o m m e s e t a l . (23) 
Bottger (28) 
Yosh idae ta l . (29) 
Grover et al. (22) 
Brunet tee ta l . (30) 
Tang(24 ) 
Mortier and Michaelis (31) 
Scrutton (12) 
Maesaka et al. (32) 
Robinson et al. (33) 
This report 
K m VALUES OF PYRUVATE AND BICARBONATE FOR PYRU-
VATE CARBOXYLASE IN RAT AND HUMAN LIVER HOMOGE-
NATE 
Species 
Rat 
Human 
K m values (mM) 
Pyruvate Bicarbonate 
0 .095 0.62 3.4 
0.25 3.0 
0.20 2.3 
0.22 3.2 
0.20 4.0 -
0.40 5.7 -
0.67 3.2 
References 
McClure et al. 
Scrutton (14) 
This report 
(2) 
Scrutton and White (12) 
Brunette et al. (31) 
Delvin et al. (35) 
This report 
7.4. Discussion 
Our Km value of bicarbonate is in quantitative agreement with other 
reports (Table 7.2.) in contrast to the value of pyruvate. Delvin et al. 
(34) suggested the presence of multiple forms of human liver pyruvate 
carboxylase. This postulate of functional heterogenity was based on the 
observation (30) of a biphasic Lineweaver-Burk plot for pyruvate in 
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studies performed on homogenates prepared from control liver samples 
and on the apparent absence of this behaviour for a liver homogenate 
prepared from a patient suffering from thiamine responsive lactic aci­
dosis (30). We could not confirm such a double K
m
 value of pyruvate 
carboxylase for pyruvate in rat and human liver homogenate. We have 
no explanation for this discrepancy. In contrast with our method no 
provision was made for maintenance of the initial acetyl-CoA concen­
tration in the study of Brunette et al. (30). We do not agree with the 
comment of Scrutton and White (12) on these observation, that the 
deficiency of the low-K
m
 component of pyruvate carboxylase could be 
explained by a pyruvate dehydrogenase defect in liver, resulting in a 
deficit of acetyl-CoA. The activity of pyruvate dehydrogenase is not 
detectable in the absence of cofactors of pyruvate dehydrogenase and in 
the presence of 2.5 mM ATP in liver homogenate. Our values of the 
activity of pyruvate carboxylase agree with most of the values reported 
previously (Table 7.1.) except those of Brunette et al. (30) and Scrutton 
et al. (12) in human liver homogenate. The described method gives an 
independent and sensitive assay for the activity of pyruvate carboxylase. 
carboxylase. 
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8.1. Introduction 
Pyruvate oxidation is frequently studied as a system for investiga­
tions of metabolic capacity and regulation. The purity of radio-active 
substrates such as [1-14C] pyruvate and [2-14C] pyruvate is a crucial 
factor for correlating the trapped 1 4COj with the total radioactivity 
originally present in these substrates. Moreover, if the impurity influences 
metabolism the results obtained may be misleading (1). 
Several authors (2,3) described the presence of the dimer of pyru­
vate in aqueous solutions. The oxidative decarboxylation of 2-oxogluta-
rate in rat heart mitochondria is inhibited by this compound. Sub­
sequently it was demonstrated that this compound produces a block in 
the citric acid cycle so that also pyruvate cannot be oxidized with nor­
mal rate (4). Pyruvate can also decompose by a nonenzymatic decarboxy­
lation. In aqueous solutions this likely results from radicals arising from 
water in the presence of the radiation which attack the dissolved 1 4 C 
compounds (5). Metal ions especially Zn2+, present in solutions of pyru­
vate, catalyze not only the decarboxylation of pyruvate (6) but also the 
enhancement of pyruvate aldolization (7). 
In this paper the conversion of pyruvate into 2,4-dihydroxy-2-methyl-
glutaric acid, the reduced form of parapyruvate, is demonstrated. This 
structure of this compound was established by mass-spectrometry. We 
could not detect any inhibition of this compound on pyruvate and 2-oxo-
glutarate oxidation in rat liver homogenate. 
8.2. Materials and Methods 
High voltage electrophoresis was performed with a Camag apparatus 
on Whatmann (3MM) for 40 min at 2000 V in formic acid/acetic acid/ 
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water (1.7:1.7:100, by vol.) adjusted with pyridine t o pH 3.1. The paper 
strokes were scanned with a Packard paper scanner. Radioactivity was 
quantitatively determined with liquid scintillation counting. Pyruvate 
was determined enzymatically according to Czok (8). 
Chemical-ionization mass spectra were recorded with a Hewlett-
Packard 5982A mass spectrometer equipped with a dual EI/CI source. 
CH4 at a pressure of 2x10" 4 torr was used as CI reagent. Source tem­
perature was 55 0C and probe temperature 260°C. Electron emission 
current was 300 μ A and electron energy 300 eV. The solution of the 
unknown compound in ethylacetate was introduced into the source. 
A 5% rat liver homogenate was prepared in 10 mM Tris-HCl buffer 
(pH 7.4), containing 0.25 M sucrose and 2 mM EDTA, with a Potter-
Elvejhem homogenizer. The supernatant, obtained after centrifugation 
at 600 χ g for 10 min at 4 0 C, was used in the assay. The basic incuba­
tion medium contained 50 mM potassium phosphate buffer, 0.5 mM 
EDTA, 6 mM MgCl2, 2 mM ADP and 75 mM KCl adjusted to pH 7.4. 
The final substrate concentration of [1- 1 4C] pyruvate or [ l - l 4 C ] 2-oxo-
glutarate (0.5 μ^/ιηπιοί) amounted to 1 mM in a final volume of 0.5 ml. 
In the experiments with pyruvate as substrate 1 mM malate was added 
to the incubation medium. Incubation with 0.1—0.5 mg protein was 
performed in 20 ml glass scintillation vials, sealed by rubber stoppers, 
containing two small glass tubes, one fitting inside the other (9). The 
enzyme assay was stopped with 0.2 ml of 3 M perchloric acid and the 
1 4 C 0 2 was trapped in Hyamine hydroxide (Packard). Radioactivity 
was measured after addition of 10 ml scintillation fluid (4 g Omnifluor/ 
1 toluene). Radioactive substrates were purchased from the Radiochemi­
cal centre, Amersham. 
8.3. Results 
An electropherogram of a four days old aqueous solution of [1- I 4 C] 
pyruvate stored at — 20°С is presented in Fig. 8.1. The peak with the high­
est electrophoretic mobility represents the authentic [1- 1 4C] pyruvate 
as judged by its convertibility to [1- 1 4C] lactate under conditions for 
quantitative conversion with lactate dehydrogenase. The peak with the 
lower electrophoretic mobility could not be converted under the same 
conditions, not even after prolonged incubation for 22 h. The migration 
rate of the impurity was about the same as that for [1- 1 4C] 2-oxogluta-
rate under the conditions used. 
A pure solution of the unknown compound was obtained after storing 
a 1 mM pyruvate solution (pH 5.5) at —20oC for two months. In this 
solution no pyruvate could be detected enzymatically. The formation 
of the impurity appeared to be irreversible. The sample was adjusted to 
pH 1 and after that it was prepared for mass-spectrometry by freeze 
drying and solving in ethylacetate. 
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Fig. 8.1. High voltage electrophoresis of radioactive [1-1 4C] pyruvate, stored at 
—20°C as an aqueous solution for 4 days. Electrophoresis was performed as described 
in Methods. Radioactivity was 25 nCi, concentration of pyruvate 300 μΜ and sam­
ple size 5 μ\. 
Earlier studies (2, 5, 7) revealed the presence of parapyruvate in stored 
solutions of pyruvate. Therefore our solution was tested as to the pres­
ence of a compound, which react with 2,4-dinitrophenylhydrazine. For­
mation of a hydrazone was not observed at 483 nm. 
The compound could be identified by mass-spectrometry as 2,4-dihy-
droxy-2-methylglutaric acid (Fig. 8.2 and Table 8.1). 
Addition of this substance up to 0.25 mM caused no inhibition of the 
oxidation of [1-14C] pyruvate and [1-14C] 2-oxoglutarate with rat liver 
homogenate (Table 8.2.). About 20% inhibition occurred in the presence 
of 0.5 mM of this substance. 
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Fig. 8.2. Mass spectrum of 2,4-dihydroxy-2-methyl glutaric acid. 
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Table 8.1. 
MASS-SPECTRUM OF 2,4-Ό1ΗΥΌΚΟΧΥ-2-
METHYL GLUTARIC ACID (m=178) 
m/e Fragment Relative intensity (%) 
73 
89 
133 
151 
179 
207 
219 
γ m - 1 6 
τ
 m 
m + 1-46 
m + 1-28 
m + 1 
m + 29 
m + 41 
100 
38 
17 
65 
57 
11 
3 
The peak at m/e 179 represents the proton-
ated molecule (m + 1). The loss of a carbo-
nylgroup from m/e 179 yields the peak of 
m/e 151. The peak at m/e 133 is due to loss 
of the terminal protonated carboxylgroup. 
The peak at m/e 89 is due to the cleavage of 
the molecule between C-3 ad С-4. The base 
peak (m/e 73) is formed by loss of an oxygen 
atom from m/e 89. 
Table 8.2. 
INFLUENCE OF гД-ВІН ОНОХ -г-МЕТН Ь 
GLUTARATE ON PYRUVATE AND 2-OXOGLUTA-
RATE OXIDATION IN RAT-LIVER HOMOGENATE 
Concentration (μΜ) Pyruvate 2-Oxoglutarate 
0 
25 
50 
100 
150 
200 
250 
500 
100 
104 
99 
95 
103 
98 
95 
81 
100 
98 
99 
102 
95 
96 
94 
85 
Incubation during 1 h was performed as described in 
analytical procedures. Concentrations of the com­
pound is given in μΜ. Relative activities of oxidation 
are given in percentage of the control value. 
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8.4. Discussion 
Artificial decreases in apparent activity of pyruvate dehydrogenase 
resulted with [1-14C] pyruvate when the substrate was not stored with 
meticulous care (1). The marked formation of the impurity, that may 
occur in aqueous solutions of pyruvate, necessitates a control of the 
purity of the radioactive substrate. After storage for several months 
multiple impurities appeared to be formed (2). Data presented previously 
(2, 5, 7), suggested that parapyruvate (2-hydroxy-2-methyl-4-oxogluta-
rate) was formed in aqueous solutions of pyruvate. We found an irrevers-
ible conversion of pyruvate into the reduced form of parapyruvate. The 
mechanism of this conversion is not known. The discrepancy between 
our results and those of other investigators (2, 5, 7) cannot be explained. 
Our compound does not react with 2,4-dinitrophenylhydrazine which 
indicates that the compound contains no carbonyl group. As far we 
know identification of this substance by means of massspectrometry 
was not reported uptil now. 
Earlier findings (4, 10—13) that pyruvate and 2-oxoglutarate could 
not be oxidized in the normal manner in the presence of the impurity 
are in contrast with our findings. This disagreement might be due to the 
fact that the reduced form of parapyruvate was present in our incuba-
tion medium. Preliminary experiments indicated that aqueous solutions 
of 2-oxoglutarate are unstable, too, probably as a consequence of a 
similar conversion as in the case of pyruvate. 
Batches of radioactive pyruvate and 2-oxoglutarate should, therefore, 
be freeze dried immediately after dilution and stored at —20°C in small 
aliquots as dry sodium salt sealed under nitrogen. 
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A patient with pyruvate decarboxylase 
deficiency in liver 
Sir, 
Blass et al.1'2 described three patients with an intermittent ataxia 
and increased pyruvate levels in the blood. They demonstrated a defect 
in the oxidative decarboxylation of pyruvate in white blood cells and 
cultured skin fibroblasts. 
Our patient, a 9 months old boy, with mental and motor retardation, 
microcephaly and severe hypotonia showed a quite different clinical 
picture. When he was 3 months he had several generalized convulsions. 
After admission to our clinic he had three periods of respiratory arrest. 
Twice he recovered after artificial ventilation. He had a high pyruvate 
concentration in the blood (0.2—0.3 mmol/1) consisting with a meta­
bolic acidosis. 
The patient was normoglycemic at the end of a fasting period of 
22 hours. During such a period a low production of ketoacids (1.0 mmol/ 
1, 3-hydroxybutyrate and acetoacetate) was observed although serum 
free fatty acids were normally raised as normal values for serum free 
fatty acids have been found. 
Enzyme studies were performed with pyruvate-l-14C and pyruvate-
2-14C as substrates on white blood cells, cultured skin fibroblasts and 
liver homogenate using a modification of the method of Blass et al.2 
EFFECT OF THIAMINE THERAPY DURING FASTING 
mmol/1 glucose 
controls 
± 1 SO 
{9 healthy 
children) 
patient 
without 
thiamine 
therapv 
patient 
with thiamine 
therapy orally 
(600 mg/kg b w 1 
conversion factors 
12 hours fasting 
22 hours fasting 
4 7 i 0 7 
4 0 1 0 8 
lactate 
1 52 ± 0 54 
1 7 3 ± 0 50 
12 hours fasting 4 3 2 14 
22 hours fasting 
12 hours fasting 
22 hours fasting 
mmol/1 -«mg/IOOm 
4 5 
3 8 
4 5 
1 8 0 
3 34 
3 4 6 
2 0 0 
8 9 
pyruvate 
0 0 7 6 ± 0 0 2 0 
0 114 ± 0 0 1 0 
0 3 2 8 
0 284 
0 208 
ketoacids 
0 26 ± 022 
2 86 • 0 64 
0 07 
1 12 
free fatty acids 
0 76 ± 0 26 
1 36 ί 0 32 
0 2 0 
1 92 
0 3 6 1 0 0 
I 
0 180 , 2 4 8 
8 8 1 1 0 
2 5 4 
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(liver cells were obtained with a needle biopsy). Pyruvate carboxylase 
(Utter and Keech3) and phospho-enolpyruvate carboxy-kinase 
(Cooper4 ) activities were assayed in the same liver homogenate. In con­
tradiction to Blass et al.1·2 a normal decarboxylation of pyruvate-1-
1 4 C and a normal oxidation of pyruvate-2-14C was found in leucocytes 
and fibroblasts. However, the oxidation of pyruvate-l-14C in liver was 
reduced to 10% of that in liver cells of normal subjects. Pyruvate car­
boxylase activity in liver was lowered to 20% of control values and the 
oxidation of pyruvate-2-14C and 2-ketoglutarate-5-14C was normal as 
well as phospho-enol-pyruvate carboxykinase activity. 
Administration of thiamine (500 mg/kg body weight per day orally) 
resulted in pyruvate concentration in blood of 0.18 mmol/1. A 24 hours 
fasting period during thiamine therapy resulted in a normal ketoacid 
levels in the blood (2.5 mmol/1). 
Post-mortem studies in liver cells (the patient died at the age of 
12 months) revealed a complete deficiency of pyruvate decarboxylase, 
reduced values of pyruvate carboxylase (30% of normal) and normal 
values of phospho-enol-pyruvate carboxykinase activity. 
It is considered that our patient suffered from a pyruvate decarboxy­
lase deficiency in liver, which was not demonstrated in white blood cells 
and fibroblasts. A patient with similar biochemical features has pre­
viously been described by Brunette et al.5. 
J. L. Willems 
L. A. H. Monnens 
J. M. F. Trijbels 
R. C. A. Sengers 
J. H. Veerkamp 
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Report of a Patient with Severe, Chronic Lactic Acidaemia 
and Pyruvate Carboxylase Deficiency 
J. P. G. M. Van Biervliet L. Bruinvis С. van der Heiden 
D. Ketting S. К. Wadman J. L. Willems L. A. H. Monnens 
Introduction 
Since the original description by 
Hommes and colleagues (1968) of a 
patient with pyruvate carboxylase defic­
iency and the association of this chemical 
disorder with Leigh's disease, only a few 
other reports on decreased pyruvate car­
boxylase activity have appeared (Yosh-
ida et al. 1969, Grover el al. 1972, Tang 
et al. 1972, Grobe et al. 1975). Abnormal 
kinetics of pyruvate carboxylase have been 
reported twice (Adriaenssens et al. 1973, 
Brunette et al. 1972). 
In contrast, many reports have appeared 
about Leigh's disease. The relationship 
between the clinical symptoms of Leigh's 
disease and pyruvate carboxylase defic­
iency is still a matter of controversy. 
Several patients with proven Leigh's 
disease have normal pyruvate carboxylase 
activity (Murphy 1974), and some cases 
reported by Pincus (1972) had normal 
blood lactate. 
Cooper and colleagues proposed inhi­
bition of thiamine-pyrophosphate-adeno­
sine-triphosphate-phosphotransferase as a 
possible cause of the neuroanatomical 
abnormalities in Leigh's disease (Cooper 
et al. 1969, Cooper and Pincus 1972), but 
this inhibition seems to have been a 
methodological artefact (Hommes 1976). 
The abnormalities in Leigh's disease re­
semble those in thiamine deficiency (Wern­
icke's encephalopathy) (Leigh 1951, Feigin 
and Wolf 1954). Clinical diagnosis is 
difficult during life: generally the first 
symptoms appear in early infancy in the 
Correspondence to Dr. J. Ρ G. M. Van Biervliet, 
A.Z. St. Jan Ruddershove, B-8000 Brugge, Belgium. 
form of weakness, failure to thrive, alter­
ation in muscle tonus and regression of 
acquired psychomotor development. Other 
possible symptoms are ataxia, myoclonus, 
nystagmus, loss of pupillary light-reaction, 
blindness and paralysis of external eye-
muscles. Respiratory symptoms are dis­
turbance in rhythm, tachypnoea and 
Cheyne-Stokes' breathing. Progressive 
deafness and altered consciousness also 
occur. 
Most symptoms appear in the second 
half of the first year of life. The prognosis 
is poor and death follows before the fifth 
year. In rare instances Leigh's disease has 
been observed in adolescents, and even in 
adults. A relationship between the disease 
and chronic lactic acidaemia was suggested 
by Worsley et al. (1965), and in fact 
chronic lactic acidaemia does seem to be 
present in many patients with Leigh's 
disease. 
In this paper we describe a child with 
severe, chronic lactic acidaemia with hyper­
tonia, hyperventilation and psychomotor 
retardation, in whom pyruvate carboxylase 
deficiency was demonstrated. However, 
most of the clinical symptoms of Leigh's 
disease were absent. The lactic acidaemia 
was much more pronounced than in the 
other eight patients with low pyruvate 
carboxylase activity described in the 
literature. 
Case Report 
This girl was born after an uneventful 37i-week 
pregnancy. Birthweight was 2100g and length was 
48cm. Mild respiratory distress and severe meta­
bolic acidosis were noticed in the neonatal period. 
Because of feeding difficulties, failure to thrive, 
1 0 2 
hypotonia and floppiness the child was referred 
to our hospital at eight months. 
Chromatography of amino acids in a 24-hour 
urine sample revealed an increased excretion of 
alanine, and gas chromatography showed strongly 
increased lactic aciduria. 
On admission, the child was seen to have both 
weight and height on the third percentile (5720g, 
65cm). Trigonocephaly, a normal head-circumfer-
ence, strabismus convergens and abundant sub-
cutaneous fat deposition were noted. Active 
movements of the limbs were rare, but they were 
not atactic. Major muscle movements were merely 
twisting movements of the fingers. Severe muscular 
hypotonia and floppiness were present, but at the 
same time there was hyperreflexia of all tendon 
reflexes. The child was mentally retarded. 
METHODS 
Orientating amino-acid analysis was done by 
the method of micro two-dimensional thin-layer 
chromatography described by Wadman et al. 
(1975). For quantitative amino-acid analysis of 
serum and urine, automated ion-exchange column 
chromatography (Technicon TSMI, standard 
method for physiological fluids) was used. 
Aliphatic acids were extracted from serum and 
urine with ethylacetate and determined by gas 
chromatography (trimethylsilyl derivatives), main-
ly as described by Wadman el at. (1971). The 
temperature programme was modified to 75° 
for 10 minutes, followed by an increase of 2° per 
minute up to 220°, and finally isothermal for 10 
minutes. Packing material was 5 per cent 
GESE-52 on Chromosorb W-AW-DMCS 100-
120 mesh. 
Identifications were performed by gas chroma-
tography-mass spectrometry with a Jeol-DlOO 
GC-MS combination.* We used the following 
method for enzyme determinations. Oxidation of 
pyruvate, oxoglutarate and citrate was performed 
in liver homogenates. The concentrations of the 
constituents of the incubation medium were 50mM 
potassium phosphate, 0-5mM EDTA, 6mM 
MgSO», 2mM ADP and 75mM KCl adjusted to 
pH 7-4. The incubation medium had a final 
volume of 0-5ml and contained approximately 
0-lmg protein. [1-14C] pyruvate, [5-14C] 2-oxy-
glutarate and [I-5-14C] citrate were obtained from 
the Radiochemical Centre, Amersham. Homo-
genates were prepared in an isotonic medium with 
a Potter-Elvejhem homogeniser. 
The assay of pyruvate carboxylase was per-
formed as described by Utter and Keech (1963). 
Phospho-enolpyruvate carboxykinase activity was 
measured as described by Cooper and Wood 
(1971) and fructose-l,6-diphosphatase according 
to Latzko and Gibbs (1970), with slight 
modifications. 
ROUTINE LABORATORY INVESTIGATIONS 
There was a constant, chronic granulocytopenia, 
but no other haematological abnormalities were 
noted. Serum sodium, potassium, chloride, cal-
cium and phosphate were normal. There was a 
variable metabolic acidosis, mostly compensated 
or over-compensated. 
Glucose levels after overnight fasting were 
between 4 and 6mM. Normal values were 
found for serum triglycerides, cholesterol, lipo-
proteins, alkaline phosphatase, 5'nucleotidase, 
leucine aminopeptidase, creatine kinase and 
aldolase. 
The glomerular filtration rate and tubular re-
sorption of phosphate were also normal. Urinary 
pH, without neutralising therapy, ranged from 
4-3 to 7-4. Reduction and protein were negative. 
Alanine was strikingly elevated in serum and 
urine. 
The concentrations of important amino-acids 
in plasma after an overnight fast are shown in 
Table I. Lactate, pyruvate and their ratio were 
increased, ß-hydroxybutyrate and acetoacetate 
were sometimes increased, their ratio being normal. 
SPECIAL LABORATORY INVESTIGATIONS 
Liver glycogenosis was excluded by means of 
various monosaccharide and glucagon tolerance-
tests described elsewhere (Fernandes et al. 1965, 
1969). The oral glucose eolerance test (2g/kg) 
showed a 19 per cent increase of lactic acid, 
normal clearing of glucose and normal free fatty 
acid response (Fig. 1). The results of the galactose 
tolerance test (l-5g/kg) are given in Fig. 2. No 
significant increase of lactic acid was seen, glucose 
and free fatty acid responses were normal, but 
TABLE I 
Concentration of some Important metabolites after 
overnight fast (enzymatic determinations) 
Plasma 
Lactate 
Pyruvate 
Lactate pyruvate 
ratio 
ß-hydroxybutyrate.. 
Acetoacetate 
ß-hydroxybutyrate 
acetoacetate ratio 
vmoljl 
8150 
184 
44 
478 
164 
2-9 
Normal 
<1700 
< 75 
< 15 
< 200 
< 100 
< 3 
•With the support of PraeventJefondg, Den Haag. 
actate 
r t  
Lactate pyruvate 
ratio 
l- r t r t .. 
cetoacetate 
J- r t rate 
acetoacetate ratio 
8150 
 
44 
 
164 
2-9 
1700 
  
< 15 
  
 10C 
< 3 
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Fig. 1 . Ora l glucose tolerance test (2g glucose'kg ) 
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Fig 3. Intramuscular glucagon test (0 5mg 
glucagon) 
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Fig. 2. Ora l galactose tolerance test (1 5g 
galactose/kg) 
galaclose clearing was s low This c o u l d be ex­
pected, because the UDP-gdlactose-4-epimerase 
reaction is redox-sensitive and c o u l d be rate-
l i m i t i n g f o r galactose clearance » h e n cytoplasmic 
N A D H 2 is increased (Forsander 1966) 
T h e glucagon test demonstrated n o r m a l glucose 
m o b i l i s a t i o n and an increase in lactate f r o m 9 to 
1 2 m M ( F i g 1) 
F r o m the experiments described above, the 
presence o f any o f the k n o w n f o r m * o f l iver 
glycogenosis were excluded N o excessive depo­
sit ion o f glycogen was present o n e lectronmicro-
scopy o f a l iver biopsy specimen 
D i u r n a l var iat ions in lactic acid, glucose and 
insul in arc given m F i g 4 Insul in levels were very 
l o w and lactic acid increased d u r i n g the day 
Fasting resulted in hypoglycaemia, indicat ing 
defective gluconeogenesis 
ENZYMI DETFRMINATIONS 
Enzymes o f the g l y c o l ) t i c pathway in e r y t h r o ­
cytes were f o u n d to be n o r m a l or o n l y sl ightly 
deviant Concentrat ions o f A T P (1 4μπιο1/πι1) and 
o f diphosphoglycerate (4 S i m o l / m l ) in the ery­
throcytes were also n o r m a l ( D r G Staal) 
Table I I shows the determinat ions of enzyme 
and citr ic-acid cycle act iv i ty in l iver and leucocytes, 
measured w i t h the substrates 2-oxoglularate and 
citrate Pyruvate dehydrogenase act iv i ty in the 
l iver was n o r m a l , as was citric-cycle act iv i ty PEP 
carboxykmase in the liver was f o u n d to be n o r m a l , 
fructose-1,6 diphosphatase being somewhat i n ­
creased N o perceptible act iv i ty o f pyruvate car­
boxylase could be detected in the l iver 
O x i d a t i o n o f pyruvate in leucocytes, tested with 
the substrates p y r u v a t e - l - l a C and p y r u v a t e - 2 - 1 4 C , 
revealed no a b n o r m a l i t y 
Fructose-1,6-diphosphatase act iv i ty was sl ight ly 
d i m i n i s h e d 
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TABLE И 
Enzyme determination and citric-acid cycle activity measured with 2-oxoglutarate and citrate 
Tissue 
Liver 
Leucocytes 
Enzyme 
Pyruvate dehydrogenase 
2-oxoglutarate oxidation 
Citrate oxidation 
Pyruvate carboxylase 
PEP carboxykinase 
Fructose-l,6-diphosphatase 
Pyruvate dehydrogenase 
Pyruvate oxidation 
Fructose-1,6-diphosphatase 
Substrate 
(l-,4C)pyruvate 
(5-,4C)2-oxoglutarate 
(l-S-'Ocitrate 
NaKP'OTj 
NaH'O), 
Fructose-1,6diP 
((-"Opyruvate 
(2-1*C)pyruvate 
Fructose-l,6diP 
Control* 
27-30-77-126 
4 7-31 
10 9-10 9 
22-34-35 
20-31-14-52 
1800-1440-2100 
1 1 ± 0 5 (9)· 
0 6 ± 0 2 (9)* 
6 8 ± l 8(9) 
Patient 
146 
15 
10 
Non-detectable 
15 
3060 
1 3* 
1 0» 
2 3 
* expressed in nmol/hr/10' leucocytes 
ORGANIC ACIDURIA 
Urinary profiles of organic acids, determined 
by gas chromatography, are shown in Table III 
Urine was collected on days when the patient was 
not receiving therapy and was on a normal diet 
Lactic acid was up to 17mM, or 179mmol/g 
creatinine On the same day. Tasting serum lactic-
acid was 16 7mM Urinary pyruvate was in­
creased Usually the samples contained moderate 
amounts of ß-OHbulyric acid Fumane and malic 
acids were constantly increased, as was ot-keto-
glutanc acid m relation to our control values In 
parallel with tr-ketoglulanc acid, x-hydroxyglutanc 
acid was also increased in most urine samples 
Normally this latter compound is absent or very 
low As x-hydroxyglutanc acid was not commer-
cially available, calibration was impossible and 
concentrations cannot be given in Table III The 
ratio a-ketoglularate n-hydroxyglutarate (both 
expressed as integration units) was between 2 5 
and 16 No increase of these compounds was seen 
in the blood Urinary and serum a-hydroxybutync 
acid were both increased 
EFFECTS OF FASTING 
The first fasting experiment (see Fig 5 and 
Table III) resulted in asymptomatic hypogly-
caemia (blood glucose 1 3mM after 14$ hours), 
followed by sudden lethargy and sub-coma Blood 
lactic-acid did not change significantly and urinary 
lactic-acid was at the usual level of 68mmol/g creat-
inine ß-OHbulync acid increased to 26mmol/g 
creatinine Succinic, fumane, malic and a-keto-
glutanc acids did not change strikingly Severe 
hyperglycaemia occurred during parenteral infus-
ion of glucose at the end of the fasting experiment, 
probably the result of hypomsulinism Lactic acid 
rose to 1351 mmol/g creatinine and urinary 
P-OHbutync acid increased to 195mmol/g creati-
nine The other acids did not increase strikingly 
Another fasting experiment was performed six 
months later, during a period when 2g thiamine 
HCl was being given each day After \1\ hours 
blood glucose was 3 ImM and no clinical signs 
of hypoglycaemia occurred (Fig 5, Table 111) 
Blood lactic acid did not change strikingly, being 
6 5mM at the end of the experiment Urinary 
lactic acid was 135mmol/g creatinine and urinary 
ß-OHbutync acid was 159mmol/g creatinine in 
urine collected between 14 and 17$ hours Succinic, 
fumane, malic and x-ketoglutanc acids were in 
the usual range When the standard diet was 
reintroduced, urinary lactic-acid rose to 301 mmol'g 
creatinine and ß-OHbutync acid to 192mmol/g 
creatinine 
In the following 17-hour collection period, 
fumane, malic and a-ketoglutanc acids decreased 
EFFECTS OF SUBSTRATES FOR 
GLUCONEOGENESIS 
Isocalonc protein-rich diet for three days 
(4g/kg) resulted in an increase of fasting blood-
lactatetol2 8mM Urinary lactate was 59mmol/g 
creatinine The clinical condition of the patient 
deteriorated During oral administration of glu-
tamic acid (6 χ 150mg/kg/day) and of aspartic 
acid (4 χ 167mg/kg/day), blood and urinary lactic 
acid remained high A lower dose of glutamic-
acid (as was given by Tang et al 1972), 6 X 35mg/ 
kg, in combination with pyridoxine 4 χ 50mg, 
did not improve blood lactic acid 
EFFECT OF VITAMINS 
Thiamine HCl (up to 2000mg'day), biotin (up 
to 3 x 50mg/day), hpoic acid (20mg/day), pyri­
doxine (4 χ SOmgiday) and folic acid (5mg/day), 
separately or in combinations, produced no real 
improvement in blood lactate 
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TABLE HI 
Profiles of urinary organic acids (mmol g creatinine) 
Sample date 
Without therap\ 
30-1 -74 
10-2-74 
23 /24-4-74 
19,20-11-74 
26/27-11-74 
Fasting 
8—3-74' 
8 .9 -3 -74 ' 
1-8-74' 
1 /2-8-74 ' 
Controls* 
xolume 
imi) 
28 
48 
270 
305 
340 
6 
900 
34 
500 
creatinine 
(mg,l) 
455 
235 
105 
160 
170 
695 
85 
140 
100 
tactic 
acid 
39 
151 
179 
61 
109 
68 
1351 
135 
301 
2 
a-OH-
but\ric 
acid 
0 7 
0 6 
1 6 
1 0 
1 9 
1-6 
17 0 
3 8 
9 2 
0 
ß-ОЯ-
butync 
acid 
6 3 
4 8 
14 4 
6 7 
11 5 
26 
195 
158 
192 
0-9 
\uccimc 
acid 
0 5 
1-2 
1 1 
0 7 
0 5 
2-4 
1 2 
0-6 
pres. 
0 9 
fumane 
acid 
1-6 
1 2 
2 8 
1 6 
2 1 
1 6 
1-4 
2 7 
1 2 
0 01 ' 
malic 
acid 
2-3 
3 8 
5 7 
2-5 
4 I 
3-7 
5 8 
4 1 
1-5 
0 
I 
л-keto· 
glutamic 
acid 
ι
 2
-
5 
1
 4 4 
0 7 
3 7 
5 4 
3-6 
3 2 
5-5 
1 0 
1 0-12 
1
 Urine sample after 14*hrs fasting (sub-coma) 
' Urine sample during and after parental glucose and bicarbonate 
' Urine sample collected during fasting (14-17&lirs) 
• Urine sample (2g thiamine HCl day) 
' 15 convalescent children 0-6 years (maximal values) 
Discussion 
In this patient the features of chronic 
lactic acidaemia were very pronounced. 
The family history is suggestive of an 
autosomal recessive defect. Chronic lactic 
acidaemia can be caused by increased 
production of lactic acid in the muscles, 
as is seen in mitochondrial myopathies 
(Wijngaarden et al. 1967, Tarlow et al. 
1973, Van Biervliet 1977). Normal elec­
tron microscopic results make this type 
of lactate over-production improbable in 
the present case. Increased production of 
Loci« Acid Glucos·. 
Loche Acid during 
TniOTiinpHD 
^ " ~ " ~ -A*~_ Γ 
0 - o Glucose ~ - ~ - J 
'0 12 H 16 1β 20 22 2¿ hours 
Fig. 5. Evolution of glucose and lactic acid during 
fasting. — — - first experiment, no extra 
thiamine; — = six months later, 2g thiamine HCl 
daily. Hatched area - normal range for controls 
of same age. 
lactate is also seen in liver glycogenosis 
(Sadeghi-Nejad et al. 1974), which was 
also excluded. Accumulation of pyruvate 
and lactate occurs in patients with defective 
pyruvate oxidation (Blass et al. 1970, 
1971, 1972), but this possibility also was 
excluded in our patient by examination of 
liver and leucocytes. 
A deficiency or inhibition of one of the 
gluconeogenesis enzymes (fructose-1, 6-
diphosphatase, pyruvate carboxylase and 
PEP-carboxykinase) disturbs the recon-
version of lactate to glucose. Fructose-1, 
6-diphosphatase and pep-carboxykinase 
were normal. 
Hepatic pyruvate carboxylase deficiency 
has been described in only a small number 
of patients who exhibit a rather hetero-
geneous chemical, and to some extent 
clinical, picture (see Table IV). In our 
patient this type of defect was proved to 
be present by the inability to detect pyru-
vate carboxylase in the liver. Although the 
enzyme activity was not determined under 
the conditions of acetyl-CoA regeneration 
recommended by Scrutton and White 
(1974), it seems unlikely that this imper-
fection could account for the low level 
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TABLE IV 
Prominent clinical and biochemical findings of patients with pyruvate carboxylase deficiency reported in literature 
Findings 
Mental 
retardation 
Onset 
Convulsions 
Neuro-anatomy 
Leigh s disease 
in sibs 
Lactate in blood 
(mM) 
Metabolic acidosis 
(base excess) 
Residual 
pyruvate carboxy­
lase activity 
Decarboxylase 
activity 
Fasting glucose 
(mM) 
Improvement after 
therapy 
Hommes 
et al 
(1968) 
Progressive 
From 
3-6 mths 
+ 
LD· 
+ 
3 37 
0 1% 
n d t 
2 5 
(4-) hpoic 
acid 
+ vit Bi + 
aspartic 
acid 
Yoshida 
et al 
(1969) 
1 
Before 
18 mths 
0 9 2 - 4 0 
— 9 5 
19% 
Nil (liver) 
4 4 
None 
Grover 
et ai 
(1972) 
τ 
After 
7 mths 
h 
LD 
α­
ϊ 0 - 6 I 
Liver nil 
during life 
Post mortem 
low in liver, 
kidney, 
cerebrum 
n d 
Nil 
None 
Tang 
et al 
(1972) 
+ 
8 7 
0 
n d 
n d 
(-( ) glutamate 
+ vit B, 
Brunette 
et al 
(1972) 
f 
From birth 
+ 
3 5 -16 0 
Severe 
l o w Km 
activity 
absent 
High Km 
activity 
normal 
Nil 
(leucocyte) 
Low in 
neonatal 
period 
( + )vit B! 
Tarlow 
et al 
(1973) 
2 1 - 6 7 
— 12 8 
3 4 % 
Nil 
4 4 
None 
Saudubray 
et al 
(1974) 
2 1 - 6 0 
— 3 - - 1 3 
< 5 % 
n d 
Nil 
None 
Grobe 
et al 
(1975) 
LD 
3 2 
— 0 5 
Very low 
n d 
4 4 
( - ) v i t B!-!-
asparlate 
Present 
report 
+ 
From birth 
— 
4 - 1 8 
+ 2 16 
< 1 % 
High (liver, 
leucocytes) 
1 1 
None 
* LD — Leigh's disease, t η d = not determined 
found, because a high concentration of 
acetyl-CoA (0 7mM) was used 
In patients with pyruvate carboxylase 
deficiency, a severe lactate overproduction 
can be expected In normal adults, lactate 
turnover is 0 91mmol/kg/hr (Kreisberg 
1972) and 20 per cent of the lactate pro-
duced is reconverted to glucose If we 
extrapolate these data to our patient 
weighing 7kg, the excess of lactate will be 
some 3lmrnol/day From this amount 
some 5 5mmol are excreted in the urine, 
the remainder accumulates and may be 
utilized for the synthesis of fat, will be 
oxidized through the citric-acid cycle, or 
may be converted to amino acids It is 
amazing to observe in the literature that 
some patients with pyruvate carbox)lase 
deficiency have much lower lactic acid 
concentrations in the blood than was 
found in our patient (see Table IV) 
Brunette et al (1972) pointed to the 
presence of two kinds of pyruvate car-
boxylase activity, one with a low Km(Pyr) 
of 0 2 to 0 4m M and the other with a 
high Km(Pyr) of 2 to 4mM 
The first component, which is thought 
to be the most efficient in the range of 
normal physiological concentrations of 
pyruvate, seemed to be missing in their 
patient The unusually quick return to 
normal pyruvate metabolism in lesponse 
to a low dose of thiamine, however, could 
point to a defective pyruvate dehydroge-
nase complex Such a defect, resulting in 
decreased metabolism m vivo, can easily 
be missed under the optimal conditions of 
m vitro enzyme studies Moreover, the 
administration of thiamine could have 
stimulated the formation of acetyl-CoA, 
the positive effector of pyruvate carboxy-
lase activity A similar mechanism might 
have caused the return to normal pyru-
vate metabolism in the patient described 
by Hommes et al (1968) 
Simultaneous studies of pyruvate car-
boxylase and pyruvate dehydrogenase 
should always be performed in this type 
of patient After administration of carbohy-
drate, lactic acid production increased in 
our patient, as is to be expected In the 
first of our two experiments, prolonged 
fasting induced hypoglycemia, however 
this did not occur in the second experiment 
during thiamine therapy six months later 
Apart from the neonatal hypoglycemia in 
the patient of Brunette et al (1972) and 
the low fasting glucose-levels in the patient 
of Hommes et al (1968), no data suggest-
ive of hypoglycemia are given by other 
authors The absence of hypoglycemia 
could be explained by assuming the pres-
ence of an increase of glycogen deposition, 
as was shown by Grobe et al (1975) 
Increased urinary malate, fumarate and 
a-ketoglutarate could reflect increased 
renal production or decreased tubular 
resorptions of these compounds, because 
they were not detected in the blood In the 
presence of a large excess of cytoplasmatic 
NADHJ —, the conversion of malate to 
oxaloacetate will be decreased We ques-
tion whether this abnormal excretory 
pattern is characteristic of pyruvate car-
boxylase deficiency 
In another patient with chronic lactic 
acidaemia resulting from pyruvate dehy-
drogenase deficiency, with overflow of 
both lactate and pyruvate, no abnormal 
excretion of malate, fumarate or a-keto-
glutarate was observed (Bremer and Wad-
man, unpublished results) Increased 2-
hydroxybutync acid has been correlated 
with an increased cytoplasmatic NADH2/ 
NAD ratio (Landaas 1975, Landaas and 
Pettersen 1975) 
Up to now our patient has no evidence 
of a full-blown Leigh's syndrome and the 
disease could not be traced in the family 
for four generations In our opinion a 
relationship between Leigh's syndrome 
and pyruvate carboxylase deficiency has not 
yet been sufficiently established (Table IV) 
All therapeutic attempts in our patient 
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were disappointing. Oral administration of 
the subtrates aspartic and glutamic acids 
did not influence the lactic acidaemia, nor 
improve the clinical condition. Apparently 
in our patient the tricarboxylic acid cycle 
was not ineffective as a result of deficiency 
of oxaloacetate, as was proposed by Tang 
et al. (1972). Unlike previous cases 
(Hommes et al. 1968, Brunette et al. 1972), 
the administration of vitamins, thiamine, 
biotin, lipoic acid and pyridoxine plus 
aspartate were without significant effect. 
More knowledge of pyruvate carboxylase 
deficiency is necessary in order to arrive 
at a better therapeutic approach to this 
type of patient. 
ALTHORS' APPOINTMCNTS 
J P. G. M. van Biervliet, M D., Staff Paediatrician,* 
L. Bruinvis, Technical Assistant, 
С van der Heiden, Ph.D., Staff Clinical Chemist; 
D. Ketting, Technical Assistant; 
S К Wadman, Ph.D., Associate Professor, Staff 
Clinical Chemist, 
Department of Inborn Errors, University Child-
ren*s Hospital, Het Wilhelmina Kinderziekenhuis, 
Utrecht, The Netherlands 
J L. Willems, Ph D , Clinical Chemist; 
L. A. H Monnens, M D., Associate Professor, 
University Children"s Hospital, Nijmegen, The 
Netherlands. 
'Present address A. Z. St. Jan Ruddershove, 
В-8СЮ0 Brugge, Belgium. 
SUMMARY 
A patient suffering from severe lactic acidaemia due to pyruvate carboxylase deficiency 
is presented. The clinical picture is different from the full-blown Leigh's disease. The 
child had severe mental retardation, muscular hypotonia and abundant subcutaneous fat. 
As could be expected in defective neoglucogenesis, hypoglycaemia was provoked by 
prolonged fasting. Besides high urinary concentrations of lactic acid, increased concen­
trations of malic, fumaric, succinic and a-ketoglutaric acids were observed. 
All therapeutic attempts towards treatment of the severe hyperlactacidaemia have been 
unsuccessful. 
RESUME 
Un patient souffrant d'une lactacidémie grave provoquée par un déficit en pyruvate-
carboxylase est présenté. Le tableau olinique est différent de celui de la maladie de Leigh 
floride. Une arriération mentale sévère, une hypotonie musculaire et une accumulation 
excessive de graisse souscutanée étaient présentes. Comme on pourrait s'attendre lors 
d'une trouble de la néoglucogénèse une hypoglycémie était provoquée par une période 
de jeûne prolongée. A coté d'une excrétion urinaire massive d'acide lactique des concen-
trations élevées d'acide malique, fumarique, succinique et o-cétoglutanque étaient présentes. 
Toutes les mesures thérapeutiques, visant à diminuer la lactacidémie, ont échoué. 
ZUSAMMENFASSUNG 
Ein Patient mit schwerer Milchsäureazidämie infolge Pyruvat Carboxylase Mangels 
wird beschrieben. Das klinische Bild unterscheidet sich von der komplett entwickelten 
Leigh Krankheit. Eine schwere geistige Unterentwicklung, Muskelschwäche und starke 
subkutane Fettbildung wurden festgestellt. Wie erwartet im Fall einer mangelhaften 
Gluconeogenese, wurden Hypoglykämien durch längeres Fasten verursacht. Im Urin 
wurden, neben hohen Milchsäurekonzentrationen, erhöhte Konzentrationen von Apfel-
säure, Fumarsäure, Bernsteinsäure und a-ketoglutarsäure festgestellt. 
Alle therapeutische Maßnahmen in der Behandlung dieser schweren Hyperlaktata-
zidämie waren nicht erfolgreich. 
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RESUMEN 
Paciente con acidemia láctica crónica grave y deficencia de piruvato carboxdasa 
Se describe un paciente que sufría de acidemia láctica grave debido a una deficiencia 
de piruvato carboxilasa. El cuadro clínico es diferente de la enfermedad de Leigh 
Presentaba un retraso mental grave, hipotonía muscular y una abundante grasa subcu-
tánea Tal como podía esperarse en un defecto de la neoglucogenesis, la hipoghcemia 
era provocada por un ayuno prolongado Además de una alta concentración urinaria de 
acido láctico, se observó un aumento en la concentración de los ácidos màlico, fumánco, 
succlmco y a-cetoglutarico 
Todas las tentativas terapéuticas encaminadas al tratamiento de la hiperlactacidemia 
grave no han dado resultado 
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Summary nearly absent, but cet was present. In heart muscle cytochromes 
BBj and b were at the level of the controls. 
A patient sufTering From a mitochondrial myopathy leading to 
severe insufficiency of the voluntary muscles is described. Severe speculation 
cerebral damage was present. Major biochemical symptoms In many patients with hereditary lactic acidemia the enzyme 
were extreme lactic acidemia, hypophosphatemia and hyper- defect has not been identified. Based on the finding of cyto-
phosphaturla, and generalized aminoaciduria, renal glucosuria, chrome aa, and cytochrome b deficiencies in our patient, we 
and polyuria. Muscular Insufficiency resulted in lethal asphyxia, suggest that disorders of oxidative phosphorylation, especially a 
All therapeutic trials were insufficient. The patient and two defective respiratory chain, have to be considered as a possible 
other children of the same family with a similar clinical picture causal factor in lactic acidemia of unknown etiology. Although 
all died before the 41h month of life. The condition is probably no direct evidence is available from our patient, more attention 
Inherited in an autosomal recessive way. A defective respiratory is recommended for the hypothesis that a similar defect, located 
chain in the mitochondria of the striated muscles is proposed as in the kidney, might be involved in the DeToni.Fanconi'Debré 
the underlying mechanism. Cytochromes aa·, were absent, b was syndrome. 
Introduction 
Hereditary infantile lactic acidemia is a rather frequently occurring 
defect. In nearly all patients prognosis is poor. Up to the present no 
adequate treatment is available. In many patients described in the liter-
ature the etiology has not been elucidated. However, in a limited num-
ber of cases the underlying enzyme defect has been characterized. 
Known enzyme deficiencies causing severe lactic acidemia are a.o. defi-
ciency of: glucose-6-phosphatase (15), fructose-1, 6-diphosphatase (3) 
(16), hepatic pyruvate carboxylase (6)(8), and pyruvate dehydrogenase 
phosphatase (21). A moderate lactic acidemia was reported in a patient 
with a pyruvate decarboxylase deficiency (13)(27). Still more enzyme 
defects causing lactic acidemia are to be expected to come to light in 
the near future. Theoretically also a decreased mitochondrial transport 
of pyruvate, citrate and malate may result in the accumulation of lactic 
acid and a defective respiratory chain in the mitochondria of the striated 
muscles. The family history suggests that we are dealing with an auto-
somal recessive inherited trait. Three patients in this family exhibited 
the same clinical picture. 
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Case no. 1 
History 
R.B., a boy, was the fourth child of healthy non-consanguineous 
parents. Throughout the pregnancy his mother noticed few fetal move-
ments. Delivery was uncomplicated, birth weight was 4070 g and the 
neonatal condition was satisfactory. During the first seven weeks of life 
increasing feeding difficulties and deterioration of his general condition 
necessitated admission. Extreme metabolic acidosis was assessed, for 
which he was referred to our hospital. 
Clinical examination 
At clinical examination a lethargic floppy child was seen (see figure 1). 
His weight was 4490 g; abundant subcutaneous fat was observed. The 
thorax was bellshaped. Neither cardiac nor circulatory anomalies were 
obvious: liver and spleen were not enlarged. Besides diaphragmatic 
respiratory movements and scanty movements after painful stimuli no 
other spontaneous muscular movements were seen. All tendon reflexes 
were absent. Fontanelle tension was normal. The patient was nursed in 
an incubator. Respiratory insufficiency necessitated artificial ventilation 
soon after admission. He died when he was 13 weeks old. 
Fig. 1. The patient at the age of 8 weeks during the second week of admission. 
Artificial ventilation was necessary. Notice the striking muscular hypotonia. 
Cases 2 and 3 
Twin sisters were bom in 1969 after an uncomplicated pregnancy. 
Progressive feeding difficulties necessitated admission to a general hos-
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pital. They presented the same clinical symptoms as seen in case 1: 
hypotonia, absence of visual contact, lethargy and extreme muscular 
weakness. Conditions deteriorated and they died at the age of 11 weeks. 
Biochemical findings, as far as investigated, were the same as in case 1 : 
metabolic acidosis, normal blood sugar, anemia, elevated LDH, GOT, 
GPT, proteinuria, glucosuria and polyuria. In these children lactic acid 
was not determined. 
General laboratory results 
A combined respiratory and metabolic acidosis was present; the base-
excess ranged from 0 to —15 mM. High blood lactate levels were seen 
(see special section). During artifical ventilation pH, рСОг and even 
base-excess, as well as calculated bicarbonate concentration returned to 
almost normal, despite severe lactic acidemia. The sodium, potassium 
and chloride concentrations were normal in most instances. Blood glu­
cose levels were normal. Hypoglycemia was absent after a 10 hours 
fasting episode. Neither dietary measures nor fasting influenced blood 
lactate. Parenteral glucose tolerance-, adrenaline-, and glucagon tests 
gave normal responses for free fatty acids and glucose, but insignificant 
changes of blood lactate. However, an extreme blood lactate increase 
was provoked by muscular efforts. After one hour weaning-off the 
ventilator lactate increased from 8.9 to 13.7 mmol/1. During this experi­
ment oxygen tensions were normal and so was the oxygen dissociation 
curve. Massive parenteral doses of thiamine and lipoic acid did not 
diminish blood lactate, nor did oral administration of supplementary 
minerals: calcium, magnesium, phosphate and trace elements according 
to the Winitz formula. The renal symptoms of the DeToni-Fanconi-
Debré syndrome were present: proteinuria, glucosuria with low renal 
glucose threshold (5 mmol/1), hyperphosphaturia (phosphate clearance: 
24 — 13 nil/min/1.73 m2, tubular reabsorption of phosphate: 54% — 
86%), hypercalciuria: 0.22 — 13 mmol/kg/day and generalized amino 
aciduria. Serum lactate dehydrogenase (LDH) was elevated: 625 and 
915 IU; the LDH-isoenzyme distribution was normal; serum glutamic-
oxalacetic transaminase (GOT) 33 (normal up to 20), and serum gluta-
mic-pyruvic transaminase (GPT) 16 (normal up to 15), while the hepatic 
'excretion' enzymes were normal. Serum creatine kinase (CK) was 54 IU 
(normal up to 66). Hemoglobin concentration was 6.3 mmol/1, reticulo-
cyte count 4.90/00. In the erythrocytes hexokinase, phosphoglucose iso-
merase, phosphofructokinase, aldolase, and triosephosphate isomerase 
activities were normal and so was the adenosinetriphosphate concentra-
tion. Urinary creatinine was not elevated. 
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Laboratory methods 
Amino acids were analyzed by automated quantitative column chro­
matography using the Technicon TSM1 standard procedure for physio­
logical fluids. 
Aliphatic acids in serum and urine were determined by gas chro­
matography of their trimethylsilyl derivatives, mainly as described pre­
viously (29). See the following sections A — E. 
A. Isolation and concentration of non-volatile acids: To 5 ml urine 
is added 5 ml saturated NaCl-solution and internal standard phenyl-
butyric acid (0.5 mg) and the sample is acidified to pH 1.5 with concen­
trated HCl. As a routine 10 mg vitamin С is added as an anti-oxidant. 
This solution is extracted with 20 ml ethylacetate. The pooled extracts 
are dried over anhydrous N32804 and then evaporated to dryness at 
reduced pressure (Rotavapor) at 40°. The residue is transferred to a 
glass-stoppered test-tube with a few ml acetone and then evaporated to 
dryness again at reduced pressure (40°). Volatile acids that are also 
extracted, are lost for the greater part in the evaporation steps. 
Trimethylsilylation of the compounds is performed with 0.5 ml Ν,Ο-
bis (trimethylsilyl) acetamide in chloroform (1:3 v/v) at 30°C for 
20 minutes. One microliter of this mixture (=0.01 ml urine) is injected. 
B. Conjugated acids: To 5 ml urine and equal amount of concentrated 
HCl is added. In a screw-capped vial this mixture is heated at 100° for 
3 hours. After cooling below 5° the sample is processed in analogy to 
unhydrolyzed urine after adjustment of the pH to 1.5 without the addi­
tion of saturated NaCl. 
C. Serum: One ml serum is acidified to pH 1.5. The following manipula­
tions are identical to those for urine, except that the endvolume is 0.1 ml. 
Accordingly an amount corresponding to 0.01 ml serum is injected. 
D. Gas chromatography. Apparatus: F & M810, dual column, double 
FID, with Hewlett-Packard integrator 3370 A. Columns: stainless steel, 
8 ft χ 1/8 inch. 5% GESE-52 on Chromosorb W AW DMCS 100-120 
mesh. The temperatures: oven first 75° isothermal for 10 minutes, then 
75°—220° (27min), and finally 220° isothermal for 10 minutes; injec­
tion port 190°; detector 220°. Gasflows: N2 27 ml/min; H2 28 ml/min; 
air 450 ml/min. Range: 10 2 ; attenuation: 8; chartspeed: 5 inch/min. 
For standardization synthetic compounds were run through the whole 
procedure. Gas chromatographic fractions were identified by mass 
spectrometry. 
E. Gas chroma tography-mass spectrometry: This was performed with a 
Jeol JMS-D100 mass spectrometer, LC-20KP gas Chromatograph com­
bination. The mass spectra were recorded at an electron energy of 
70 eV; ionizing current of 300 μ A; accelerating voltage 3 kV; ion source 
temperature 200°. 
Enzymatic determinations. Urinary pyruvate could not be determined 
in a sufficiently reproducible way by the gas chromatographic method. 
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This compound was therefore determined enzymatically; also urinary 
citrate and for a part 2-oxoglutarate were determined enzymatically. 
Standard Boehringer techniques based on the methods described in 
Bergmeyers book (5) were used. In one blood sample lactate and pyru­
vate were determined enzymatically (5) as well as 3-oxobutyrate and 
3-hydroxybutyrate (32). 
Leucocytes, liver and skeletal muscle: Pyruvate oxidation in leuco­
cytes was studied mainly according to Blass et al. (7). Leucocytes were 
isolated with dextran and incubated during 60 minutes at 37° with 
(1-14C) pyruvate and (2-14C) pyruvate as substrates. The substrate con­
centration was 0.5 mM (spec. act. for (1-14C) pyruvate and (2-14C) pyru­
vate was 0.5 мСі/ттоІ) in a final volume of 2 ml, containing 3—5. 106 
leucocytes. Liver and muscle tissue of the patient were obtained by 
biopsy. Liver and muscle homogenate (1%) were prepared in 10 mM 
Tris buffer (pH 7.4) containing0.25 M sucrose and 2 mM EDTA supple­
ment with 50 U/ml of heparin for muscle tissue. Homogenisation was 
performed with a Potter — Elvehjem homogenizer. After centrifugation 
(600 χ g during 10 minutes) the supernatant was used for the enzyme 
assays. The incubation medium consisted of 50 mM phosphate buffer 
pH 7.4, 75 mM KCl, 2 mM ADP, 0.5 mM EDTA, 10 mM MgCl2 and 
1 mg protein. The substrate concentration was 1 mM with a specific 
activity of 0.5 juCi/mmol for (I-14C)pyruvate and (5-14C) 2-oxoglutarate 
in a final volume of 0.5 ml. All enzymatic assays were based on the 1 4C02 
capture method. The enzymatic reaction was stopped with 3N perchloric 
acid. The 1 4C02 trapped in hyamine hydroxide as counted with 10 ml 
scintillation fluid (4 g omnifluor/liter toluene) in a scintillation counter. 
Liver fructose-l,6-diphosphatase was determined according to (4). 
Determination of the components of the electron transport chain : These 
determinations were performed in muscle tissue obtained immediately 
after death and frozen at —70°. Mitochondria were isolated according 
to Luft et al. (18). Cytochrome determinations were performed by 
differential spectrophotometry in isolated mitochondria, mainly accord­
ing to Chance and Williams (10). Cytochrome с oxidase activity in 
muscle was measured according to van Buuren et al. (9) Details of the 
Fig. 2. The respiratory chain. The site of action of inhibitors is indicated w i t h = * . 
Fp is flavoprotein. 
Succinate 
I 
Fp 
rotenone ¡ antimycin A KCN 
SUBSTRATE—* NAD*—*· F p ^ | > CoQ—> Cyt b ^U- Cyt cc ,—• Cyt a a s - j ^ o2 
ATP "f ATP 
ATP 
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method will be published separately (Bookelman es . in preparation). 
In figure 2 the components of the respiratory chain are shown and the site 
of action of inhibitors. Cytochrome in patients' mitochondria (hardly 
contaminated with hemoglobin or myoglobin) and mitochondria from 
the control were reduced by succinate plus antimycin A, followed by 
addition of dithiomte. 
Results of special investigations 
Amino acids The patient had a generalized amino aciduria. Serum 
amino acids were normal except for alanine which was increased and 
for arginine which was low. In table 1 serum and urine data are given. 
Table 1 
Serum and urine amino acids and some other compounds (мтоі/і) in patient В 
On 26 11 and 27 11 only intravenous administration of glucose 10 g/kg, no protein. 
On 25 11 (oral) protein intake 5 6 g/kg On 15/16-12 and 21/22-12 oral protein 
2 g/kg 
Abbreviations tr — trace, pr — present, max — maximal, nd — not detected. 
serum serum urine urine urine urine 
27 11 15 12 25/26 11 26/27 11 15/16 12 21/22 12 
aspartic 
hydroxyproline 
threonine 
serine 
asparagine 
glutamic 
glutamine 
proline 
glycine 
alanine 
citrullme 
a amino butyric 
valine 
cystine 
methionine 
isoleucine 
leucine 
tyrosine 
phenylalanine 
tryptophane 
ornithine 
lysine 
histidine 
carnosine 
arginine 
creatinine 
lactic X 10"3 
39 
15 
35 
99 
31 
126 
456 
136 
269 
737 
tr 
1 5 
158 
36 
66 
105 
33 
70 
nd 
49 
144 
66 
28 
12,3 
65 
46 
2 1 3 
220 
380 
4 3 5 
459 
1100 
17 
34 
227 
60 
267 
1034 
771 
9 2 4 
75 
2781 
2183 
2240 
5225 
320 
1 6 5 
1402 
171 
27 max 41 
107 
160 
56 
9 3 
nd 
89 
204 
4 6 
18 
66 
16,3 
496 
855 
3 4 3 
3 1 5 
1 0 8 
182 
1288 
1310 
18 
149 
841 
58,4 
30 
1 5 3 
521 
457 
5 1 5 
54 
1699 
704 
1427 
2719 
137 
pr 
624 
1 8 3 
max 60 
1 6 8 
321 
1 3 3 
188 
39 
46 
781 
632 
35 
6 3 
620 
55,0 
150 
321 
1059 
819 
720 
88 
2164 
1122 
2200 
4157 
137 
pr 
530 
242 
pr 
244 
290 
66 
1 8 8 
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tr 
206 
497 
tr 
12 
752 
nd 
68 
1 8 3 
4 7 1 
619 
591 
48 
1041 
609 
1493 
2888 
91 
pr 
4 0 2 
max 171 
pr 
160 
199 
149 
1 8 8 
tr 
tr 
3 4 3 
342 
13 
tr 
752 
49. 
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Table 2 
Aliphatic acids in urine of patient B, as determined by gas chromatography (μιηοίθβ/ΐ). 
nd = not determined; * = calculated as 3-OH butyric acid; ** = calculated as 2-oxyglutaric acid. 
Feeding 
conditions 
25/26-11-1973 
protein 5.6 g/kg 
ml creat. 
mg/1 
lactic 
X IO"3 
3-OH 
butyric 
2-OH* 
butyric 
550 95 58.1 1787 2229 
2-oxo 
glutaric 
tr 
2-OH** 
glutaric 
tr 
aconitic succinic 
51 
5/6-12-1973 
protein 2.0 g/kg 360 85 32.0 989 884 75 243 80 42 
3/4-12-1973 
protein 1.2 g/kg 425 60 19.4 1047 634 62 230 40 17 
21/22-12-1973 
protein 2.3 g/kg 260 85 48.6 932 413 nd nd 75 34 
26/27-11-1973 
no protein i.v. 
glucose 10 g/kg 450 70 54.8 1066 1076 110 40 
28/29-11-1973 
no protein i.v. 
glucose 10 g/kg 266 31.6 17.3 413 279 144 26 
Most strikingly increased was alanine, probably resulting from trans­
amination of excessive pyruvate. Amino acid excretions were studied 
during 2 successive days when only glucose, 10 g/kg, was given intra­
venously. Even under these circumstances renal loss of many amino 
acids was evident. 
Lactic acid and related compounds: In table 2 a number of values for 
lactic and related acids are given. There was a substantial overflow of 
lactic acid, pyruvic acid and alanine. Most serum lactic acid values were 
between 6 and 19 mmol/1. The mean urinary lactic acid was 3 mmol/kg/ 
day (SD 2.4). Normal excretions are 8.8 μmol/kg/day (SD 7.4) accord­
ing to (2). The highest urinary lactic acid concentration was 105 mmol/ 
1 and, expressed as nmol/g creatinine a highest value of 1467 was 
observed. Urinary pyruvic acid was strikingly increased, both as deter­
mined by gas chromatography and enzymatically. From enzymatic 
determinations a mean pyruvate excretion of 53 pmol/kg/day (SD 33) 
resulted. Compared with the data of (2) for normal infants: 6.9 μτηοί/ 
kg/day (SD 8.8), the pyruvate excretion of our patient was highly 
increased. Blood pyruvate was determined only once, during glucose 
infusion, just before the biopsy was performed. At a lactate level of 
12.7 mmol/1 the pyruvate concentration was 0.27 mmol/1, corresponding 
with an increased lactate/pyruvate ratio of 47 (normal 20) indicating 
Table 3 
Pyruvate oxidation, 2-oxoglutarate oxidation and fructose-1, 6-diphosphatase in 
tissues. 
Data are expressed as nmol/mg protein/hour. 
Leucocytes 
Pyruvate oxidation 
(І-^С pyruvate) 
(2- , 4C pyruvate) 
Fructose-1,6-diphosphatase* 
Muscle 
Pyruvate oxidation 
(1-I4C) pyruvate 
2-Oxoglutarate oxidation 
(5-14C)2-oxoglutarate 
Liver 
Pyruvate oxidation 
(1-14C) pyruvate 
2-Oxoglutarate oxidation 
(5- l4C)2-oxoglutarate 
Fructose-1,6-diphosphatase* 
controls mean t SD 
1.1 ± 0.5 (N=9) 
0.6 ± 0.2 (N=9) 
0.4 ± 0.1 X 103 (N=8) 
controls 
mean 85.6; 
range 4 0 . 0 - 1 4 6 (N=6) 
29.7; 49. 
controls 
mean 66; 
range 2 7 - 1 2 6 (N=6) 
4 , 7 , 3 1 , 4 6 . 
1.8, 1.4,2.1 X 103 
patient 
1.3 
0.7 
0.7 X 103 
patient 
36.1 
2.7 
patient 
108 
19 
1.4 X 10» 
* AMP-inhibition was not investigated. 
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excess of cytoplasmatic NADH. In the same sample 3-hydroxybutyrate 
and 3-oxobutyrate were 0.165 and 0.054 mmol/1, resp. yielding a ratio 
of 3.1 (normal 2.0). Serum alanine was increased despite extensive renal 
losses, as can be seen from table 1. Urinary 3-hydroxybutyrate varied 
from 0.5 to 2 mmol/1, being only moderately increased. Of the same 
order of magnitude was 2-hydroxybutyrate (from 0.2 to 1.6 mmol/1), a 
compound which was present continuously. In the serum mean concen­
trations of both acids were 200(36—780) and 117(36-180) μπιοΐ/ΐ 
respectively, in 14 determinations. Urinary 2-oxoglutarate, 2-hydroxy-
glutarate, citrate, aconitate and succinate were in the normal range. 
Malate and fumarate were absent, unlike in our patient P.D. with lactic 
acidemia due to pyruvate carboxylase deficiency, who had increased 
urinary excretions of these acids (6). 
550 600 650 
Wavelength (nml 
Fig. За. Difference spectrum of normal human skeletal muscle mitochondria. After 
addition of succinate plus antimycin A the spectrum of cytochrome b is obtained 
(middle curve). Subsequent addition of dithionite results in reduction of cytochrome 
ааз and cytochrome cc! (upper curve). The increase in absorbance at 565 nm ob­
served after addition of dithionite indicates contamination of the mitochondrial 
suspension with either hemoglobin or myoglobin. The lower curve represents the 
difference spectrum between the dithionite reduced and succinate plus antimycin A 
reduced mitochondrial suspension. 
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Fig. 3b. Difference spectrum of skeletal muscle mitochondria of patient R.B. The 
lower curve is obtained after reduction with succinate plus antimycin A and shows 
the presence of a very limited amount of cytochrome b. Addition of dithionite 
(upper curve) reveals the absence of cytochrome ааз . 
Special biochemical studies in tissues 
The activity of pyruvate dehydrogenase and the rates of oxidation 
via the citric acid cycle of [2-14C] pyruvate in leucocytes and 2-[5-14C] 
oxoglutarate in muscle and liver homogenates are given in table 3. Pyru­
vate dehydrogenase activity is little influenced by changes in NADH/ 
NAD* ratio has been shown in the bovine kidney and heart (2). In leuco­
cytes no subnormal values were encountered. In liver the activity of 
fructose-l,6-diphosphatase was rather low, but did not clearly approach 
the level in patients with a hereditary defect. Pyruvate and 2-oxogluta-
rate oxidation were normal. 
The components of the electron transport chain 
The observation of the defective 2-oxoglutarate oxidation in the 
patients muscle led us to investigate some mitochondrial components 
of the respiratory chain. In skeletal muscle no cytochrome aaj and 
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only a trace of b were detected, cc, being 326 pmol/mg protein. Spectra 
are shown in fig. 3. In a control we found: ааз 420; b 345; CC| 833. The 
patients mitochondrial cytochrome cc, , although lower than that in the 
control (being fresh muscle tissue), was in the range as obtained from 
normal muscle stored at —70°. The deficiency of ааз were confirmed 
by the values of cytochrome с oxidase activity in periferal muscle. In 
two different muscle samples of RB 6.9 and 13.8 nmol/min/mg protein 
was found and in 6 controls: 151 ± 52 (SD), range 72—226. In heart 
muscle mitochondria the cytochromes were in the normal range as was 
the cytochrome с oxidase activity. 
Electron microscopy 
The ultrastructure of the mitochondria of the skeletal muscle tissue 
was strikingly abnormal. The number of large mitochondria with irre-
|r ^ f 
^ j S » 
Fig. 4. Part of a muscle fiber showing the presence of giant mitochondria with ir­
regular, polygonal contour containing numerous short cristae in their pale, fine 
granular matrix. Magnification 21.800 X. 
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Fig. 5. Four mitochondria in a muscle fiber with concentric arrangement of their 
packed cristae. L: lipid inclusions; G: glycogen granules. Magnification: 21.800 X. 
guiar shape was increased; numerous cristae were short en slightly 
dilated and showed a disorderly (fig. 4) or regularly, concentric arrange­
ment (fig. 5). Lipid inclusions in close proximity to the mitochondria 
were a constant feature (fig. 6). In addition, the cytoplasm of some 
muscle fibers contained large amounts of glycogen particles (fig. 5). A 
general view of many photographs of hepatocytes showed the presence 
of only a few lipid droplets. However, the photographs as presented in 
fig. 7 did not show lipid droplets. 
Discussion 
Most of the mitochondrial myopathies described until now are still 
obscure in etiology. Their classification is made on a pure morphological 
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Fig. 6. Numerous lipid droplets surrounded by a membrane (L) can be observed 
within this section of a muscular fiber. Magnification: 17.400 X. 
base (30). Biochemical investigations of isolated mitochondria are 
necessary to define the rather loose concept of 'mitochondrial myo-
pathies' (23). Myopathy, abnormal muscle mitochondria and a hyper-
metabolic state were seen in two patients (18) (1). The mitochondria 
failed to show significant respiratory control with various substrates. 
Spectra of cytochromes were normal in the patients described by 
Dimauro es . (11). Other patients, showing loosely coupled oxidative 
phosphorylation without clinical hypermetabolism have been described 
(35)(12). Reports concerning defects in the respiratory chain itself are 
rare. In human achondroplasia (Mackler c.s. (19)) found decrease oxi-
dative phosphorylation possible caused by a defect occurring at the 
first phosphorylation site in mitochondrial preparations isolated from 
muscle biopsy specimens. Studies of Spiro c.s. (26) on isolated muscle 
mitochondria revealed a marked reduction of the cytochrome b con-
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Fig. 7. Parts of three hepatocytes containing mitochondria with normal size and 
shape. Note the absence of lipid inclusions. Magnification: 17.400 X. 
tent. In cerebro-hepato-renal syndrome a defect in the mitochondrial 
oxidation between the succinate dehydrogenase flavoprotein and co­
enzyme Q in brain, liver and muscle mitochondria has been proposed 
(Goldfischer (14)). Recently a patient has been described suffering from 
Leigh's encephalomyelopathy with a deficiency of cytochrome с oxidase 
in skeletal muscle (33). Shapira c.s. (25) described two siblings with 
familial poliodystrophy encephalopathy, mitochondrial myopathy and 
a moderate lactic acidemia. Hyperlactacidemia in mitochondrial myo­
pathy was observed by van Wijngaarden c.s. (35) and by Tarlow c.s. 
(28). In both cases no definite enzyme defect could be detected. Many 
other cases of mitochondrial myopathies are mentioned in the literature, 
each with its distinct course, clinical and biochemical pattern. Senior 
and Jungas (24) briefly reported two siblings with extreme stunting 
growth and severe mental retardation with elevated levels of lactate and 
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normal levels of pyruvate. Liver mitochondria failed to utilize NADH 
dependent substrate as judged by oxygen consumption in the presence 
of ADP. However, succinate oxidation proceeded efficiently and the 
patients exhibited normal respiratory control. They concluded to a 
failure of oxidation of intramitochondrial NADH, a defect in the initial 
step of the respiratory chain. 
The present report deals with a combination of a severe (congenital) 
hyperlactacidemia, a DeToni-Fanconi-Debré syndrome and a mitochon-
drial myopathy. A severe hyperlactacidemia and a Fanconi syndrome 
has occasionally been observed in patients with glucose-6-phosphatase 
deficiency (17). Severe hyperlactacidemia combined with a generalized 
renal amino aciduria was discovered in two twin sisters with Leigh's 
syndrome (34). No evidence for glucose-6-phosphatase deficiency or 
other severe deficiencies of one of the enzymes of gluconeogenesis was 
present in our patient as no reduction of lactic acid levels resulted from 
parenteral glucose administration and no hypoglycemia occurred after 
a 10-hours' fast. In our patient, and also in his deceased twin sisters, 
evidence of Leigh's disease was lacking at neuropathologic examination 
of the brain. Urinary analyses revealed only an increased excretion of 
lactic and pyruvic acids in our patient. From table 2 we can conclude 
that no firm evidence for increased excretion of citric acid cycle com-
ponents was obtained. The urinary excess of lactate and pyruvate is in 
agreement with the strikingly increased concentrations of lactate and 
pyruvate in the blood. The lactate/pyruvate ratio was elevated, which 
suggests an increased NADH/NAD+ ratio in the cytoplasm whereas this 
ratio in the mitochondrial compartment seemed only slightly increased. 
This phenomenon could be explained by a reverse of the malate/aspar-
tate shuttle, which normally transport NADH from the cytoplasm into 
the mitochondria. The impairment of the respiratory chain, caused by 
the absence of cytochrome b and cytochrome с oxidase, pushed the excess 
of NADH, produced by the citric acid cycle and the fatty acid oxida­
tion, into the cytoplasm by means of the reverse action of the malate/ 
aspartate shuttle. With the absence of cytochrome b and ааз we can 
hardly expect any functional activity of the respiratory chain, which 
will lead to a defective oxidative mechanism for 2-oxoglutarate. The 
abnormal mitochondrial structure and also the accumulation of fat in 
cytoplasm of the cells of voluntary muscles are probably consequences 
of the defective oxidation. The heart muscle does not seem to be affect­
ed. Also the liver mitochondria were normal. The defect seemed to be 
limited to the skeletal muscles. 
Because of the presence of a DeToni-Fanconi-Debré syndrome it would 
be interesting to analyse also the cytochromes in renal tissue. If they 
were absent in the kidney as well, this might have been a keyfactor in 
the genesis of the DeToni-Fanconi-Debré syndrome in our patient. We 
regret that not enough material was present in order to prove the 
absence of cytochromes b and ааз · 
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It is very peculiar to find a double defect in the components of the 
respiratory chain. It is obvious to suppose one underlying defect in the 
biogenesis and assembly of a respiratory component. Especially the bio­
genesis of cytochrome с oxidase and cytochrome b results from the 
joint expression of two distinct systems, mitochondrial and cytoplasmic, 
composed of two discrete genomes and two physically separated pro­
tein synthesis systems (22)(31). We are aware of the fact that our study 
of patient R.B. is not complete and many questions remain open. The 
short life of the patient and the severe medical problems as well as the 
complexity of the biochemical aspects such as the absence of 2 different 
cytochromes, in skeletal muscle but not in other organs investigated 
such as heart muscle and liver, have imposed great difficulties. However, 
this case report may contribute to a more intensive research in this 
field. 
Addendum 
During the preparation of the present paper a patient with a strongly 
reduced hepatic cytochrome b and a completely different clinical picture 
was described. Versmold, H. T., Bremer, H. J., Herzog, V., Bassewitz, 
D. B.V., Irle, U., Voss, H.v., Lombeck, I. and Branser, В.: A metabolic 
disorder similar to Zellweger syndrome with hepatic acatalasia and 
absence of peroxisomes, altered content and redoxstate of cytochromes, 
and infantile cirrhosis with hemosiderosis. Europ. J. Pediat. 124, 261, 
1977. 
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Leigh's Encephalomyelopathy in a Patient With 
Cytochrome с Oxidase Deficiency in Muscle Tissue 
J. L Willems, Ph.D., L. A. H. Monnens, M.O., J. M. F. Trijbels, Ph.D., J. H. Veerkamp, 
Ph.D., A. E. F. H. Meyer, M.D., K. van Dam, Ph.D., and U. van Haelst, M.D. 
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ABSTRACT. A patient is described with subacute necro­
tizing encephalomyelopathy proven by autopsy A slight 
increase of blood pyruvate and lactate levels with an 
increased lactate/pyruvate ratio and frequently increased 
/3-hydroxybutyrate/acetoacetate ratio suggested a disorder 
of mitochondrial oxidation 
A cytochrome с oxidase deficiency was shown in periph­
eral muscle tissue with some residual cytochrome с oxidase 
activity in heart muscle Normal cytochrome с oxidase 
activity was present in liver tissue Because of the markedly 
higher levels of pyruvate and lactate in CSF compared with 
blood and an increased lactate/pyruvate ratio in CSF, there 
may also have been defective activity of cytochrome с 
oxidase in brain tissue After a period of apparently normal 
development, the child's clinical condition gradually deteri­
orated and she died at age β years due to respiratory 
insufficiency. This study illustrates the fact that Leigh's 
disease is not linked to a single inherited molecular defect 
Pediatrics 60 850-857, 1977, LEIGH'S ENCEPHALOMYELOPA­
THY, LACTIC ACIDOSIS, CYTOCHHOME С OXIDASE 
Subacute necrotizing encephalomyelopathy 
(SNE) or Leigh's disease is a degenerat ive nervous 
system affliction with a well-characterized neuro­
pathology. Necrotizing lesions including cell loss, 
demyehnat ion, and reactive microgliosis with 
relative sparing of neurons and a marked increase 
in the number of capillaries are considered typi­
cal. These lesions are seen mainly in dièn—and 
mesencephalon, the spinal cord, thalamus, basal 
ganglia, denta te nucleus of the cerebellum, and 
often the optic nerve and tracts. ' In contrast to 
the neuropathological findings, a great variabil-
ity in the clinical picture is presented. ' 
To explain the clinical and biochemical find-
ings in SNE, three different mechanisms have as 
yet been proposed. Thiamin tr iphosphate was 
demonstrated by Cooper et al.- to be absent in the 
brain. Inhibitory material of thiamin pyrophos-
phate-ATP-phosphotransferase was found in 
urine, blood, and CSF. Decreased pyruvate 
carboxylase activity in liver tissue was shown by 
several investigators in children with SNE proven 
by autopsy.1 ' Yoshida et al.5 suggested that abnor-
mally high levels of pyruvate and lactate in CSF 
of their patient could be explained on the basis of 
a possible defect of pyruvate carboxylase activity 
of the brain tissue. A normal activity of hepat ic 
pyruvate carboxylase has been reported by 
Murphy6 in an infant with a diagnosis of Leigh's 
disease supported by autopsy. In a brief commu-
nication Farmer et al . ' presented a child with 
Leigh's disease and a deficiency of pyruvate 
dehydrogenase in fibroblasts. Recently a similar 
deficiency was shown by Blass et al . ' in two other 
boys. A deficiency of pyruvate dehydrogenase in 
fibroblasts is not necessarily associated with 
Leigh's disease."10 
In the present report a pat ient is described with 
SNE proven by autopsy. A slight increase of blood 
pyruvate and lactate levels with an increased 
lac ta te /pyruvate ratio and frequently increased 
/5-hydroxybutyrate/acetoacctate ratio suggested 
a disorder of mitochondrial oxidation. A defi-
ciency of cytochrome с oxidase was shown in 
muscle but not in liver tissue. Because of the 
markedly higher levels of pyruvate and lactate in 
CSF compared with blood and an increased 
lactate/pyruvate ratio in CSF, there may also 
have been a defective activity of cytochrome с 
oxidase in brain tissue. 
Received December 13, 1*376, revision accepted for publica­
tion March 1, 1977 
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CASE REPORT 
The patient, a girl, was the first child of unrelated healthy 
parents The family history was unremarkable Pregnancy 
and delivery were reported to have been normal Birth 
weight was 3,000 g The neonatal period was uneventful 
Acquisition of developmental skills during the first year 
seemed to be normal She was able to sit without support at 
the age of 9 months and to stand at 1 year She smiled at 5 
weeks and said a few words at 1 year The rate of weight gam 
during the first year, however, was diminished Vomiting was 
a regular feature She was first admitted to our clinic when 
she was 2 years old She weighed 8,700 g, the length was 73 
cm, and she had a head circumference of 46 cm She was not 
able to walk and could stand although unsteadily She 
exhibited fine hair over the limbs, upper lip, and back She 
was hypotonic and ataxic with normal deep tendon reflexes 
and flexor plantar responses The eyes showed a vertical 
nystagmus Fundoscopy revealed bilateral partial atrophy of 
the optic nerve Electroretinography showed no abnormali­
ties Very remarkable were episodes of deep sighing respira­
tions and sobbing The liver and spleen were not enlarged 
The laboratory findings revealed a compensated metabolic 
acidosis (pH, 7 39 Pt о , 21 mm Hg bicarbonate level, 11 2 
mEq/liter, base excess, 12.5 mbq/liter) and a slight increase 
of pyruvate and lactate The metabolic acidosis was treated 
by high doses of sodium bicarbonate (9 g/24 hr) Based on the 
experience reported by Pmcus et a l , " 1 5 g of thiamin and 
later 300 mg of thiamin propyl disulfide was given to our 
patient No improvement in weight, neurologic status, and 
lactate and pyruvate levels was noted The following years 
the child s clinical condition gradually deteriorated She 
could no longer sil when she was 4 years old She never 
learned to speak in simple sentences At 5 years, she was 
operated on for a hiatus hernia At 6 years symptoms of 
respiratory lasufficiency became evident ^fter a short 
period of artificial ventilation, the child died Muscle 
strength was insufficient to maintain respiration 
LABORATORY STUDIES 
Without treatment a persistent metabolic acidosis was 
present, with a base excess ranging from —6 to —13 mEq/ 
liter, pH 7 39 to 7 19 P r o 19 to 24 mm Hg and 
bicarbonate level 11 to 15 mfcq/hter The serum sodium and 
potavsium levels were normal Strum chloride level was 107 
to 109 mEq/hter Serum calcium, magncbium, phosphonis, 
and copper levels were normal 
No disturbance of liver function was evident (normal 
SCOT SCPT and alkaline phosphatase levtls) The creat­
inine Phosphokinase activitv * d s 10 7 units/liter, which is 
normal The RBC tramketolase level was 106 units/hter 
(normal 52 to 85 units/liter) Serum uric acid level was 0 14 
mM and choleslerol level was 5 7 m M Thyroid function wa* 
normal 
The С SF was clear, with two to three cells per cubic 
inilluneter and a total protein level of 20 mg/100 ml 
The ECG was repeatedlv normal The EEC had general 
ized slow curves 
Nerve conduction velocities were reduced (nervus 
peroneus and nervus mcdianus) Needle electromyography of 
several míeseles showed no abnormalities 
\t necropsy, brain weight was 1 050 g (normal 1,240 gì 
Gross examination revealed a gravish discoloration and 
cystic degeneration of the central part of the basal ganglia 
thalamus, around the occipital extension of the ventricular 
system, mesencephalon tegmentum pontis, and in the mesial 
side of the dentate nut leus Fxamination of representative 
blocks and frozen sections of the affected areas showed the 
typical lesions of SN E degeneration of the preexisting 
structures with formation of cysts, some signs of active 
myelin disintegration, an intense astrocytic proliferation, 
and a tremendous increase of thin walled blood vessels 
There was no mflammator) exudate 
Performing the renal acidification test according to Berg 
et a t , ' a reduced bicarbonate threshold could be demon-
strated Results qf detailed гецаі function studies will be 
reported elsewhere 
SPECIAL STUDIES 
Chemical Methods 
Lactate and pyruvate levels were determined enzymati-
callv bv the technique of Hohorst ' ' and Czok and 
l-amprecht,1 ' respectively Amino acid levels were deter 
mined quantitatively by ion exchange chromatography on a 
multichrom amino acid analyzer (Beekman) \celoacetate 
and β hydroxybutyrate levels were measured enzymatically 
according to the method of Wildenhoff ' 
Enzymatic Methods 
The pyruvate oxidation in leukocytes was studied 
according to Blass et al IH The leukocytes were isolated with 
dextran and incubated for 60 minutes at 37 С with (1-"C) 
pxnivate as substrate The substrate concentration was 0 5 
mM m a final volume of 2 ml 
Fibroblasts were cultured in TC 199 medium enriched 
with 20% fetal <alf serum and 5% chicken embryo extract, 
supplemented with 100 units/ml of penicillin and 100 ^g/ml 
of streptomycin After trvpsinization and washing with 50 
mM buffered saline, 5 10 to 10* intact fibroblasts were 
incubated in phosphate buffer (40 mM phosphate, 50 mM 
sodium chloride, pH 7 4) for 60 minutes at 37 С The 
substrate concentration was 0 16 mM pyruvate in a final 
volume of 1 5 ml 
Liver and Muscle Tissue 
Liver and muscle tissue from control subjects was obtained 
at operation for other purposes Liver and muscle tissue of 
the patient was obtained by biopsy and immediately after 
death Liver and muscle homogenate was prepared in 10 mM 
tris (hydroxymethvlì aminomethanc (TRIS) buffer (pH, 7 4) 
containing 0 25 M sucrose and 2 mM ethylene diamine 
tetraacetic acid (EDTA) supplemented with 50 units/ml of 
heparin for muscle tissue Homogcmzation was performed 
with a homogenizer (Potter Elvehjem) After centnfugation 
(600 g for ten minutes) the supernatant was used for the 
enzymatic assays Incubation medium consisted of 50 mM 
phosphate buffer at pH 7 4, 75 mM chloride, 2 mM 
adenosine diphosphate (ЛОР), 0 5 mM E O T λ, and 10 mM 
magnesium chloride The substrate concentration was 1 mM 
in a final volume of 0 5 ml All enzymatic assays were based 
on the " C O capture method " The enzymatic reaction was 
stopped with 3N perchloric acid The " C O trapped m 
hyainme hydroxide was counted with 10 ml of scintillation 
fluid (4 g of omnifluor per liter of toluene) in a scintillation 
counter (Nuclear Chicago) Cytochrome с oxidase was 
measured according to van Buuren et al ^ 
Hlstochemkal Investigation 
The muscle specimen was rapidly frozen by immersing 
small blocks of tissue ш isopenlane cooled to —150 С with 
liquid nitrogen Longitudinal and transverse serial sections 
with a thickness of 7 μ were cut in a cryostat The activity of 
cytochrome r oxidase was measured according to the method 
of Burnstone1'' with the substrate ρ aminophenylamine The 
en¿yme reaction was performed with and without the 
presence of cytochrome с 
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TABLE I 
BLOOD AND CSF М Ь Т Л В Ш І Т Е LEVELS A F T F B OVERNIGHT 
F A S T " 
Lattale 
Blood 
CSF 
Pyruvate 
Blood 
CSF 
/Ï-Hydroxybutyratc (blood) 
Acetoatetate (blood) 
Ljctate/pvnivate ratio 
Blood 
CSF 
β Mvdroxybiityrale/ 
acetoacetate ratio (blood) 
Patient 
1,720-3,260 
4,083t 
42-135 
202t 
49-830 
34 256 
12-46 
20 
0 85-5 82 
Ccmfrois 
1,042 ± 444t 
(n = 102) 
1,534 ± 300t 
(n = 54) 
55 г 19t 
(n = 96) 
90 ± 20t 
(n = 52) 
< 3 0 0 
< 2 0 0 
12 20 
Π 17 
< 3 
"Valut", expressed in mitromoles 
fMean value ± 1 SD 
ÎThe lactate and pyruvate levels in blood taken just prior to 
the lumbar puncture amounted to 2,117 and 57 μιηοΙο/ΙιΙβΓ, 
respectively, with a lactate/pyruvate ratio of 37 
Studies of Mitochondria 
Milochondna were isolated of the muscle specimen 
according to the method of van \\ ijngaarden et al The 
rates of oxidation of pyruvate and glutamate bv the i4)lated 
niitochondna were measured bv the W arburji ІесЬпнціс 
The reaction medium conlaimd 25 inM glucose, 0 03 m M 
cytochrome с, 2 5 mM тацпечшш chloride, 20 т М potas­
sium phosphate buffer, 0 5 m M ATP, 0 5 inVl EDT V 50 mM 
potassium chloride, 25 m M TRIS-HCl buffer, 0 75 mg bovine 
serum albumin, about 1 nig of mitochondrial protein ideler-
nuned by the b. iret method), and 15 mM ι-glutamate or 15 
mVI pyruvate and 0 1 mVl 1 malate, in 0 9 ml The center 
well of the manometer vessels was provided with 0 05 ml of 
2N potassium hydroxide and a filter paper The side arms of 
the flasks contained 1 4 IU of hexokinase in 0 1 ml of 
solution The reaction volume was 1 ml, the temperature 25 
C, and the pH 7 5 Oxvgcn uptake was calculaled bv 
extrapolat'on \fter 20 to 24 minutes hexokinase was added 
from the side arms and after 20 minutes the reaction was 
slopped by the addition of perchloric acid (final concentra­
tion 4%) Phosphors lat ion was measured spcctrophotomeln-
cally at 340 mn by de lennmmg the glut ost-ß-phosphatc 
formed in cuvettes containing in 1 ml, in addition to the 
sample, 0 5 mM NAI5P 50 mM TRIS HCl (pH 7 6), 5 ug of 
glucose 6 phosphate dehydrogenase and 5 μg of phosphoglu-
cose isomerase The oxvgen uptake and glucose 6 phosphate 
production occurring in the presence of oxvdi/able 
substrates were corrected for the values found with absence 
of substrate, in which case the oxygen uptake was actuallv 
negligible The P/O ratio was determined by dividing the 
corrected number of micromoles of glucose 6 phosphate 
formed by the total oxygen uptake as calculated over the 
period in which hexokinase participated in the reactions 
The respiratory control index (HCl) was calculated by 
dividing oxygen uptake in the presence of hexokinase by 
oxygen uptake in its absence 
Determination of Components of 
Electron Transport Cham 
After thawing, the muscle specimen wa.s weighed and 
finely minced with scissors at 4 С Homogeimalion was 
ptrformed bv hand wiih a Potter Llvehjem-type homog 
en ι ¿er in 14 ml of an ice-cold medium containing sucrose 
(250 mM) and TRIS HCl (10 m VI, pH 7 5) 
The homogenale was cenlnfuged for ten minutes at 14,000 
g (0 С') After discarding the siipernaiant the pellet was 
reMispcnded, homogenized in the same medium, and centri 
fuged a second time The same procedure was repealed 
another tune in order lo remove contaminating hemoglobin 
Afler the last centnfugalion the pellet was taken up in 3 ml 
of a medium containing potassium phosphate buffer (GO mM, 
pl l 6), Tween (0 5%\ azolcctinc (40 Mg/ml), and EDTA (1 
mM) and sonicated four times for 30 seconds cooled in ice, in 
a somheator ^VISE) (frequency 21 VÌI/, amplitude 4 μ) 
Crude material was removed by filtration under suction 
through cheesecloth Two cuvettes (volume 1 2 ml, pathway 
10 mm) were filled wilh the suspension and difference 
spectra were recorded from 400 to 700 nm with a spectro­
photometer (Ammco I)\V 2 I'V/VIS) The reference cuvette 
contained the oxidized suspension, dithiomte was used to 
reduce the suspension m the sample cuvette The concentra­
tion of cytochromes was calculated from the difference in 
absorption between the reduced and oxidized forms of the 
respiratory carriers at 551 m/i (cytochrome cc,), 605 νημ 
(cytochrome пя,) and 562 ιημ (cytochrome b) As millimolar 
extinction coefficients were used cytochrome cc, 21 0, 
cytochrome сш, 24 0, and cytochrome b 2Θ 5 
Electron Microscopy 
Skeletal muscle tissue foi electron microscopy was minced 
into 1 cu mm blocks and fixed in buffered 1% osmic acid 
(Cauldfield's method), ' pH 7 2, for 1 5 hour Following 
dehydration in graded alcohols, the tissue blocks were 
embedded m Epon 812 Sections were mounted on form va r-
toated grids, stained with uranylacetate and lead citrate, and 
examined with a Siemens Elmiskop 101 
Materials 
The (1- 'C Ì pyruvate sodium salt (12 n i C i / m M \ ( S ^ ' Q a -
kctoglutarale sodium salt (8 3 mCi/mM), and (1-5 "C) 
citrate sodium salt (27 mCi/mM) were obtained from 
Radiochemical Centre \niersham, England 
RESULTS 
The results of the quanti tat ive analysis of 
lactate, pyruvate, jQ-hydroxybutyrate, and aceto-
acetate in blood and of lactate and pyruvate in 
CSF are s u m m a n / e d in Table I. The lactate level 
in the blood showed a slight to modera te increase, 
with an elevated lac ta te /pyruva te ratio, which is 
indicative of an increased cytosohc N A D H / 
NAD ratio. 
The frequently increased ß-hydroxybutyra te / 
acetoacetate ratio in blood reflects an increased 
NADH/NAD* ratio for the mitochondrial cris-
tae ' This abnormality strongly suggests a distur-
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RESULTS 
Min Glucose 
(mM¡ 
0 3.7 
30 8.4 
60 7.4 
90 5.4 
120 3.9 
'Glucose dose was 
Enzymal 
TABLE 11 
OF GLUCOSE TOLERANCE TE 
Lactate 
(μΜ) 
2,569 
4,169 
4,494 
4,618 
5,596 
1.75 g/kg 
tic Studie: 
Pyruvate 
(μΜ) 
83 
136 
102 
101 
94 
of body weight. 
S 
:ST· 
Lactate/ 
Pymvate 
Ratio 
31.0 
30.6 
44.1 
45.7 
59.5 
FIG. 1. Lactate, pyrtivate, and glucose levels after intrave-
notis injection of glucagon (30 /ig/kg). 
bance in the electron transport system of the 
mitochondria. During thiamin therapy, /î-hydrox-
ybutyrate/acetoacetate ratio tended to decrease. 
As compared with the blood levels, lactate and 
pyruvate levels were abnormally high in CSF. As 
might be expected, the alanine level in serum was 
slightly increased. The other amino acid levels in 
serum were in the normal range. 
Carbohydrate Metabolism 
A severe defect in gluconeogenesis could be 
excluded since fasting for 22 hours provoked no 
hypoglycemia. The mobilization of free fatty 
acids was normal. A fasting glucagon stimulation 
test and a standard oral glucose tolerance test 
yielded normal results with respect to the blood 
glucose response. A distinct rise of pyruvate level 
in blood was observed after glucagon stimulation 
(Fig. 1) and during a glucose tolerance test (Table 
II). 
In leukocytes, a normal "CO., production from 
(1-"C) pymvate was measured (Table III). Pyru-
vate dehydrogenase activity was also normal in 
cultured fibroblasts. In liver homogenate, pyru-
vate dehydrogenase activity and the 2-oxogluta-
rate and citrate oxidation rate were normal (Table 
III). In muscle homogenate, however, the pyru-
vate dehydrogenase activity was lowered. 
Although the permeability of muscle mitochon-
dria for citrate is low, the inability to show any 
oxidation of (l-5-"C) citrate is clearly abnormal. 
Histochemlcal Studies 
Histochemical investigation revealed no abnor-
malities except for the absence of cytochrome с 
oxidase activity. No atrophy of type I and type II 
muscle fibers was present. 
Mitochondrial Studies 
As can be seen from Table IV, the oxygen 
consumption of the mitochondria was very low. 
The mitochondria practically failed to increase 
the rate of oxygen consumption upon addition of 
TABLE III 
ENZYMATIC ACTIVITIES IN INTACT LEUKOCYTES AND FIBROBLASTS AND IN HOMOCENATES OF LIVER AND MUSCLE" 
Tissue 
Leukocytes 
Fibroblasts 
Liver 
Muscle 
Enzyme/Citric Acid 
Cycle Activity 
Pymvate dehydrogenase 
Pyruvate dehydrogenase 
Pyruvate dehydrogenase 
2-Oxoglutarate oxidation 
Citrate oxidation 
Pymvate dehydrogenase 
Citrate oxidation 
Substrate 
(\-"C) pymvate 
(1-"C) pymvate 
(1-'*C) pymvate 
(S-'O) 2-oxoglut 
(1-5- "C) citrate 
(1-MC) pymvate 
(1-5-"C) citrate 
Controls 
1.1 ± 0.5 (n -
Range 0.4-1.9 
13.7 ± 6.7 (n -
Range 3.4-23.9 
27-l&Mn - 6) 
4.7-48 (n = 4) 
11-40 ( n - 3 ) 
27-146 (n - 4) 
2.1 
l l ) t 
mi 
Patient 
0.8. 1.0, 0.9t 
16.4 
136 
13 
21 
12 
0 
"Nanomoles per hour per milligram of protein. 
t Act i vi ties expressed in nanomoles per hour per 10е leukocytes. 
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TABLE IV TABLE V 
P/O RATIO RESPIRATORY CONTROL INDEXES AND OXYGEN 
CONSUMPTION IN ISOLATED MUSCLE MITOCHONDRIA' 
Substrate Respiratory P/O Oxygen 
Control Rath Uptake^ 
Index , * . 
Confrois Patient 
Pyruvate malate 1 7 3 0 2 5 6 24 7 164 
16 9 
Glutamate NDJ 3 0 26 9 23 3 172 
17 2 
"Mitochondria from imisculus femons 
tExpressed in rtlicrohters of oxygen per hour per 100 mg of 
tissue 
Î N D * not determined 
phosphate acceptor but they are able to produce 
normal amount!» of gliiLOse-6-phosphate per 
amount of oxygen consumed (expressed as P/O 
ratios) It can be concluded that the mitochondria 
in the patient's muscle were "loosely' coupled 
The concentrations of respiratory chain compo 
ncnts are presented in Table V In heart muscle, a 
reduced content of cytochrome аа
л
 was present 
In peripheral muscle, cytochrome aa, could not 
be detected The enzymatic activity of cyto 
chrome с oxidase was deficient in heart muscle 
and completely absent in peripheral muscle 
(Table VI) In liver tissue a normal cytochrome с 
oxidase activity was present 
Electron Microscopy 
Ultrastructural study of the muscle biopsy 
specimen shows the myofibrils and myofilaments 
to be well preserved The dominant feature is the 
aggregation of enlarged mitochondria in the 
juxta-nuclear and subsarcolemmal regions of the 
muscle fibers (Fig 2) These mitochondria have a 
bizarre shape and vary greatly in size and form 
The large mitochondria contain an excessive 
number of cristae, which are irregularly arranged 
and distorted Fine granular elee tron dense male 
rial cah be observed in the mitochondrial matrix 
TABI F VI 
ACTIVITY OF CYTOCHROME Г OXIDASE" 
Tissue Controls Patient 
Heart muscle 188t 16t 
Peripheral muscle 18 9 13 20 0 
Liver tissue 22 Г г 40 45 48 
"Expressed in nanomoles per minute per milligram of 
protein 
tPostmorlem examination 
CONTENT OF RESPIRATORY C H A I N COMPONENTS IN MUSCLE 
Heart muscle 
Cytochrome aa 
Cytochrome b 
Cytochrome re, 
Peripheral muscle 
С уtochronic aa, 
Cytochrome b 
Cvtochrome re, 
T I S S C E " 
Control 
34 
24 
65 
13 9 10 : 
12 27 14 
35 27, 21 
^ 
25 : 
23 
55 
--
28 
32 
за 
Patient 
12 
21 
62 
0 
16 
32 
"Expressed in picomolcs per milhgram of protein 
but paracrvstallmc inclusions or large spherical 
dense bodies are not visible (Fig 3) The same 
findings applv to the mitochondria lying between 
the myofibrils Л various amount of lipid droplets 
is intimately associated with these abnormal 
mitochondria (Fig 4) No lysosomal abnormalities 
or an increase of hpofuscin bodies are seen The 
glycogen content between the mvofilamcnts and 
under the sarcolennna appears normal The sarco-
tubular system, the plasma membranes, and 
muscle nuclei with huge nucleoli arc normal 
DISCUSSION 
The clinical picture of SNE is variable The 
ambiguity of the clinical signs is exemplified by 
the fact that in six cases an intracranial tumor was 
suspected J 1 The clinical symptoms of our patient 
are in agreement with the clinical diagnosis of 
Leigh's disease In his excellent review Pincus' 
stresses the importance of respiratory symptoms 
In three quarters of the cases included in his 
review disturbances of respiration occurred, most 
often in the latter part of the illness, and consti­
tuted the major terminal problem in 60 out of 86 
cases The respiratory abnormalities varied in 
kind and included such problems as dyspnea, 
tachypnea, and apnea Our patient also died due 
to respiratory insufficiency, but her death was 
definitely due to muscle failure After the period 
of artificial ventilation she was able to maintain a 
normal Pco2 for a few days We agree with the 
speculation of Crosby and Chou * that muscle 
often may be involved in l-eigh's disease In their 
patient with chronic Leigh s encephalomyelopa 
thy, cardiomyopathy and a prominent "mito­
chondrial myopathy were demonstrated No 
biochemical studies were reported 
An increasing number of patients has been 
reported with defects in biological oxidation Luft 
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Fie. 2. Portion of muscle fiber showing subsarcolemmal 
accumulation of irregularly shaped mitochondria. Note 
disorderly arrangement and branching of mitochondrial 
cristae. С " capillary with erythrocyte m lumen; S = sarco-
lemmal sheath {original magnification X23.000.. 
et al.25 and Afifi et al.26 2 ' described two patients 
with the triad of hypermetabolic state, myopathy, 
and abnormal muscle mitochondria. The mito­
chondria failed to show significant respiratory 
control with various substrates; mitochondrial 
respiration cannot be increased by adding ADP, 
yet the mitochondria can still couple respiration 
to phosphorylation ("loosely coupled" mitochon­
dria). Spectra and content of cytochromes were 
normal in the patient described by Afifi et al. 
They suggest that recycling of calcium between 
mitochondria and cytosol may take place in vivo 
and results in sustained stimulation of respiration. 
Other cases have been described showing loosely 
coupled oxidative phosphorylation. However, 
none had clinical hypermetabolism. 1 2 0 2 ' 3 0 In 
human achondroplasia, Mackler et al.31 found 
decreased oxidative phosphorylation possibly 
caused by a defect occurring at the first phosphor­
ylation site in mitochondrial preparations isolated 
from muscle biopsy specimens. Reports concern­
ing defects in the respiratory chain itself are rare. 
Spiro et al.'2 " described an unusual hereditary 
disease of the nervous system and muscle 
consisting of progressive ataxia, predominantly 
proximal muscle weakness, areflexia, extensor 
plantar responses, and insidious dementia. Studies 
on isolated muscle mitochondria revealed a 
marked reduction in the cytochrome h content 
according to the authors. In our opinion however, 
their conclusion might be incorrect due to the 
presence of hemoglobin in their mitochondrial 
suspensions. Studies of mitochondrial oxidation in 
the cerebro-hepato-renal syndrome pointed to a 
FIG. 3. Mitochondria with dense granules (arrows) in their 
matrix lying in between myofibrils together with glycogen 
particles (original magnification X 19.000). 
defect between the succinate dehydrogenase 
flavoprotein and coenzyme Q in brain, liver, and 
muscle.34 A deficiency of cytochrome с oxidase (a 
copper-containing enzyme) activity was shown 
by Shokeir and Shreffler15 in leukocytes of 
patients with Wilson's disease and was considered 
to be the consequence of deficiency of serum 
cemloplasmin. Also in Menkes' kinky-hair syn­
drome a secondary lack of cytochrome с oxidase 
in brain, muscle, and liver has been demonstrated 
which is due to copper deficiency.1" Senior and 
Jungas'" briefly reported two siblings with 
extreme stunting of growth and severe mental 
FIG. 4. Between myofibrils are numerous lipid droplets 
(arrows) that are closely associated with mitochondria (orig­
inal magnification X 23.500) 
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retardation with elevated levels of lactate and 
normal levels of pyruvate Liver mitochondria 
failed to utih/e β hydroxybutyrate glutamate, or 
malate as judged bv oxvgen consumption in the 
presence of \DP Houe\er, succinate oxidation 
proceeded efficiently and exhibited normal respi 
ratory control They concluded that there was 
failure of oxidation of intramitochondrial N'ADH, 
a defect early m the respiratory chain 
The ultrastructural abnormality of mitochon 
dría noted in our patient although not specific,1* 
suggests a mitochondrial dysfunction In muscular 
disuse the mitochondrial structure is well 
preserved ' In our patient an almost complete 
deficiency of cytochrome с oxidase in peripheral 
muscle could be demonstrated The lou oxygen 
consumption of isolated uniscle mitochondria is in 
agreement with this finding In heart muscle 
however, some residual activity was present This 
residual activity may explain the apparently 
normal cardiac function in this child This 
lowered activity of cytochrome с oxidase in heart 
muscle excludes disuse as a cause of diminished 
activity '" The absence of cytochrome с oxidase 
activity in peripheral muscle tissue causes the 
increase of the mitochondrial N ADH/NAD ratio 
as reflected in the frequently elevated β hvdroxv 
butvrate/acetoacetate ratio in blood Scrum 
copper and scrum iron levels in our patient were 
normal In this way a secondar) deficiency of 
cytochrome с oxidase was excluded Other argu­
ments for a primary deficiency of cytochrome с 
oxidase activity are the normal activity of cvto 
chrome г oxidase in liver tissue and the normal 
content of cytochrome b and cr, in muscle 
tissue " If the glucose output from the liver was 
increased, an excessive increase of pyruvate and 
lactate in blood was observed The glucose output 
was stimulated either by glucagon injection or 
by oral loading ' permitting an increased entry of 
glucose into muscle The abnormal level of blood 
pyruvate can be explained by an impairment of 
pyruvate oxidation in muscle" (and brain"1) The 
normal cytochrome с oxidase activity m liver 
tissue corresponds with the normal oxidation of 2-
oxoglutarate in this tissue 
We can only speculate about a defect m 
biological oxidation in the brain or part of the 
brain in our patient As in other tissues, hypoxia 
causes an increase in lactate production and 
concentration m the brain At least in the steady 
state there is diffusion equilibrium between CSF 
and the tissue fluid of the brain ' The abnormally 
elevated lactate concentration in CSF compared 
with the blood level supports the suggestion of a 
disturbance in the mitochondrial function of the 
brain or part of the brain More data about 
lactate, pyruvate, β hydroxybutyrate, and aceto-
acétate levels in С SF in patients with suspected 
Leigh's disease in a period of normocapnia may 
be helpful in the understanding of this disorder " 
The absence of cytochrome с oxidase activity in 
the peripheral muscle and possibly in the brain, 
with normal activity m the liver, demonstrates 
that more than one gene either codes for the 
structure of the enzyme or regulates its activity in 
different tissues 
REFERENCES 
1 Pineas JH Subacute necrotizing eneephalomyelopalhy 
(Leigh s diMtisc) Л consideration of clinical 
features and etiology Dev Med Child Neurol 14 87 
1972 
2 Cooper JR Pincus JEI Itokawa Y Piros К Experience 
with phosphoryl transferase inhibition in subacute 
necrotumg encephalomyelopathy N Engl J Med 
283 793 1970 
3 Hommes FA Polman HA Heennk JD Leigh s encepha 
lomyelopathy An inborn error of gluconeogenesis 
Arch Dis Child 43 423 196« 
4 Crover WD Auerbach VH Patel VIS Biochemical 
studies and therapy in subacute necrotizing enceph 
alomyelopathy (Leigh s syndrome) J Pediatr 81 39, 
1972 
5 Yoshida Τ Tada К Arakawa Τ Abnormally high levels 
of lactate and pyruvate in cerebrospinal fluid of 
hyperalaninemia with hyperpyruvicemia Tohoku J 
Exp Med 101 375 1970 
6 Murphy JV bfficacy of recommended therapeutic 
regimens in I^eigh s disease Dev Med Child Seurol 
16 362 1974 
7 Farmer TW Veath L Miller AL et al Pyruvate 
decarboxylase deficiency m a patient with subacute 
necrotizing enccphalomyclopathy Neurology 
23 429 1973 
8 Blass JP Cederbaum SD Dunn HG Biochemical abnor 
malities in Leigh s disease Lancet ] 1237 1976 
9 Cederbaum SD Blass JP Minkoff N et al Sensitivity to 
carbohydrate m a patient with familial intermittent 
lactic acidosis and pyruvate dehydrogenase defi 
ciency Pediatr Res 10 713 1976 
10 Strommc JH Bonid О Мое PJ Fatal lactic acidosis In a 
newborn attributable to a congenital defect of 
pyruvate dehydrogenase Pediatr Res 10 60 1976 
11 Pincus JH Cooper JR Itokawa Y Cumbmas M Sub 
acute necrotizing encephalomyelopathy Effects of 
thiamine and thiamine prophyldisulfìde Arch 
Neurol 24 411 1971 
12 Berg U Apena A Broberger О Subclinical defects in 
renal regulation of acid base balance in children 
with recurrent urinary tract infections Acta 
Paediatr Scand60 521 1971 
13 Hohorst HJ in Bergmeyer HK Methoden der enzyma 
tischen Analyse Verlag Chemie Weinheim II 
1970 ρ 1425 
14 Czok R Lamprecht W in Bergmeyer HK Methoden 
der enzymatischen Analyse Verlag Chemie Wein 
heim II 1970 ρ 1407 
15 Wildenhoff KL· A micro-method for the enzymatic 
determination of acetoacelate ahd /Miydroxybutyr 
ate m blood and urine Scand J Clin Lab Invest 
136 
25 171, 1970 
16 Blass JP, Avigan J, Uhlendorf BW A defect in pvnivate 
decarboxylase in a child with an intermittent move­
ment disorder J Clin Invest 49 423, 1970 
17 Рож RVI A simple incubation flask for " C O collection 
Anal Biochcm 41 578, 1971 
Id van Buuren KJH, Zu urendonk PF, van Gelder В, 
Muy sers АО Biochemical and biophysical studies 
on cytochrome aa-, V Binding of cyanide to cvto 
chrome aan Biochim Biophys Acta 256 243, 1972 
19 Burnstone MS Modifications of histochemical 
techniques for the demonstration of cytochrome 
oxidase J Histochem Cytochem 9 59, 1961 
20 van Wijngaarden CK. Bethlem J, Meijer 4 F F H , et al 
Skeletal muscle disease with abnormal mi toe hon 
dna Bram 90 577, 1967 
21 Cauldfìeld JB Effect of varving the vehicle for osmium 
tetroxide in tissue fixation J Biophys Biochem 
Cytol 3 827, 1957 
22 Williamson DH Lund P, Krcbs HA The redox state of 
nicotinamide adenine dinucleotide in the cytoplasm 
and mitochondria of rat liver Biochcm J 103 514, 
1967 
23 Montpetit VJA, Andermann F, Carpenter S, et al 
Subacute necrotizing encephalomyelopathy Brain 
94 1. 1971 
24 Crosby TW, Chou SM Ragged red fibers in I^igh's 
disease. Neurology 24 49, 1974 
25 Luft H, Ikkos D, Palmieri G, et al A case of severe 
hypermetabolism of nonthyroid origin with a defect 
jn the maintenance of mitrochondnal respiratory 
control J Clin Invest 41 1776 1972 
26 Afifi AK, Ibrahim MZM Bergman RA, et al Morpho-
logic features of hypcrmctabohc mitochondrial 
disease A light-microscopic, histochemical and 
electron-microscopic studv J Neurol Sci 15 271, 
1972 
27 Di Mauro S, Bonilla E, Lee CP, et al Luft s disease 
Further biochemical and ultrastructural studies of 
skeletal muscle in the second case J Neurol Sci 
27 217, 1976 
28 Hudgson P, Bradley WO, Jenkison M Familial ' mito 
chondnal myopathy" A myopathy associated with 
disordered metabolisms in muscle fibers Part 1 J 
Neurol Sci 16 343, 1972 
29 Worsfold H, Park DC, Pennington RJ Familial 'mito 
chondnal myopathy A mvopalhv associated with 
disordered oxidative metabolism in muscle fibers 
Part 2 J Neurol Sci 19 261, 1973 
30 Black JT, Judge D, Demers L, Gordon S Ragged-red 
fibers A biochemical and morphological study J 
Neurol Sci 26 479, 1975 
31 Mackler В, Haynes В, Inamdar R, et al Oxidati\e 
energy deficiency III Human achondroplasia 
Arch Biochem Biophys 159 885, 1973 
32 Spiro AJ Moore CL, Prineas JW, et al A cytochrome 
related inherited disorder of the nervous svstem and 
muscle Arch Neurol 23 103 1970 
33 Spiro AJ Prmcas JW, Moore C L A new mitochondrial 
mvopathv in a patient with salt craving Arch 
Neurol 22 259, 1970 
34 Goldfischer S, Moore CL, Johnson AB, et al Peroxi 
soma) and mitochondrial defects in the cerebro-
hepato renal syndrome Science 182 62, 1973 
35 Shokeir MHK, Shreffler DC Cytochrome oxidase defi 
ciencv in Wilson s disease A suggested cenilo 
ріампш function Proc Natl Acad Sci 62 867, 
1969 
36 French JH, Sherard ES, Lubell H, et al Trichopoliodvs 
trophy 1 Report of a case and biochemical studies 
Arch Neurol 26 229, 1972 
37 Senior B, Jungas RL A disorder resulting from an 
enzymatic defect of the respiratory chain Pediatr 
Res 8 438a, 1974 
38 Di Mauro S, Schotland DL, Bonilla E, et al Mitochon 
drial m) opathies Which and how many 9, in 
Milhorat Г (ed) Exploratory Concepts II 
Control Mechanisms in Development and Function 
of Muscle Amsterdam, Excerpta Medica, 1974, 
p 5 0 6 
39 Mendel! JR. Engel WK The fine stmcture of type 11 
muscle fiber atrophv Neurology 21 358, 1971 
40 Booth FW, Kelso JR Cytochrome oxidase of skeletal 
muscle Adaptive response to chronic disuse Can J 
Physiol Pharmacol 51 679, 1973 
41 Finch CA Miller 1 R, Inamdar Afl, et a) Iron deficiency 
in the rat Physiological and biochemical studies of 
muscle dysfunction J Clin Invest 58 447, 1976 
42 Fei ig Ρ Wahren J Hendler R Influence of physiologic 
hvperglucagonemia on basal and insulin inhibited 
splanchnic glucose output in normal man J Clin 
Invest 58 761 1976 
43 Levine R Haft DL С arbohydrate homeostasis N Engl J 
Med 283 175, 1970 
44 Pozefsk\ T. Tancredi RG Effects of intrabrachial 
arterial uifusion of pyruvate on forearm tissue 
metabolism J Clin Invest 51 2359 1972 
45 Wcvnc J, Leasen I Lactate in CSF in relation to brain 
and blood, in С serr H D , Fenstermacher JD, Fenel V 
(eds) Fluid tnvironmcnt of the Brain New York, 
Academic Press, 1975. ρ 255 
46 Grobe Η Bassewitz DB van, Dominick Η, Pfeiffer RA 
Subacute necrotizing encephalomyelopathy Acta 
Paediatr Scand 64 755, 1975 
ACKNOWLEDGMENT 
We wish to thank Dr J Slooff who performed the 
pathological examination, and Ms Τ de Kort, Ms Y 
Henrichs and J \rends for the expert technical help 
137 
Summary 
This thesis is limited to the study of disturbances of pyruvate meta-
bolism related to hereditary metabolic disorders. In Chapter 1 a short 
review of the knowledge about the utilization of pyruvate is given and 
some regulatory aspects of pyruvate metabolism are discussed. 
The pathophysiology of lactic acidemia is briefly summarized in 
Chapter 2. A survey is given of the various enzyme deficiencies, which 
are associated with elevated concentrations of lactate and pyruvate in 
blood and/or cerebrospinal fluid. 
In the third Chapter our procedure used for the determination of 
lactate, pyruvate and ketoacids in blood and cerebrospinal fluid is out-
lined. Normal values of these acids in both physiological fluids of 
children are given. Values of the lactate/creatinine ratio in urine of 
children (5 months — 10 years) are presented. 
A fasting test is performed to get some information concerning the 
pathway and the organ affected. Results of this test on 13 normal 
children are described in Chapter 4. The value of the fasting test is 
illustrated by findings in patients suffering from a defect in pyruvate 
metabolism. The course of the concentration of metabolites in blood 
and cerebrospinal fluid during a fasting period may give information 
not only when defects in glycogenolysis or gluconeogenesis but also 
when aberrations of pyruvate and fatty acid oxidation and ketogenesis 
are expected. 
A reliable measurement of the pyruvate oxidation can be performed 
in intact leukocytes and fibroblasts with [1-14C] pyruvate as substrate 
(Chapter 5). A concomittant assay of the 14C02 production from 
[2-14C] pyruvate can provide an indication for the total activity of the 
citric acid cycle. The activity of the individual steps of this cycle can 
only be determined with isolated mitochondria or disrupted cells, due 
to the low transport rate of the citric acid cycle intermediates across 
the cellmembrane. 
Since normal oxidation rates of pyruvate in leukocytes and/or fibro-
blasts cannot exclude defects in other tissue, the determination of 
enzyme activities in homogenates of liver and muscle tissue remains 
necessary. It was shown that pyruvate dehydrogenase represents the 
rate limiting step in the 14C02 production from [1-14C] pyruvate in the 
presence of malate in liver and muscle of the rat. 
It was investigated in homogenates and mitochondria of the rat, 
which experimental conditions might be adequate to detect defects in 
the citric acid cycle in human tissues. Addition of malate to liver mito-
chondria oxidizing [14C] citrate results in an increase of the 14C02 pro-
duction from [14C] citrate by an increase of citrate transport. In this 
condition 2-oxoglutarate accumulates, due to transport out of the mito-
chondria in exchange of malate. 
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The oxidation rates of citric acid cycle intermediates are linear with 
respect to time but the 14C02 production from [5- , 4C] 2-oxoglutarate 
and [1,4- I 4C] succinate shows alag phase. Addition of pyruvate elimina-
tes this lag phase in rat liver mitochondria. In rat muscle mitochondria 
the addition of pyruvate markedly increased the oxidation rate of 
[5-14C] 2-oxoglutarate and [1,4-14C] succinate but a significant lag phase 
remained. 
Malate and pyruvate are converted almost stoichiometrically in rat 
liver mitochondria. About 60 percent of the metabolized malate is 
recovered as citrate and about 20 percent as 2-oxoglutarate. 
Since the '"CC^ production rate from [5-14C] 2-oxoglutarate is a para-
meter of the overall citric acid cycle, defects in the cycle can be es-
tablished with this substrate. The first segment of the cycle (citrate to 
2-oxoglutarate) can be measured with [6- I4C] citrate in liver tissue. In 
the second segment (2-oxoglutarate to malate) only the first step can be 
measured with [1-14C] 2-oxoglutarate and the rest of the second segment 
with [1,4- , 4C] succinate. The third segment (malate to citrate) can be 
investigated with malate and pyruvate as substrates by measuring the 
accumulation of citrate and 2-oxoglutarate. The rates of 14C02 pro-
duction by homogenates and mitochondria of rat liver and muscle are 
presented for [1-14C] pyruvate and various 14C-labeled citric acid cycle 
intermediates together with control values in human liver and muscle 
homogenates. 
We found only one Km value of pyruvate carboxylase for pyruvate in 
human liver in contrast with other investigators (Chapter 7). 
The instability of pyruvate in aqueous solution is described in Chapter 
8. Analysis of the compound, which is formed in aqueous solution, re-
vealed the structure of the reduced form of the dimer of pyruvate: 2,4-
dihydroxy-2-methylglutaric acid, an analogen of 2-oxoglutarate. This 
compound did not inhibit either pyruvate dehydrogenase or 2-oxogluta-
rate dehydrogenase activity in rat liver homogenate. 
In Chapter 9 four case reports are described. A pyruvate dehydro-
genase deficiency in liver tissue was established in a boy with mental 
and motor retardation, microcephaly and severe hypotonia. He had a 
high pyruvate and lactate concentration in blood and a metabolic 
acidosis. The deficiency could not be demonstrated in white blood cells 
and fibroblasts. 
A child suffering from severe lactic acidemia had severe mental retar-
dation, muscular hypotonia and abundant subcutaneous fat. Hypo-
glycaemia was provoked by prolonged fasting. A pyruvate carboxylase 
deficiency in liver tissue was demonstrated in this patient. 
Severe cerebral damage, a mitochondria myopathy, extreme lactic 
acidemia and a Detoni-Fanconi-Debré syndrome were present in a third 
patient. Low oxidation rates of pyruvate and 2-oxoglutarate in muscle 
tissue were measured. In the mitochondria of striated muscle cytochrome 
ааз was absent and cytochrome b was nearly absent. In heart muscle 
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cytochromes aa3 and b were at the level of the controls. 
A cytochrome с oxidase (ааз ) deficiency was shown in peripheral 
muscle in a girl suffering from subacute necrotizing encephalomyelo-
pathy (Leigh's disease). The frequently increased 3-hydroxybutyrate/ 
acetoacetate ratio and the low oxidation rate of pyruvate in muscle 
homogenate indicated a disorder of the respiratory chain. The high ratio 
of lactate and pyruvate in cerebrospinal fluid/lactate and pyruvate in 
blood suggested that also cytochrome с oxidase in brain tissue was 
defective. 
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Samenvatting 
In dit proefschrift zijn enkele aspecten beschreven van het onderzoek 
naar erfelijke stoornissen in het pyruvaat metabolisme. In Hoofdstuk 1 
wordt een beknopt overzicht gegeven van de kennis over het metabolis-
me van pyruvaat en worden enkele aspecten van het regulatie mechanis-
me besproken. 
De pathofysiologie van de lactaat acidemie wordt samengevat in 
Hoofdstuk 2. Een overzicht wordt gegeven van de verschillende enzym 
deficiënties, welke gepaard gaan met verhoogde concentraties lactaat en 
pyruvaat in bloed en/of liquor. 
In het derde Hoofdstuk staan de toegepast methodieken vermeld 
voor de bepaling van lactaat, pyruvaat en ketozuren in bloed en liquor. 
De normale waarden van deze metabolieten in beide fysiologische vloei-
stoffen en de waarden van de lactaat/kreatinine ratio in urine van kinde-
ren tussen 5 maanden en 10 jaar, zijn in dit hoofdstuk vermeld. 
Een stoornis in een bepaalde metabole route kan in een aantal geval-
len opgespoord worden met behulp van een vastencurve, die soms ook 
informatie verschaft ten aanzien van het orgaan waarin zich het enzym-
defect manifesteert. De resultaten van deze test bij 13 normale kinderen 
zijn weergegeven in Hoofdstuk 4. De betekenis van de vastencurve voor 
de diagnostiek wordt geïllustreerd aan de hand van de bevindingen bij 
patiënten, die lijden aan een defect in het pyruvaat metabolisme. Het 
verloop van de concentratie van metabolieten in bloed en liquor gedu-
rende een vastenperiode levert niet alleen informatie op bij defecten in 
de glycogenolyse of gluconeogenese, maar ook bij stoornissen in de 
pyruvaat- en vetzuuroxidatie en ketogenese. 
De pyruvaat oxidatie snelheid kan betrouwbaar worden gemeten in 
intacte leukocyten en fibroblasten (Hoofdstuk 5) met [1-14C] pyru-
vaat als substraat. Gelijktijdige bepaling van de l 4C02 productie uit 
[2-14C] pyruvaat kan dienen als een maat van de totale activiteit van de 
citroenzuurcyclus. De activiteit van de individuele reacties van deze 
cyclus kan alleen bepaald worden met geïsoleerde mitochondrieën of 
kapotte cellen, hetgeen veroorzaakt wordt door de lage transportsnel-
heid van citroenzuurcyclus intermediairen over het celmembraan. 
Aangezien een normale oxidatie snelheid van pyruvaat in leukocyten 
en fibroblasten defecten in andere weefsels niet uitsluit, blijft de meting 
van enzym activiteiten in homogenaten van lever- en spierweefsel nood-
zakelijk. In lever en spier van de rat werd aangetoond dat pyruvaat-
dehydrogenase de snelheidsbeperkende stap is voor de l4C02 productie 
uit [1-14C] pyruvate in aanwezigheid van malaat. 
In homogenaten en mitochondrieën van de rat werd onderzocht wel-
ke experimentele omstandigheden optimaal zijn om defecten in de 
citroenzuurcyclus in menselijk weefsel op te sporen. Toevoeging van 
malaat aan lever-mitochondrieën, die [ I 4C] citraat oxideren resulteert in 
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een toename van de , 4C02 productie ten gevolge van een stimulering 
van de transportsnelheid van citraat over het mitochondriële membraan. 
Onder deze condities hoopt 2-oxoglutaraat zich op, hetgeen veroorzaakt 
wordt door uitwisseling van 2-oxoglutaraat met malaat. 
De oxidatiesnelheid van de geteste citroenzuurcyclus intermediairen 
verloopt lineair met de tijd, uitgezonderd de '"СОг productie uit 
[5- 1 4C] 2-oxoglutaraat en [1,4-1 4C] succinaat, welke een lag fase verto­
nen. Toevoeging van pyruvaat elimineert deze lag fase in rattelever 
mitochondrieën. In rattespier mitochondrieën heeft toevoeging van 
pyruvaat een duidelijke verhoging van de oxidatiesnelheid van [б-^С] 
2-oxoglutaraat en [1,4- 1 4C] succinaat to t gevolg, maar een significante 
lag fase blijft aantoonbaar. 
Malaat en pyruvaat worden nagenoeg stoichiometrisch omgezet door 
rattelever mitochondrieën. Ongeveer 60% van het gemetaboliseerde 
malaat wordt teruggevonden als citraat en ongeveer 20% als 2-oxo-
glutaraat. 
Aangezien de 1 4 C0 2 productie snelheid uit [5-14C] 2-oxoglutaraat 
een parameter vormt van de activiteit van de totale citroenzuurcyclus, 
kunnen defecten in de cyclus opgespoord worden met dit substraat. 
Het eerste segment van de cyclus (van citraat tot 2-oxoglutaraat) kan in 
leverweefsel gemeten worden met [6-14C] citraat. In het tweede segment 
(van 2-oxoglutaraat tot malaat) kan de eerste stap gemeten worden met 
[ l-14 C] 2-oxoglutaraat en de rest van het segment met [ 1,4-14 C] succinaat. 
Het derde segment (van malaat to t citraat) kan worden getest met 
malaat en pyruvaat als substraten door de meting van de accumulatie 
van citraat en 2-oxoglutaraat. De 14C02 productie snelheden uit [1-1 4C]-
pyruvaat en 14C-gemerkte citroenzuurcyclus intermediairen door homo-
genaten en mitochondrieën van rattelever en -spier worden vermeld, als-
mede controle waarden verkregen voor menselijke lever- en spierhomo-
genaten (Hoofdstuk 6). 
In tegenstelling to t andere onderzoekers werd door ons slechts één 
Km waarde van pyruvaat carboxylase voor pyruvaat in menselijke lever 
gevonden (Hoofdstuk 7). 
De instabiliteit van pyruvaat in een waterige oplossing wordt be-
schreven in Hoofdstuk 8. Analyse van de verbinding leverde de structuur 
op van de gereduceerde vorm van de dimeer van pyruvaat: 2,4-dihydroxy-
2-methylglutaarzuur, een analogen van 2-oxoglutaraat. Deze verbinding 
remt noch pyruvaat dehydrogenase noch 2-oxoglutaraat dehydrogenase 
in ratteleverhomogenaat. 
In Hoofdstuk 9 is het klinisch en biochemisch onderzoek beschreven 
van 4 patientjes. Bij een jongen met mentale en motorische achter-
stand, microcephalic en ernstige hypotonie werd een pyruvaat dehydro-
genase deficiëntie in leverweefsel vastgesteld. Hij had een hoge pyruvaat 
en lactaat concentratie in bloed en een metabole acidóse. De deficiëntie 
kon niet worden aangetoond in witte bloedcellen en fibroblasten. 
Een kind, lijdend aan een ernstige lactaat acidemie was ernstig men-
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taal geretardeerd en hypotoon en vertoonde overvloedig subcutaan vet. 
Een verlengde vastenperiode veroorzaakte een hypoglycémie. Bij deze 
patient werd een pyruvaat carboxylase deficiëntie in leverweefsel aan-
getoond. 
Bij een derde patient waren ernstige cerebrale beschadiging, mito-
chondriële myopathie, extreme lactaat acidemie en een Detoni-Fanconi-
Debré syndroom aanwezig. In spierweefsel werden verlaagde oxidatie-
snelheden van pyruvaat en 2-oxoglutaraat gemeten. In de mitochondrieën 
van de dwarsgestreepte spier was cytochroom ааз afwezig en het cyto-
chroom b gehalte zeer laag. In de hartspier waren de gehalten van de 
cytochromen ааз en b vergelijkbaar met controle waarden. 
Een cytochroom с oxidase (ааз ) deficiëntie werd aangetoond in 
perifere spier van een meisje lijdend aan subacute necrotiserende 
encephalomyelopathie (ziekte van Leigh). De frequent gevonden ver-
hoogde ratio van 3-hydroxybutyraat/acetoacetaat en de lage oxidatie 
snelheid van pyruvaat in spierhomogenaat duidde op een defect in de 
ademhalingsketen. De hoge ratio van lactaat en pyruvaat in liquor/ 
lactaat en pyruvaat in bloed doet vermoeden dat cytochroom с oxidase 
ook in de hersenen ontbreekt. 
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De schrijver van dit proefschrift werd geboren te Nijmegen op 
20 maart 1948. Hij behaalde het diploma H.B.S.-B aan het Canisius-
College aldaar in 1967 en begon in datzelfde jaar zijn chemiestudie 
(S 2) aan de Katholieke Universiteit te Nijmegen. Deze studie werd 
van maart 1968 tot augustus 1969 onderbroken voor het vervullen van 
de militaire dienstplicht. Het doctoraalexamen met hoofdvak Biochemie 
(Dr. J. Veerkamp) en bijvakken Cito-Histologie (Prof. Dr. Chr. Jerusa-
lem) en Microbiologie (Prof. Dr. Ir. G. D. Vogels) werd behaald in 
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Het onderzoek, waarvan de resultaten in dit proefschrift zijn neer-
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Scheme 
The metabolism of pyruvate in the cytoplasmic and matrix compart-
ments of liver and muscle cell. 
Enzymes/Metaboiic pathways 
EC Number 
1. Hexokinase 2.7.1.1. 
2. Glucose-6-phosphatase 3.1.3.9. 
3. Glycogenolysis 
4. Glycogenesis 
5. Gluconeogenesis 
6. Glycolysis 
7. 
8. 
9. 
10. 
1 1 . 
12. 
13 . 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
2 1 . 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
3 1 . 
32. 
33 . 
34. 
Pyruvate kinase 
Lactate dehydrogenase 
Glutamic-pyruvic transaminase 
Pyruvate dehydrogenase 
Pyruvate carboxylase 
Citrate synthase 
Aconitase 
Isocitrate dehydrogenase (mitochondrial) 
2-Oxoglutarate dehydrogenase 
Succinyl-CoA hydrolase 
Succinate dehydrogenase 
Fumarase 
Malate dehydrogenase 
Glutamic-oxaloacetic transaminase 
Glutamate dehydrogenase 
Phosphoenolpyruvate carboxykinase 
Acetoacetyl-CoA thiolase 
3-Hydroxy 3-methylglutaryl — CoA synthetase and 
3-Hydroxy 3-methylglutaryl — CoA lyase 
3-Hydroxybutyrate dehydrogenase 
Carnitine palmitoyltransferase 
Carnitine acetyltransferase 
Fatty acid oxidation (ß-oxidation) 
Citrate lyase 
Isocitrate dehydrogenase 
Fatty acid synthesis (lipogenesis) 
Succinyl-CoA acetoacetyl-CoA transferase 
Acetoacetic thiokinase 
Lipoprotein lipase 
2.7.1.40 
1.1.1.27. 
2.6.1.2. 
1.2.4.1. 
6.4.1.1. 
4.1.3.7. 
4.2.1.3. 
1.1.1.41. 
1.2.4.2. 
3.1.2.3. 
1.3.99.1. 
4.2.1.2. 
1.1.1.37. 
2.6.1.1. 
1.4.1.2. 
4.1.1.32. 
2.3.1.9. 
4.1.3.5. 
4.1.3.4. 
1.1.1.30. 
2.3.1.21. 
2.3.1.7. 
4.1.3.6. 
1.1.1.42. 
2.8.3.5. 
6.2.1.2. 
3.1.1.3. 
Transport systems 
A: Glucose transport 
B: Lipid transport 
I: Ketoacid transport 
II: Dicarboxylate translocator 
III: Aspartate-glutamate translocator 
IV: Tricarboxylate translocator 
V: 2-Oxoglutarate translocator 
VI: Pyruvate translocator 
VII: Adenine nurleotirlp tranelnnotr.!· 

2-oxog!utarate · ^ ^~^ alanine ^• 
acetoaceîate 
acetoacetyf CaA 
ι» 
acetyl CoA 
[j^uvaS] 

Stellingen 
I 
De hypothese van Scrutton en White betreffende het ontbreken van een 
dubbele Michaelis-Menten konstante van pyruvaat carboxylase voor 
pyruvaat, zoals beschreven door Brunette et al., is onjuist. 
Brunette, M. G., Delvin, E., Hazel, В. and Scriver, С. R. (1972) 
Pediatrics 50, 702—711. 
Scrutton, M. С. and White, M. D. (1974) 
Biochem. Med. 3, 271—292. 
II 
De door Borud en Stramme vermelde waarden voor de CO2 produktie 
uit citroenzuurcyclus intermediairen in gekweekte fibroblasten worden 
ten onrechte door deze auteurs beschouwd als een maat voor de oxida­
tiesnelheid. 
Borud, O. and Stramme, H. (1977) 
Scand. J. Clin. Lab. Invest. 37, 419—432. 
Dit proefschrift, hoofdstuk 5. 
III 
De stijging van de a-ketoglutaraat concentratie tijdens malaat oxidatie 
door rattehersenenmitochondrièn berust niet uitsluitend op een rem-
ming van a-ketoglutaraat dehydrogenase. 
Lysiak, W., Szutowicz, A. and Angielski, S. (1976) 
Acta Biochim. Pol., 23, 325—333. 
Dit proefschrift, hoofdstuk 6. 
IV 
De keuze van de kilogram als basiseenheid in het SI-eenhedenstelsel is 
niet consequent. 
V 
Kwaliteitskontrole met behulp van een gekodeerd kontroleserum kan 
aanleiding geven tot overschatting van de kwaliteit van de meetresul-
taten in een klinisch-chemisch laboratorium. 
VI 
De frequentie waarmee het syndroom van Zellweger voorkomt kan 
aanzienlijk hoger zijn dan algemeen verondersteld wordt. 
VII 
Het verdiend aanbeveling de namen van auteurs, betrokken bij een 
publikatie, in alfabetische volgorde te plaatsen. 
VIII 
In de klinische chemie bestaat grote behoefte aan een betrouwbare 
bepaling van occult bloed. 
IX 
Het frequenter voorkomen van enterocolitis bij de praematuur op 
kunstmatige voeding vormt een nieuw argument voor de waarde van 
moedermelk. 
X 
Ook bij de meest intensieve geneeskundige behandeling dient de privacy 
van de patiënt zoveel mogelijk gewaarborgd te worden. 
XI 
De geringe afstand tussen de regeringstafel en de oppositiebanken in de 
Tweede Kamer der Staten-Generaal is kenmerkend voor de geringe 
marges die in de Nederlandse politiek mogelijk zijn. 
J. L. Willems 
Nijmegen, 16 maart 1978 
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